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SUMMARY
The metabolism of 1- [2-(4~carbamoylphenoxy)ethylamin6]-3-- 
(2-methylphenoxy)propan-2~ol (1tolamolol1), a new beta-adrenoceptor 
blocking agent, has.been studied in the mouse, rat, guinea pig, rabbit, 
dog and man. For these studies tolamolol was labelled with tritium and 
carbon-14.
4 ' “ - - .
In all six species there was evidence for good absorption after
-I
oral administration, but the routes for excretion of radioactivity showed 
considerable variation between the species. The major route for excretion 
in mice, rats and guinea pigs was the faeces, but in rabbits and man 
the major route was the urine; the dog showed intermediate behaviour.
Tolamolol was extensively metabolised, little unchanged drug 
being excreted. Two main metabolic pathways we re identified. The most 
important pathway was hydroxy lation of the 2-methylphenoxy ring, and 
this was the major biotransformation in all species except the dog. The 
second metabolic pathway, and the major route in the dog, was hydrolysis 
of the aromatic carbamoyl group. Significant hydrolysis also occurred in 
the rabbit but in other species this was a minor route. x
Glucuronide and sulphate conjugates of the hydroxylated 
metabolite were excreted in the urine of rabbits and man, and accounted 
for most of the excreted radioactivity in these two species. In the rat 
and guinea pig, and probably the mouse, conjugates were excreted in the 
bile rather than the urine, subsequently appearing in the faeces as the 
aglycones. The species difference in excretory routes is therefore due 
to differences in the extent of biliary excretion.
A polar metabolite in dog urine has been tentatively identified 
as a sulphate ester, the aglycone being a secondary metabolite in which 
both aromatic hydroxylation and hydrolysis of the carbamoyl group have
j
occurred. Cleavage of the alkyl cfyain did not occur to a significant 
extent in any of the species investigated.
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ABBREVIATIONS
The abbreviations used in this thesis are all generally 
recognised, but for convenience are summarised here.
i.v. intravenous
p.o. per os (for oral administration)
d.p.m. disintegrations per minute t
c.p.m. counts per minute \
p.p.m. parts per million
TLC thin layer chromatography
PLC preparative layer chromatography
R„ migration of a chromatographic band relative to thei?
solvent front 
GC gas chromatography or gas chromatograph
GC/MS gas chromatography coupled with mass spectroscopy
MS mass spectrum, or mass spectroscopy, or mass spectrometer
DIP direct insertion probe (for introducing samples into the MS)
IR infrared
BV ultraviolet
M molar (concentration)
The following chemical abbreviations have been used:
Me methyl
Et ethyl
Pr1 iso-propyl
Bu11 normal-butyl
Ac acetyl (CH^CO
Bz benzyl
The product of an electrophoresis experiment is referred to as a 
’pherogram’, not an 'electrophoretogram’.
Abbreviations for tolamolol and its metabolites are given in Appendix II.
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1.1 INTRODUCTION
The work described in this thesis had as its main objective 
the determination of the absorption, excretion and metabolite patterns 
of tolamolol in different species, including man. Tolamolol is a new 
beta-adrenergic blocking drug designed for the prophylaxis of angina, and 
in this introductory chapter a brief description of the aetiology of 
angina is given, followed by a discussion of current methods of treatment, 
and the criteria that must be met by any new anti-anginal agent. The 
relevance of drug metabolism., studies to the toxicity trials necessary to 
establish the safety of a potential new drug is then briefly considered. 
Finally, a general review of the mammalian metabolism of foreign compounds 
is given, followed by a more detailed discussion of probable metabolic 
pathways for tolamolol.
1.2 ANGINA - ITS CAUSE AND TREATMENT
Angina pectoris (usually abbreviated to ’angina') is the severe
pain resulting from oxygen starvation of the heart muscle. Any situation
. /
leading to an increased demand for oxygen by the heart, for example, 
exercise, can precipitate an attack of angina. Emotional factors are also 
important, since increased activity of the sympathetic nervous system 
results in increased myocardial oxygen demand. Normally the increased 
oxygen requirements in these circumstances are met by an increased coronary 
blood flow, but as the primary cause of angina is coronary atheroma, the 
diseased arteries are incapable of supplying sufficient blood, and 
myocardial hypoxia results.
The incidence of angina is high, particularly in the older age-
groups, although it is not a fatal disease. A recent estimate of the
annual number of consultations in the United Kingdom for angina is three
million (Medical Data Ltd., 1972); this corresponds to about half a million
patients. Angina is therefore a major problem, and an effective prophy-
\
lactic agent would benefit the whole community, since it would enable a 
considerable proportion of the population to lead a more active life.
The termination of individual attacks of angina can be achieved 
with currently available drugs (the nitrates), and these are also effective 
when taken shortly before a period of stress. The main aim of current 
research is therefore the development of drugs for the chronic prophylaxis 
of angina, to prevent attacks and increase the patient's exercise capacity.
Three main types of drug have been used in the treatment of 
angina pectoris.: the nitrates (or nitrites), vasodilators, and compounds 
producing blockade of the beta-adrenergic receptor.
Glyceryl trinitrate and other short-acting nitrates are used 
either for the immediate relief of pain, or for the short-term prevention 
of pain, and these compounds are still the only drugs of unquestioned 
value in the treatment of angina (McLamore, 1970)* The mode of action of 
the nitrates in angina is still not entirely clear, since although 
generally classed as vasodilators, it is now considered doubtful whether 
the increased blood flow, which is only transitory, has any beneficial 
effect on the symptoms of ischaemia. Nitrates are of limited value when 
used orally for prophylaxis.
Because the beneficial effect of nitrates on angina was thought 
to be due to their vasodilator action, vasodilators more potent than the 
nitrates were prepared for use in angina; These drugs have generally 
proved disappointing. Dipyridamole, for example, is a potent vasodilator, 
but neither intravenous nor oral administration of the drug prevents the 
pain, or the ECG evidence, of exercise-induced myocardial hypoxia (Nickerson 
1970).
The most recent approach to the treatment of angina is the use 
of drugs which block the beta-adrenergic receptors, and it is to this 
class of compounds that tolamolol belongs. The nomenclature used to 
describe the adrenergic receptors was originated in 1948 by Ahlquist, 
although the concept of specific receptors with which drug molecules could 
interact to produce a response was the result of work by Langley and Dale 
over 40 years earlier. Ahlquist determined the order of potency of five 
sympathomimetic amines on a variety of tissue responses, both in vivo and 
in vitro. From these studies . (summarised by Ahlquist-, 19&7) he 
postulated that the excitatory responses such.as vasoconstriction and myo- 
metrial contraction were associated with one type of receptor, the alpha- 
receptor, while the inhibitory responses such as vasodilation and smooth
muscle relaxation were associated with a different type of receptor, the
specific agonist for alpha-receptors is phenylephrine (i), and the specific
receptor blocking agent can be defined as "a substance which specifically 
blocks the catecholamine-evoked responses stated to be associated with 
beta-receptors . . . but does not block the adrenergic responses associated 
with alpha-receptors . . ." (Ahlquist, 1968).
increased mean arterial pressure, and increased cardiac output. Although 
betar-receptor stimulation normally results in an inhibitory response, the 
heart is an exception in that cardiac excitation is a beta-receptor 
response. Therefore blockade of the beta-receptors will reduce the cardiac 
work, and hence the myocardial oxygen demand, affording relief of the 
exercise-induced pain experienced by anginal patients.
activity relationships among these drugs, have been reviewed by Dollery 
et al., (1969), Fitzgerald, (19&9) > Wong and Schreiber, (1972). The 
first beta-receptor-blocking agent is usually considered to be
beta-receptor. Both types of receptor respond to adrenaline (il); the
agonist for beta-receptors is isoprenaline (ill). A beta-adrenergic
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dichloroisoproteronol (IV), but because it also possesses intrinsic 
sympathomimetic activity (producing typical adrenergic tachycardia) it has 
not been extensively studied clinically. The first clinically effective 
beta-receptor blocking agent was pronethalol (v), but this was found to 
cause thymic .tumours in mice, and- so was withdrawn from clinical use. The 
compound now regarded as the reference beta-blocking drug is propranolol
(VI), since it is the only beta-blocker which has been fully documented 
in terms of clinical effectiveness. Propranolol possesses virtually no 
beta-agonist activity, and does not appear to be toxic.
A side-effect shown by some beta-blockers is a local anaesthetic, 
or membrane-stabilising activity. Beta-blocking drugs which have local 
anaesthetic activity also have a quinidine-like action on the heart, causing 
a reduction in the velocity of conduction of nerve impulses. Quinidine- 
like properties are associated with non-specific depression of myocardial 
function, but to demonstrate this activity requires doses far larger than 
those required for beta-blockade. In the case of propranolol, resolution 
of the racemate has enabled a comparison to be made of the pharmacology
of the two optically active stereoisomers. The (~) isomer is 60 to 100 
times as active as a beta-blocker than (+) propranolol, but both isomers 
have the same local anaesthetic activity. The quinidine-like activity of 
propranolol, and probably other beta-blocking: agents, therefore seems to 
be independent of beta-blockade. Because membrane activity depresses 
myocardial contractility, it is generally, regarded as clinically undesirable
Another important side-effect, a consequence of beta-blockade, 
is bronchoconstriction. Stimulation of the beta-receptors in the smooth 
muscle of tissues other than the heart leads to relaxation, and therefore 
blockade of the beta-receptors increases the tone of vascular and pulmonary 
smooth muscle, resulting in decreased coronary blood flow and increased 
airways resistance. This last effect is of little consequence in normal 
individuals, but is particularly serious in patients suffering from asthma 
or bronchitis.
Lands et al., (1967), using a similar method to Ahlquist, but a 
wider range of sympathomimetic amines, was able to show that the beta- 
receptors in cardiac and bronchial tissue were different. He classified 
those in the heart muscle as H  type, and those in the bronchial muscle as 
^“2 type. Beta-blocking agents which show tissue selectivity have now 
been developed. Practolol, (VII), is a beta-blocker which blocks the 
cardiac receptors, but has much less effect on the smooth muscle of the 
bronchi and on the blood vessels to voluntary muscle. Although practolol 
is about 2-g- times less active than propranolol as a beta-blocking drug, it 
is 150 to 400 times less active in the bronchial tree (Barrett, 1971)> and 
has been shown to be a useful agent in the treatment of angina (Areskog,
1971> Pentecost et al.. 1971)«
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Beta-blocking agents are now recognised in Europe as an effective 
treatment for angina, and it is anticipated will soon be so recognised in 
America (beta-blocking agents are limited by the EDA to short-term use in 
dysrhythmias only). Erom the foregoing discussion it is apparent that a 
new beta-blocking drug should show selectivity for the cardiac beta- 
receptors, and have adequate potency with no myocardial depressant action.
The Chemical Research Department of Pfizer Ltd. have prepared
■ ■ ' \ ■ 
a new beta-adrenergic blocking agent, for which the generic name ^tolamolol1
has been approved by the B.P. Commission. Tolamolol is 1-[2-(4-carbamoyl-
phenoxy)ethylamino]-3-(2-methylphenoxy)propan-2-ol, (VIIl), and has been
selected for development as a drug for the long-term prophylaxis of angina
pectoris. It shows a potency comparable to propranolol, tissue selectivity
in man comparable to practolol, and no myocardial depressant activity at
doses in excess of those producing effective beta-blockade.
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.1.5 ' THE RATIONALE OF DRUG--METABOLISM STUDIES
Before any new compound can be tested in man it is the 
responsibility of the manufacturer to ensure that the subject receiving 
the drug is not exposed to any unnecessary toxic hazard. This is done 
by carrying out toxicity trials in various animal species. However, the 
fundamental problem is that there can be marked differences between species 
in their response (pharmacologic and metabolic) to a drug, and man might 
respond to the drug in a manner not predictable from the results of animal 
tests.
Experience over many years has demonstrated that properly designed 
animal studies are usually adequate.for the prediction of safety in man. 
Nevertheless, the administration of biologically active substances to 
human beings "must always be accompanied by some element of risk that cannot 
avoided by the most careful and exhaustive study of the drug" (W.H.O., 1966) 
As Black (1967) has said, in extrapolating the results of animal studies 
to man, "we cannot have precision, and we surely cannot have certainty".
in assessing the results of toxicity trials, one of the factors 
that must be considered is the metabolic fate of the drug. If the drug 
is metabolised by one route in the toxicity trial species, and by a 
different route in man, the results of the toxicity trial will bear little 
relation to the human case, because the animals are exposed to different 
chemicals than is man. For a valid toxicity trial the species used should 
"wherever practical or possible . . biologically handle the material 
qualitatively and/or quantitatively as similarly as possible to man" (Weil. 
1972). However, as toxicity studies in animals must precede human, studies, 
it is not possible to know whether the species chosen for toxicity trials 
are appropriate until after' the drug has been administered to man.
A knowledge of the absorption, distribution, metabolism and 
excretion of a drug is of "fundamental importance for the proper evaluation 
of toxicity" (V.H.O., 1966). It is therefore necessary to commence 
metabolism studies in animals as soon as possible, because the more 
information that is available about these factors in animal species, the 
more closely will it be possible to monitor the first, and subsequent 
experiments in man. -
The first requirement in these studies is an assay for unchanged 
drug, as this can give information (even if only negative information) about 
absorption, excretion, and extent of metabolism. If the drug is extensively 
metabolised, (indicated by low blood levels of unchanged drug together 
with negligible excretion of unchanged drug), then it becomes essential to 
examine metabolites in order to determine absorption and routes of 
excretion. This is greatly facilitated by the use of radioactively- 
labelled drug. The examination of metabolites should aim to determine their 
properties and behaviour, so that some means of characterising unlabelled 
metabolites is available (since early administration of labelled drug to 
man is unlikely). Until it has been shown that the metabolic fate of the 
drug is similar in the toxicity trial animals and man, the results of 
the toxicity trials will be of limited value. ' '' v-
Although it was long the hope that an anima.l species would be 
found that metabolised foreign compounds in the same way as man, it is 
now realised that the animal most like man is man himself. The primary 
objective for metabolism studies is therefore to assist in evaluating the 
safety of a drug by validating the results of toxicity trials. Secondary 
objectives which often come within the scope of metabolism studies, are 
experiments into the mode of action of the drug, correlating plasma or 
tissue levels of the drug (or metabolites) with pharmacological effect and 
therapeutic efficacy, or, indeed, with toxic or adverse side-effects.
1.4 THE METABOLISM OF DRUGS - A BRIEF REVIEW
The metabolic fate of foreign compounds has been a field of study 
Tor over 100 years (Williams, 1 9 5 9 ) In the last three decades, however, 
and particularly during the last ten years, in the wake of the tragic events 
leading to the banning of thalidomide, activity in this field has increased 
enormously. The main endeavour has been in the field of drugs, but the 
range of compounds studied is continually increasing, and now includes 
food additives, insecticides, industrial chemicals and environmental 
contaminants. This brief review will deal with the mammalian metabolism of 
compounds foreign to the organism, and particularly with those aspects 
relevant to the metabolism of tolamolol.
With the exception of drugs whose sphere of action lies outside 
the body, a compound must be present in solution in the blood stream 
before it can show biological activity. This is usually achieved by 
absorption of the drug from the gastrointestinal tract, particularly the 
intestine. As the property of a compound favouring its absorption, lipid
v'
solubility, is the opposite of that favouring its excretion, the body is 
provided with a mechanism for the conversion of the absorbed, relatively 
non-polar compounds into polar, water-soluble compounds suitable for 
excretion into urine or bile. In general, the overall process results in 
a compound of lower toxicity than the original compound, so that metabolism
i
is usually regarded as a means of detoxication.
Williams (1959) observed that the metabolism of most foreign 
compounds occurs in two phases. The first phase involves oxidations, 
reductions and hydrolyses; these 'Phase I' reactions serve to introduce 
or reveal functional groups, generally increasing the polarity of the drug, 
and providing centres capable of reacting with endogenous substrates.
Reactions occurring in the second phase of metabolism are syntheses, when 
endogenous substrates combine with the Phase I metabolites to form 
conjugates: these are usually polar and water-soluble, and therefore are 
-readily excreted. Some drugs are excreted in substantial quantities without 
undergoing any metabolism at all; some drugs are conjugated (Phase II) 
without prior Phase I metabolism, and Phase I metabolites are often 
excreted without Phase II reactions. Nevertheless, biphasic metabolism 
is generally observed.
Metabolism of a drug can occur before absorption (by the intestinal 
microflora), and during absorption, but generally occurs after absorption, 
the main site of the metabolising enzymes being the liver. The liver is 
ideally placed for the role of detoxifying foreign compounds, since the 
blood supply from the intestine passes into the portal vein which goes 
directly to the liver.
1.4.1 PHASE-I REACTIONS .
‘The cells of the liver can be disrupted and separated by 
centrifugation into fractions containing mitochondria, microsomes, and the 
cytosol. The majority of drug metabolising activity resides in the 
microsomal fraction, which is derived from the endoplasmic reticulum of the 
cell. The microsomal enzyme system is capable of a number of reactions using 
a very wide range of substrates; most of these reactions are oxidations 
which can all be considered as involving initial hydroxylation of the 
substrate. The net reaction requires an electron donor and molecular 
oxygen; only one atom of oxygen is incorporated into the product, the other
i
being reduced to water:
R-H + NAHPH + H+ + 02-*R-0H + N£DP+ + H20 
The major microsomal oxidations are summarised in Table 1.1.
TABLE 1.1 
Liver microsomal oxidations
Substrate Hiydroxylated product Final product
Ar.CH* Ar.CH20H Ar.CHgOH
Ar. CH0CH0CH-j 2 2 5 a t .c h(o h)ch2ch5 Ar.CH(0H)CH2CH5
Ar.CH0CH0CH-, 2 2 5 . Ar.CH2CH(OH)CH5 Ar.CH2CH(OH)CH5-
Ar-H Ar-OH Ar-OH
R-OCEL
2
•r -och2oh R-OH (+HCH0)
R-KH.CEL
5
r-m .ch2oh R-NHg (+HCH0)
r »-ch(m 2)-r " -R'-C(NHp)-R"
OH
R'-CO-R" (+HH5)
R'-S-R" |r ’-s (o h)-r ^]+ ' R'-SO-R"
R-,N
5
[e 3h-oh] + ' R-,N-*0
.5
N.B. 'Ar' represents an aryl group, 'R' represents an alkyl group.
These hydroxylations are mainly carried out- hy a complex multi- 
component enzyme system, intimately associated with the microsomal 
membrane, the key participant being a haemoprotein, cytochrome P-450 
(hereafter referred to as 'P-4501 )• P-450 is the most abundant haemo­
protein in the liver cell, accounting for up to 20$ of the total micro­
somal protein, and is found not only in the liver, but also in various other 
mammalian body tissues. It has also been identified in fish, reptiles, , 
bacteria, yeast, and certain plants (Markham et al., 1972).
During microsomal hydroxylation the ionic iron of P-450 undergoes 
reversible oxidation-reduction reactions, and although the precise 
mechanism of the hydroxylation reaction has not been fully elucidated, the 
main features are now believed to be as follows (Estabrook e_t al., 1972).
■The substrate first combines with the oxidised form of P-450* 
This complex is reduced by an electron derived from a flavoprotein 
reductase, and the reduced complex then interacts with molecular oxygen 
*to form a ternary substrate/P-450/oxygen; complex. The sequence of events 
after this stage is still uncertain. A second one-electron reduction 
occurs, probably giving an active oxygen intermediate (which is yet to be 
observed), and this decomposes to give the hydroxylated product, water, 
and oxidised P-450. The essentials of this mechanism are illustrated 
below.
S
1 4-4-4-
P-450Fe -
Substrate 
S
P-450Fe
Hydroxylated
substrate
S-OH
(+h20)
f 4-4-
P-450Fe
S
* I .
P-450Fe
2H
There are often changes in patterns of metabolites with age, sex, 
and particularly species, and this has led to the suggestion that there are 
a family of P-450 pigments with subtle but significant differences in 
chemical and physical properties. An alternative suggestion is that there 
exists a single P-450, and that differences in hydroxylation activities 
indicate differences in the environment of the haemoprotein. The 
controversy has not been resolved (Mannering, 1971» Estabrook et al., 1972).
Foreign compounds can also be metabolised by non-microsomal 
enzymes. These enzymes are usually those involved in normal body metabolism, 
for example monoamine oxidase, diamine oxidase, and alcohol dehydrogenase, 
and tend to show more substrate specificity than the mixed function oxidase 
system of the microsomes. A number of other extra-microsomal reactions 
such as reduction, hydrolysis, ring scission and cyclisation also occur, 
but the nature and location of the enzymes involved is often obscure, if 
not unknown. These reactions have been summarised by Parke (1.968).
The role of gut bacteria in drug metabolism has been reviewed 
by Scheline (1968); the reactions catalysed by the bacteria are usually 
degradative, e.g. dehydroxylation and hydrolysis, whereas microsomal 
reactions usually involve the addition of oxygen, as described above..
1.4.2 PHASE II REACTIONS /
Phase II reactions can occur when the drug or metabolite has a 
functional group capable of accepting an activated endogenous substrate, 
or capable of activation to accept an endogenous substrate. The major 
Phase II reactions have recently been reviewed by Mandel (1971.) j and- 
summarised in Table 1.2.
Conjugation with glucuronic acid is probably the most important 
conjugating mechanism, and results in highly polar, acidic metabolites 
which are readily excreted. Glucuronide formation is usually a true 
detoxication reaction, the conjugate being not only more water-soluble than 
the parent compound, but also less toxic. There is evidence for a variety 
of glucuronyl transferases, accounting for some species variations in 
conjugation. The cat, in particular, is deficient in glucuronyl transferases 
suitable for many foreign drugs. Although the transferases are microsomal 
enzymes, they do not use the electron transport chain described above.
TABLE 1.2
Summary of the major Phase II reactions
Precursor ActivatedMoiety
Mediating
Enzyme Substrate Product
Glucose-6-P0.
4
UDP-glucuronic
acid
Glucuronyl
transferase
R-Z-HL
(where Z is 
0, S, COO, M )
Glucuronide
Sulphate 3’-phospho- 
adenosine-5f- 
phospho-
sulphate
(PAPS)
Sulphokinase R-Z-H
(where Z is
0 or M )
Ethereal
sulphate
Lia .R'.COOH R-CO-S-CoA
(N.B.: R from 
substrate)
Transacylase R-C00H
(R is usually 
aromatic)
Amino acid 
conjugate
(Hippuric acid 
when R 1 = CHp
Acetate CH-,CO-S-CoA Transacylase ' r-nh2
(R is usually 
aromatic)
Acetylated
amine
Glutathione GSH-S-aryl (or 
alkyl) trans­
ferase
Glutathionase,
Peptidase,
Acetylase.
(in sequence)
R-X
(where X is 
H, F, Cl, Br, 
R02 or S02NH2)
Mercapturic
acid
Methionine S-adenosyl
methionine
Methyl
transferase
R-Z-H
(where Z is 
0, S or m )
Methylated
substrate
Conjugation with sulphate is an important pathway of metabolism 
for phenols and alcohols, and gives acidic, water-soluble compounds, often 
referred to as ’ethereal sulphates’. It is a general reaction carried out 
by most species, the pig being an exception. Conjugation with sulphate 
takes place in the soluble fraction of cells, and several sulphokinases 
are known. The body pool of sulphate is usually limited, so that a 
variation in extent of sulphate conjugation with dose can occur. As in . 
the case of glucuronides, sulphate conjugation is almost invariably a true 
detoxification, although in some cases sulphates (and glucuronides) can 
have toxic actions (Irving, 1971)*
I The transacylase reactions are of two types. In-one type the
foreign compound is activated, converted to its coenzyme A derivative, 
and then transferred to an endogenous substrata, usually glycine. This 
reaction occurs in the mitochondria of liver and kidney, and is 
characteristic of aromatic and heterocyclic carboxylic acids. The 
products with glycine are termed ’hippuric acids’; however, the body pool 
of glycine may be limited, giving rise to zero-order kinetics of formation. 
The choice of endogenous substrate can vary with species: man, for example, 
can form glutamine conjugates. Formation of hippuric acids usually, but 
not always, results in an increase in acidity and water-solubility of the 
foreign compound, but as active transport of hippuric acids into the lumen 
of the kidney tubules occurs, the concentration of hippuric acids is 
unlikely to approach the maximum solubility limit.
The other type of reaction involving transacylases is the transfer 
of an activated endogenous acid, usually acetic acid (present as acetyl 
coenzyme A), to the foreign compound. This is a typical reaction of 
primary aromatic amines, but is normally a minor route of metabolism.
The dog differs from most mammals in being unable (apparently) to form
acetyl conjugates of aromatic amines-and hydrazides. This may be due to 
an endogenous enzyme inhibitor (Leibman and Anaclerio, 1962), or possibly 
to a particularly active deacetylase. Acetylation often decreases the 
water solubility of foreign compounds, and thus has the reverse effect to 
that expected of a metabolic reaction, as shown by the well-known and 
oft-quoted example of the sulphonamides, and particularly sulphathiazole.
This brief review has not dealt with many important metabolic • 
routes, such as reduction, which are unlikely to be significant'in the 
metabolism of tolamolol. However, the reactions have so far been 
discussed in general terms, and it is now proposed to consider the ways 
in which drugs related to tolamolol are metabolised* with the object of 
predicting possible metabolic routes for tolamolol.-
1.5 DISCUSSION OF POSSIBLE METABOLIC: ROUTES FOR TOLAMOLOL
When studying the hiotransformation of a compound, a knowledge 
of the metabolic routes likely to he followed can materially assist in 
the search for, and identification of, metabolites. An analysis of 
possible metabolic pathways for tolamolol was therefore undertaken. For 
convenience in the following discussion, and elsewhere in this thesis, the 
two aromatic rings in tolamolol will be referred to as the alpha ring 
(containing the carbamoyl group) and the beta ring (containing the 2-methyl 
group. -
OH
CH.
From the very considerable volume of work now available on the 
metabolism of foreign compounds (Williams, 1959» Parke, 19&8; Brodie and 
Gillette, 1971)» there are at least four Phase I metabolic reactions that 
might occur with tolamolol. These are hydroxylation of the aromatic rings, 
hydrolysis of the carbamoyl group, N-dealkylation and O-dealkylation.
Considering first hydroxylation of the aromatic rings, it has 
been observed, that microsomal hydroxylation of aromatic substrates tends 
-to follow the pattern expected for electrophilic substitution, with the 
additional limitation of a marked steric effect. Thus for di-substituted 
aromatic substrates the position of hydroxylation by microsomal enzymes 
can usually be predicted from the electron-donating or electron-withdrawing 
properties of the substituents (Daly, 1971)* In "the case of the alpha ring, 
which contains an ortho/para-directing alkoxy substituent, the para
position is blocked by a meta-directing carbamoyl group. Therefore
hydroxylation of this ring is likely to take place ortho to the alkoxy 
group. However, the steric shielding of these positions, together with 
the general deactivation of the ring by the carbamoyl group, makes it 
unlikely that the alpha ring will be hydroxylated.
5y contrast, the beta ring has two activating groups, both with 
free para positions, and therefore 4~ and/or 5-kydroxylation must be 
considered as probable metabolic reactions (3- or 6-hydroxylation is 
unlikely from steric considerations). Investigations into the mechanism 
of microsomal hydroxylation of aromatic substrates suggests that in many 
cases epoxides are the initial metabolites. Indeed, Udenfriend (1971) 
states that it is probable that all microsomal hydroxylations of aromat-ic 
substrates involve the initial formation of ah epoxide. If this occurs for 
tolamolol, rearrangement of the 4»5-oxide could give rise to either 4- or 
5-hydroxylated tolamolol. However, since the effect of a group such as 
alkoxy, exerting its effect via an unshared pair of electrons, is more
potent than the hyperconjugative effect of a methyl group, hydroxylation
\
of the 4 position would be expected to predominate (assuming that the 
eventual product conforms to the expectations of electrophilic substitution) 
This conclusion is supported by the isolation and identification of XI from 
human urine after oral" administration of myanesin (IX), the identification 
of the corresponding metabolite of guaiacol glyceryl ether in rabbit urine 
Naito et al., 1969)> and also the work by Daly (1970) which showed the 
major metabolic reaction of 2-methylanisole (XII) to be 4-hydroxylation.
<?H
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Many methyl-substituted aromatic substrates are metabolised by 
hydroxylation of the benzylic carbon to give hydroxymethyl compounds. The 
alcohol can be further metabolised to the carboxylic acid (Daly, 1971)* 
‘However, steric factors are again important, and ortho-substituted 
methylbenzenes are usually metabolised by routes other than benzylic 
oxidation if alternative routes are available. Nevertheless, the methyl 
group of 2-methyl anisole (XIl) is hydroxylated to some extent, although 
4-hydroxylation is the major route. Hydroxylation of the methyl group of 
tolamolol must therefore be considered a possible metabolic route.
Metabolic hydrolysis of the aromatic carbamoyl group could occur, 
but apart from the classic studies of Bray et al., (1950), little seems 
to have been published on this reaction. Bray's group investigated the 
hydrolysis of benzamide and 18 mono-substituted benzamides by a rabbit liver 
homogenate which, from the method of preparation, probably contained 
mitochondria as well as microsomes. The percentage of the amide hydrolysed 
in five hours was determined by estimation of the ammonia liberated.
The position of the substituent has a marked influence on the 
extent of hydrolysis, maximum hydrolysis occurring with para substit\ients. 
There is one exception: little variation with position is found for 
fluorine, the extent of hydrolysis for all three isomers being similar to 
benzamide. The influence of substituent position is therefore almost 
certainly a steric effect, since fluorine is approximately iso-steric with 
hydrogen. The nature of the substituent also has a profound effect on the 
extent of hydrolysis. In Table 1.3 the extent of hydrolysis for different\ 
para-substituted benzamides, derived from Figure 2 of Bray's paper, are ’ 
given together with the Hammett C  values, Hansch fT values, and log P values 
calculated according to Tute (1971) (P is the octanol/water partition 
coefficient; the higher the value of P, the greater the lipophilicity).
TABLE 1.3
Enzymic hydrolysis of para-substituted ~benzajnid.es
Percentage hydrolysis estimated from Figure 2 of Bray et al., (l950)«
It values taken from the compilation of Tute (l97l)> using the figures 
for phenoxyacetic acids. Log P values calculated from log P for benzene 
+Tf values for -CONH^ and R. (N.B. See footnote*).
Substituent(r ) fo Hydrolysis % Log P
-nh2 5 3 -0.66 -1.17 -0.53
-OH 4 -0.37 -0.61 +0.03
‘-H 44 0 0 . O.64
-F 45 +0.06 +0.15. 0.79
-CH,
5
52 ;-0.17 O.52 1.16
-Cl 61 +0.23 0.70 1.34
-N02 80 0.78 0.24 0.88
A. '
The correlation with Hammett a  values is less satisfactory than 
the correlation with log P values, which suggests that lipid solubility 
is a more important factor than the electron-donating or electron- 
withdrawing properties of the substituent. Nevertheless, the high 
percentage of 4-uitrobenzamide hydrolysed indicates that electronic effects 
may also play some part in determining the extent of hydrolysis.
Further evidence for the importance of partition coefficient
comes from the data given by Bray (loc. cit.) for aliphatic amides.
* A Hansch analysis of the data in Table 1.3? carried out by Dr. M. Tute, 
gave a significant equation of the form: log(fc hydrolysis) = acr+ + bTf + c.
A significant equation involving could not be established. This 
indicates an enzymic mechanism (Tf significant) proceding via a carbonium 
ion(<r^ significant).
Maximum hydrolysis occurs for the amides of hexanoic and heptanoic acids, 
amides containing higher or lower numbers of carbon atoms being less 
extensively hydrolysed. This is consistent with the parabolic relationship 
between lipophilic character and bi£.o$gical activity suggested by Hansch 
and Clayton (1973)* The calculated log P for the most extensively 
hydrolysed amides is 1.29 and 1.79» and these values are not too far 
removed from the value of 2 proposed by Hansch et al., (1968) as the ideal
lipophilic character for metabolism.
- , ' \ ■
The partition coefficient for tolamolol has been calculated from 
measurements made on related-compounds (Tute, 1972, personal communication), 
and gives a log P 1 value at pHJ7«4 of 1.36. Therefore, if partition 
coefficient is the predominant factor in deciding the extent of hydrolysis 
of amides, tolamolol should be readily susceptible to amide hydrolysis.
(Note that log P value, refers to the unionised compound; the log P 1 value 
refers to the ionised species, and is related to the pK of the compound 
and the relevant pH; Tute, 1971)*
\N- and O-dealkylation are both well-established microsomal
s, _
reactions,(McMahon, 1966; Gram, 1971)* In general tertiary amines are 
more readily dealkylated than secondary amines, and the extent of cleavage 
of N- and 0-alkyl compounds decreases as the chain length increases. It 
might be expected therefore that microsomal dealkylation would not be a 
significant route of metabolism for tolamolol. Nevertheless, in man, 
fenetylline (XIV) is cleaved predominantly on the theophylline side of the 
nitrogen to give amphetamine and amphetamine metabolites equivalent to '
nearly 50$ of the dose (Ellison et al., 1970). The alkyl chain of
i
CH.
(XIV)
CH. CHqCH0NH . CHCH, 
CH-,
prenylamine (XV) is cleaved either side of the nitrogen in the rat (Palm 
and Grobecker, 1968; Hornke and Hajdn, 1970j Volz, 1971)j and in man also 
the chain is cleaved to give amphetamine (Palm et al., 1969). In both 
species, however, this metabolic route represents only a small percentage 
of the dose, and. there is evidence that the dealkylation is not a micro­
somal reaction (Palm et al., 1969); this possibility is considered in
more detail later. .
-amine
OH {H
• isO.CH2CH.CH2tN
CH,
ch2ch2.o
CH.O
.p-amine**
; (oti)
The metabolism of the Pfizer compound (XVl), closely related to 
tolamolol, was studied in vitro using 10,000 g supernatant from rat liver. 
The amines corresponding to cleavage either side of the nitrogen atom were 
found, and assay of. these amines by GC gave a ratio for the o(-amine to 
^-amine of about 3*1 (Wood, 1969* unpublished). This is the reverse of 
the expected ratio, since Beckett et al., (1971) observed that a hydroxyl 
group on the f*, carbon atom inhibits oxidation of the o( carbon of amines 
in microsomal preparations. The extent of metabolism of (XVl) under the 
in vitro conditions used was low, less than 5$ of the substrate being 
metabolised. One in vivo experiment was performed and no products arising 
from chain cleavage (i.e., the amines, and the corresponding acids) could 
be detected by GC. Although N-dealkylation of tolamolol is likely to
occur, therefore, it will probably not be a major route for metabolism. 
Considering the size of the groups involved, O-dealkylation is also 
unlikely to occur, and this is borne out by studies on the metabolism of 
several beta-blocking drugs, which are more closely related to tolam'olol 
than the aryl-alkyl ethers reviewed by Gram (1971)•
Since the introduction of dichloroisoproteronol ( iv ), more than 
20 beta-blocking drugs have been reported (Wong and Schreiber, 1972).
Both beta-blocking drugs and beta-stimulant drugs can be considered as 
derivatives of ethanolamine, having the general structure:
• T OH H
I I
r '-ch-ch2-n-r u
R 1 is an aromatic substituent, and R" is usually an isopropyl or, 
occaisionally, a tertiary butyl group. A few compounds with beta- 
receptor activity are substituted on the alpha carbon atom, but they are 
less relevant to tolamolol than the unsubstituted compounds, and are not 
considered further. Metabolism studies have been reported for several 
of the. beta-stimulant and beta-blocking drugs, and the results of these
s.
investigations will be briefly reviewed here as an additional guide in 
predicting metabolic routes for tolamolol. The compounds to be considered 
are listed in Table 1.4 (page 34; this page folds out for reference during 
the following discussion). The relationship between some of these 
compounds, tolamolol, and the Pfizer compound XVI (UK-394)» is shown in 
Appendix I.
The bio transformation of the compounds in Table 1.4 follows two 
general routes which are summarised in Scheme 1.1 (next page). The extent 
of metabolism and the relative importance of the two pathways varies with 
the compound, although in some cases the presence of other substituents in 
the aromatic ring provides alternative, and competing, metabolic routes.
^aromatic
hydroxylation \N-dealkylation
R'-CH(OH)CHqN %
deamination
R ’ is an aromatic group 
Ru is an alkyl group side-chain
oxidation
R'-CO.COOH
■SCHEME 1.1 ^
General metabolic routes for beta-blocking drugs
Salbutamol is not metabolised by rat, rabbit or man, most of • 
the dose being excreted in the urine as either salbutamol or its glucuronide 
(Martin et al., 1971)» in man an unidentified conjugate of salbutamol is 
also excreted (Walker et al., 1972). Practolol also is scarcely 
metabolised, at least 8 5 being excreted unchanged; that portion of the 
dose which is. metabolised is either hydroxylated (the major route) or 
hydrolysed to the aromatic amine. No side-chain degradation products have 
been identified (Scales and Cosgrove, 1970)• After administration of 
terbutaline to man, only unchanged drug and a sulphate conjugate of the
drug were found (Nilsson et al., 1972).
Quantitative data is not available for oxprenolol, but the
published results (Garteiz,' 1971) suggest that urinary excretion of unchanged
drug is an important factor. Metabolites corresponding to ring
hydroxylation, dealkylation of the allyloxy group, and also N-dealkylation 
have been identified in rat urine, however. A brief report on the 
metabolic fate of Roche ’A 1 in the rat (Long and Hornby, 19&9) indicates 
aromatic hydroxylation as the main route, with some oxidative deamination 
occurring to give a mixture of acids. Unchanged drug was not apparently 
excreted. Bunolol is extensively metabolised, with 18 urinary metabolites 
being reported (this includes conjugates); unchanged drug represented less 
than' Yfo of the dose (Leinweber et al., 1971a). Solvent extraction of 
urine showed similar amounts of acids (free and conjugated) and bases 
(free and conjugated) to be present so that there appears to be no marked 
preference for either of the two general routes in this case. Two products 
of side-chain oxidation have been identified as the lactic acid and acetic 
.acid derivatives (Leinweber et al., 1971b).
Pronethalol is also extensively metabolised, only about 1$ of 
the dose being excreted unchanged. Marked species variation was found 
in the extent to which side-chain oxidation and ring hydroxylation were 
followed, with the guinea pig, which favoured the first route, and the 
mouse, which favoured the second route, representing the two extremes.
The dog, cat, rabbit and man showed a preference for ring hydroxylation, 
but side-chain oxidation was significant in all these species. The 
primary amine was identified in vitro, suggesting that N-dealkylation 
precedes side-chain oxidation. This was further confirmed by the observation 
that formation of acidic metabolites was inhibited by a monoamine oxidase 
inhibitor (Bond and Howe, 1967).
*
Some controversy exists over the metabolic fate of propranolol-.
{
Bond (1967) reported .finding small quantities of unchanged drug and 4~ 
hydroxy propranolol in urine from rats, mice, guinea pigs and rabbits.
Paterson et al., (1970), found very small amounts of propranolol and
hydroxy propranolol in the blood after oral administration of the labelled 
drug to man, but no hydroxy propranolol after intravenous dosing. The 
phenol was not found in urine by these workers after either route of 
administration. This was confirmed by Hayes and Cooper (1971) who reported 
very little unchanged drug, and no hydroxy propranolol in the urine of rats 
dogs and monkeys; the phenolic metabolite was observed in blood from dogs 
and monkeys, but only after oral dosing. The explanation advanced for 
this difference in metabolism with route of administration is considered' 
in detail in Chapter 10. Recently, hydroxy propranolol has. been reported 
in the urine of man and dogs receiving propranolol orally, although no 
quantitative data were given (Walle and Gaffney, 1972).
The major metabolic pathway for propranolol appears to be side- 
chain oxidation, with naphthoxy lactic acid accounting for about 20-30$ 
of the urinary excretion in rat, dog, monkey and man (Paterson et al., 1970 
Hayes and Cooper, 1971)* The.major urinary metabolite has not been 
identified. . It is reported to be a weakly basic compound containing the 
propranolol nucleus. Evidence for its basicity is apparently derived only 
from electrophoresis at pHi4«5» Erom the published data (Hayes and Cooper, 
1971) it seems possible that electroendosmotic flow has not been allowed 
for; if this is the case, then the ’weakly basic1 compound could be one or 
more compounds which are not charged at pH<4*5> tut appear to migrate as 
bases due to the net flow of water towards the cathode. Some recent work 
by Walle and Gaffney. (1972) supports this explanation. Using GC/MS the 
propane diol and the 4“hydroxy propane diol, as well as o£-naphthol and 
1:4 dihydroxy naphthalene, have been identified in human urine. These 
compounds would behave as neutral species at pH 4»5» Indeed, Walle and 
Gaffney (l97l) state that the new metabolites "may account for the large 
proportion of the propranolol metabolism hitherto undescribed". This view 
is not shared by Thompson et al., (1972), who believe the unidentified 
urinary metabolite to be a conjugate of "a mixture of propranolol and 
hydroxy propranolol".
Additional metabolites of propranolol found by Walle and 
Gaffney (1972) are hydroxy propranolol (as mentioned above), N-desiso- ; 
propyl propranolol, naphthoxy lactic acid and naphthoxy acetic acid. 
N-dealkylation to give the primary amine is usually regarded as the* first 
step in side-chain degradation, but Walle et al., (1972), using GC/MS, 
have identified isopropylamine as a metabolite of propranolol in the 
dog; deamination is therefore a second pathway leading to the acidic 
metabolites of propranolol.
\
The metabolism of Roche 'B.1 shows marked, species variation, but 
the main metabolite is the carboxylic acid arising from oxidation of the 
6-methyl group. In the dog. and man, side-chain degradation predominates 
over aromatic hydroxylation, but in the rat the hydroxylated metabolite 
is perhaps rather more abundant than products arising from side-chain 
degradation. . -
The compounds discussed so far show a range of metabolic- 
behaviour which can in part be rationalised on the basis of their lipid 
solubility. In Table 1.5 the drugs are arranged in order of calculated 
log P values, together with an approximate indication of the major 
excretory products (conjugates being included with the aglycones). It 
would not be wise to draw detailed conclusions from this Table because the 
log P values are calculated, not measured, and the compounds do not form 
a homologous series so that side-reactions (e.g. O-deallylation in 
oxprenolol, oxidation of methyl in Roche ’B 1) can distort the picture.
In addition, quantitative data are not available in most cases, species 
variations (which undoubtedly occur) have largely been ignored, and 
differences in routes of excretion have not been considered. However, 
as log P increases, there is a trend towards increasing metabolism and.a 
tendency for more side-chain oxidation compared to ring hydroxylation; 
this suggests different sites for the two pathways.
TABLE 1.5
Variations.; in metabolism of beta-receptor active compounds 
with partition coefficient
Compound log P 1
Urinary metabolites
Unchanged
drug
Ring
hydroxylation
Side-chain
degradation
Salbutamol -1.66 -H-t-l-i-
Practolol -1.77 ++++ ■ ‘ '
Terbutaline -1.04 +++++
Oxprenolol 0.17 ++ ++ +
Roche ’A 1 0.21 +++ +
kmolol 0.75 ++ ++
Pronethalol 0.86 +++ ++
Propranolol 1.04 + ++++
Roche ’B 1 1.40 ++ +++
Tolamolol 1.36
Log P calculated using published methods (Tute, 1971) and then log P 1 
calculated for pH 7.4* The relative importance of.the metabolic routes 
is approximate only - see text. Reference number of Roche 'A* not 
known; Roche ’B f is Ro3~3528. Roche ’B' showed marked species 
differences; the major metabolic reaction is oxidation of an aromatic 
methyl group. Log P for tolamolol calculated from measurements made 
on related compounds (Tute, 1972, personal communication).
Aromatic hydroxylation is catalysed by the microsomal enzymes, 
and if deamination of the side-chain is catalysed by monoamine oxidase (MAO) 
a mitochondrial enzyme, there is indeed a difference in site of metabolism. 
Bond and Howe (19^7) showed that side-chain oxidation of pronethalol was 
completely inhibited by a MAO inhibitor; they also found that whole-liver 
homogenates were more active in oxidising the side-chain than the 10,000 g
supernatant, implicating the mitochondria (and hence MO). However, 
although Roche ’B ’ was found to be a good substrate for mitochondrial 
MAO, treatment of rats in vivo with a monoamine oxidase inhibitor had 
little effect on the amount of primary amine excreted, so that enzymes 
other than M O  must be involved in this case (Long and Hornby, 1969).
This conclusion is supported by the work of Tindell et al., (1972) on the 
metabolism of propranolol by 9,000 g supernatant (i.e. microsomal fraction) 
of rat liver. They found the N-desisopropyl compound as a significant 
metabolite. It therefore seems that deamination of the side-chain of these 
compounds can be mediated both by mitochondrial M O  and also by the 
microsomal enzymes. Considering the previous examples of secondary amines 
discussed on pages 23 and 24, it is difficult to predict how important 
N-dealkylation will be for tolamolol, but it will almost certainly occur 
to some extent, as noted earlier.
Of the drugs considered in the above discussion, four have aryl- 
alkyl ether linkages. Only for oxprenolol and propranolol have any phenols 
derived from cleavage of this bond been found. In the absence of 
quantitative data, it is difficult to determine how important this route 
is, but as the phenols have only been observed using the technique of GC/MS 
it is probable that they are minor metabolites. This metabolic route is 
therefore unlikely to be significant for tolamolol.
A drug as complex as tolamolol presents many potential sites for 
metabolic attack, and from a consideration of its calculated log P value 
it is likely to be extensively metabolised (Table 1.5). The preceding 
discussion has indicated the major metabolic pathways likely to be 
followed in vivo, and these are summarised in Scheme 1.2, which also gives 
the names used in referring to the metabolites in the remainder of this 
thesis. Scheme 1.2 also appears as Appendix II, which folds out for ease 
of reference.
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In Scheme 1.2 only Phase I metabolites arising from a single 
metabolic reaction have been considered, although secondary metabolites 
may also occur. Prom the summary of Phase II reactions in section 1.4> 
glucuronide and sulphate conjugates of hydroxy tolamolol and hydroxymethyl 
tolamolol might be expected; a glycine conjugate of tolamolol acid is 
also a possibility. The number of drug-related compounds that could be 
excreted is therefore considerable, and in order to facilitate metabolism 
studies with tolamolol it was decided to label the drug with radioactive 
isotopes. In view of the possibility of chain cleavage, both halves of 
the molecule were labelled, the alpha side with carbon-14 and the beta 
side with tritium (the position of labelling is indicated in section 2.3)• 
It should therefore be possible to establish the origin of any fragments 
arising from N-dealkylation.  ^ *
The results of various studies with tolamolol, many using the 
labelled drug, are described and discussed in the remainder of this thesis. 
Chapters 2 and 3 deal with general methods, and assay procedures, 
respectively; the following six chapters each deal with one particular 
species, and the final chapter summarises, correlates'and discusses the 
results of this work. Studies 'with tolamolol are continuing, and it is 
proposed to include important results from current work, obtained after 
the preparation of the main part of the thesis, as Addenda to the 
appropriate chapters.
TABLE 1.4 .
Structures of some compounds active at beta receptors
These compounds have the general structure
R ' -CH(OH) , CH^HH-R'1
Compound
Salbutamol HOCH,
HO
Practolol 0. CH,
Terbutaline HO
Oxprenolol
Roche ’A'
(no reference 
number)
Bunolol
Pronethalol
O.CH,
Roche 'B* 
(EoJ-3528)
CH.
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2.1 INTRODUCTION
In this chapter is given a description of general methods, 
techniques and materials used during the course of this work. Experimental 
methods applicable to only one section of the work are described in the 
appropriate chapter.
2.2 PROPERTIES OF TOLAMOLOL '
Tolamolol is prepared as the hydrochloride salt, and all doses 
were given with the drug in this form. However, concentrations or dose- 
levels are reported in terms of tolamolol base. In the text, the drug is 
referred to as 1tolamolol’, no distinction -between salt and base being
made unless confusion could occur.
Tolamolol hydrochloride is a white crystalline solid, m.p. 234- 
236° and, as prepared, is a racemic mixture. It is sparingly soluble in
water (0.2$) and methanol (0.4$), and is stable at room temperature for
\
48 hours in methanol solutions 0.1 M with respect to HC1 or NaOH. It. is
also stable (as the solid) on exposure to UV light for 24 hours. The pKa
of the basic nitrogen, determined by UV spectroscopy, is 8.1.
The carbamoyl group of tolamolol is hydrolysed by heating with 
1 M HC1 at 100° for one hour. Using the procedure in section 2.9*3» and 
chromatographing the extract in solvent VI (section 2.5), 65$ 
tolamolol was cleanly hydrolysed to tolamolol acid (quantitating the 
chromatogram by Vitatron, section 2.10).
2.3 PREPARATION OF RADIOACTIVE TOLAMOLOL
Radioactive tolamolol was prepared from jq-cresol, tritiated by 
the TR.l process (Radiochemical Centre, Amersham), and 1-[^cJ-2-chloro-. 
ethanol. The following synthesis was developed, and the labelled drug 
prepared, by hr. J. M. Allison.
,0H
Cl.CH *CHo0H'CH.
epichlor- 
by dr in
tosyl
chloride
Cl.CH *MLO.Tos
COM,‘CH.
OH
>0. CH^CH. CH^M,
’COM,‘CH.
OH' V 
0. CH„CH. OELM. CH*CH0.0
‘CH.
Chemical and radiochemical purity was established by TLC and
11oUV determination of The specific activity of the labelled drug,
determined on May 25, 1970, was:
^H: 27.7 pCi/mg
14C: 3-02 pCi/mg
The radioactive tolamolol was diluted with unlabelled drug as necessary 
to give the required specific activity.
2.4 PREPARATION OF POTENTIAL METABOLITES
2.4.1 Preparation of hydroxy tolamolol. Hydroxy tolamolol is 
4- [2-(3-{4-hydroxy-2-methylphenoxy}-2-hydroxypropylamino)ethoxyjbenzamide 
and was prepared by the Chemical Research Department. The starting material 
for this synthesis was 2-methyl-4-hydroxy acetophenone (i), which was _ 
benzylated, and the ketone converted by Bayer-Villiger oxidation with 
peracetic acid to the acetate ester. Hydrolysis of the ester gave (il).
The remainder of the synthesis was as follows:
HO ICH.
CO. CH.
5 (1)
BzO
OH
CH2
j
(II)
epichlor-
hydrin
BzO
9H Bz
0. ch2ch. ch2h. ch2ch2 .0
COM,2
2
H2/Pt
OH H
0. ch2ch . ch2h . ch2ch2 .0
HO CH. COM,2
Hydroxy tolamolol
Identity of hydroxy tolamolol (prepared as the hydrochloride) was 
established by mass spectroscopy and microanalysis. Although hydroxy
tolamolol appears to be stable as the solid, on chromatograms it.is 
converted, probably by oxidation, to an unidentified yellow material, the 
change taking about 1-2 days. Hydrolysis of hydroxy tolamolol with acid 
as described for tolamolol (section 2.2) gives approximately 54$  conversion 
to a compound whose chromatographic and electrophoretic behaviour, and 
colour reaction with spray reagents (sections 2.5, 2.6) is consistent with 
hydrolysis of the carbamoyl group to carboxylic acid having occurred.*
Hydroxy tolamolol is less potent, but: more selective than tolamolol as a 
beta-blocking agent.
2.4*2 Preparation"of tolamolol acid. Tolamolol acid is 
l-(2- [4-carboxyphenoxy] e thy lamino)-5-(2-me thylphenoxy )propan-2-ol, and was 
prepared by hr. J. Allison from tolamolol by sodium nitrite hydrolysis of 
the carbamoyl group, followed by acidic hydrolysis of the resulting R-nitroso 
acid. Identity and purity were established by mixed m.p. with authentic 
compound prepared in the Chemical Research Department, microanalysis, and 
TLC. Tolamolol acid appears to be stable under normal conditions. It 
has only weak activity as a beta-blocking agent, and shows little selectivity
- v
2.4.5 Preparation of ^-lactic acid. ^-lactic acid is 
£>-(2-methylphenoxy)lactic acid and was prepared by the author from jD-cresol 
by the method of Riley (1950). The white product had an uncorrected melting 
point of 145-6° (literature value I46-I46.50). Microanalysis gave:
C,.61.1; H, 6.15; cpoH12°4 re u^ires c» 61.2; H, 6.1756.
2.4.4 Other compounds. Theo(-amine, 2-(4-carbamoylphenoxy) 
ethylamine, and the ^-amine, l-(2-me thylphenoxy )-5-aminopropan-2-ol, were 
available as standard Pfizer compounds. 4-carbamoylphenoxyacetic acid 
(o(-acid), 4-carboxyphenoxyacetic acid (<X-di-acid), and 2-methylphenoxy- 
acetic acid (f>-acid) were prepared by Dr J. Allison using standard methods.
(Structures of these compounds are given in Appendix II)
* See Addendum, Chapter 7, page 168.
2.5 CHROMATOGRAPHS
Thin layer chromatography (TLC) was carried out using Merck 
pre-prepared plates with layers of either Silica Gel ^ 54 or Cellulose F. 
During the course of this work the specification of the silica gel plates 
was changed, plates to the new specification (with smaller particle size) 
giving better separations than the original plates. A number of solvents 
were used (Table 2.1), most of which were developed specifically for 
tolamolol and its metabolites; typical hRp (Rp x 100) values for some model 
compounds are given in Table 2.2. For the results in this table, silica 
gel plates were used (without activation), although solvent IV was also 
usecL with cellulose plates. In the work which follows, chromatography 
is assumed to be carried out with silica plates, unless cellulose plates 
are specifically mentioned.
The Rj, values in Table 2.2 are only a guide, since Rp values on 
TLC are known to be variable (Dallas, 1965), even when all reasonable 
precautions are taken, such as ensuring saturation of the vapour in the 
developing tank. The technique of co-chromatography was therefore used 
extensively. Samples were usually applied to the origin as streaks or 
bands, and marker compounds applied as bands overlapping the samples being 
chromatographed. Thus any disturbance in the Rp of the compound of 
interest caused by endogenous compounds will also occur to the same extent 
for the marker. If the marker band only half overlaps the sample band 
any difference in Rp value between the compound of interest and the marker 
is readily detected.
Oceansionally, when using solvent III, the developing tank was 
put in a cold room at +4°, and the chromatogram allowed to run overnight. 
Under these conditions the solvent ran almost to the top of the plate (about 
19 cm). Normally, however, solvent run was limited to 10 cm from the 
origin.
TABLE 2.1
Composition of chromatographic solvents
Humber Solvents Proportions
I Bropan-2-ol-ammonia*-water 80:15:5
. II Ethyl acetate-methanol-ammonia 70:25:5
III Butan-l-ol-acetic acid-water .60:15:25
IV Ethyl acetate-acetic acid-vater 60:20:20
v Ethanol-water 80:20
VI Ethyl acetate-methanol-ammonia 80:15:5
VII Ethyl acetate-acetic acid-water 80:15:5
VIII Ethyl acetate-methanol-acetic acid 80:15:5
IX Ethyl acetate-toluene-acetic acid 60:50:10
X Toluene-acetic acid 90:10
XI - Diethyl ether-acetic acid 95:5
*Ammonia in this table refers to ammonia solution, 0.88 g/ml.
TABLE 2.2
Thin layer chromatography of tolamolol and related compounds 
(hRp values in solvents I to XI)
Solvent
Compound I II III IV IV* V VI VII VIII IX X XI
Tolamolol 91 74 64 61 77 57 53 29 13 2 0 0
Hydroxy tolamolol 88 65 61 53 60 56 44 22 ll 2 0 0
Tolamolol acid 64 18 79 80 90 73 5 49 25 8 1 . 0
cC-amine 80 48 38 32 42 8s 32 8 3 1 0 0
0)ieO- 82 59 62 55 68
(11s 
' 58t 43 28 12 4
0 0
o(-acid 53 11 53 61 63 85f 3 . 47 *27 19 1 5
o(-di-acid 21s 1 69 79 86 83f 0 68 44t 43t 9 5
^-acid 63 25 85 98 100 83f 9 93 75 75 34 73
^-lactic acid 64 21 76 87 100 85f 7 75 51 48 6 29
* = cellulose adsorbent
s streaking; t ® tailing; f « compounds ran at second solvent front.
In one or two instances, Whatman 3MM paper was used in a Smith- 
type apparatus with the solvent ascending (Smith, 1969)*
Chromatograms were viewed under TJV light (254 and 3^5 or 
sprayed with one of the following reagents:
(i) Ninhydrin - spray with a solution containing ninhydrin, 300 mg; 
propan-2-ol, 95 nil; glacial acetic acid, 5 'ml; 2,4»6-collidine,
.5"nil. Heat at 120° for 15 minutes.
(ii) Gibb’s reagent - spray with 0.1% 20-dichloro~jD-benzoquinone-4- 
chlorimine in methanol, then expose to ammonia vapour.
(iii) Diazotised £-dianisidine - spray with 0.1% diazotised o_-di- 
anisidine (Koch-Light) in water; expose to ammonia vapour.
All three reagents gave readily visible colours with 0.5 pg of .hydroxy 
tolamolol, chromatographed in solvent VII. Ninhydrin (for amines),gave a 
strong colour almost immediately with primary amines, but secondary amines 
required at least 5 minutes heating before colour developed. Gibb's 
reagent gave blue spots with phenols, while diazotised o-dianisidine, also 
for phenols, gave brown spots.
Gas chromatography (GC) was carried out using Varian chromatographs 
with flame ionisation detectors. The models used were either the 1200/1400 
or the 2100. Details of column packings are given in the text. The 
retention of compounds was defined in terms of a methylene unit number 
(Dalgleish et al., 1966). This was determined by chromatographing a 
mixture of normal alkanes together with the substance under investigation. 
Retention times for the alkanes were plotted against number of methylene 
groups, and by interpolation the compound of interest- assigned a ’methylene 
unit value1, i.e. the number of methylene units required in an alkane to 
give.the same retention time. This figure is reproducible between ‘ 
instruments for a given stationary phase, and is of value in; determining 
operating conditions.
In the early work, electrophoresis was carried out with a 
Shandon low voltage electrophoresis apparatus, operating at constant 
current. In later work, a Camag High Voltage Electrophoresis apparatus 
was used. The operating conditions chosen as standard were 3 kV for 
between 10 and 15 minutes; with paper of size 40 x 5 cm, a current of 
between 40 and 60 mA was obtained using the buffers described below.
Markers of urea, to correct for electroendosmotic flow, and 4-nitrobenzene- 
sulphonic acid, for calculation of relative migration, were used (Valdron- 
Edward, 1965). The buffers'were as follows:
pH 2: NaOAc.^H^O, 13*6 g"dissolved in 1000 ml water; concentrated HC1 
added to give a measured pH of 2.0 (about 9*3 ml required). 
pH 6: NaH^PO^.2^0, 15.6 g, and Ha^HPO^. 12H20, 3*58 81 dissolved in 
1000 ml water. Measured pH. 5-97* 
pH 10: NaHCO^ (anhydrous), 3*80 g, and Ha^CO^ (anhydrous ), 5.86 g, 
dissolved in 1000 ml water. Measured pH 9-97
The buffer pH values were chosen for the following reasons. The
pK of the basic nitrogen of tolamolol is about 8, and the pK of the a a
carboxylic acid function in tolamolol acid will be about 4*5* Therefore, 
considering tolamolol acid, at pH 2 only the basic group will be ionised; 
at pHl6, both groups will be almost completely ionised, and at pH 10, only 
the acidic group will be ionised. Thus tolamolol acid will migrate as a 
base at pH 2, as an acid at pHIlO, but will not migrate tp any significant 
extent at pH 6. Electrophoresis can therefore provide useful information 
about the ionisable groups in compounds of unknown structure.
Note: In the most recent work, a buffer of nominal pH 12 has been used,
prepared by dissolving 3*75 8 KC1 and O.48 g NaOH in 500 ml water.
2.7 MEASUREMENT OF RADIOACTIVITY^
2.7*1 Liquid’ scintillation counting. Liquid scintillation 
counting was provided as a service. Radioactivity was determined using 
a Nuclear Chicago Model 6860 Liquid Scintillation Counter.. Low background 
vials were used except where a high tritium background could be tolerated 
when disposable glass vials were used. The scintillators used were: 
toluene (PPO, 4 81 dimethyl POPOP, 300 mg; toluene, 1,000 ml); phenyl- 
ethylamine (PPO, 5 8\ dimethyl POPOP, 100 mg; methanol, 270 ml; phenyl- 
ethylamine, 270 ml; toluene, 460 ml)(Voeller, 1961); NE 250 (Nuclear 
Enterprises Ltd.), a dioxan-based scintillator for aqueous samples, and 
Instagel (Packard Instrument Ltd.), a scintillator capable of accepting 
large proportions of aqueous solutions. The solubiliser NE 520 (Nuclear 
Enterprises Ltd.) was used as a 10$ solution in toluene scintillator for 
some plasma samples.
2.7*2 Counting of doubly-labelled samples. The average energy 
of the beta spectra of tritium and carbon-14 is sufficiently different to 
allow both isotopes to be determined simultaneously in a single sample.
The gain/channel width settings for the three channels of the scintillation 
counter we re adjusted so that channel A covered the major portion of the 
tritium energy spectrum, with some contribution from carbon-14, and 
channel B the major portion of the carbon-14 spectrum, with some contribution 
from tritium. The third channel was set for the external standard.
Efficiency was determined by the external standard channels 
ratio method. Standards containing known amounts of either tritium or 
carbon-14 were quenched by the addition of varying amounts of chloroform.
For each standard, a counting efficiency (observed count rate divided by 
known disintegration rate) was calculated and correlated with the external 
standard channels ratio. Curves were fitted to these values by computer,
and the curve parameters stored in the computer memory. Thus, in a sample 
containing: tritium and carbon-14, the activity of each isotope could be 
obtained by determining the efficiency for both isotopes in each channel 
from the external standard channels ratio, and solving the following 
simultaneous equations:-
°.p.m.A = EAr V +  Ea c .Bc. (2>1)
c.p.m.B « Eb t .Dt + Eb c.Dc (2.2)
' . ... \
where E^,Egrp are the efficiencies for tritium in channels A and B,
Ea_,E_._ are the efficiencies for carbon-14 in channels A and B,
are the disintegration rates for tritium and carbon-14 
c.p.m.^jC.p.m.g are the observed count rates in channels A and B.
The output from the counter is recorded on punched paper tape so that the 
efficiency can be determined and equations 2.1 and 2.2 solved by computer.
2.7.3 Isotope ratio. The isotope ratio is defined as the ratio
of the specific activities of the two isotopes, i.e.
specific activity of tritium Dm .
Isotope ratio = — ---------------------------  = -2L (2.3)
specific activity of carbon-14 D^
The isotope ratio of any sample can be expressed as a percentage of the 
isotope ratio of the original radioactive drug; if this percentage differs 
from 100$ it indicates a deficiency in one isotope relative to the other, 
as compared to the original drug.
During the course of this work, it became apparent that the 
measured isotope ratio of standard solutions of the drug was varying, over 
quite wide limits from the calculated value. This is shown in Figure 1.
In an effort to obtain more consistent results, with each set of samples 
a standard solution of tolamolol was counted, and the isotope ratio of the 
samples referred to this standard. Ratios obtained in this way are believed
FIGURE 2.1
Variability of isotope ratio
Isotope
ratio fo 
1 1 0 -1
100
Key to scintillators 
O * dioxan
toluene
0 = Instagel
80-—1
N o v
1971
D e c J a n M a yM a r
1972
A p r
P 14 1 H, CJ-tolamolol
is expressed as a percentage of the value calculated from the original 
specific activity, after allowing for tritium decay.
to be more reliable than ratios calculated from the theoretical value. The 
isotope ratio for counting results obtained in the early stages of this 
work, where standards were not used, are therefore subject to errors. In 
the'following tables the method by which isotope ratios were obtained 
(either calculated or measured) is indicated in the legend.
There are a number of potential errors which could contribute to 
the observed variations. The statistical error in counting was minimised 
where possible by choosing aliquots and counting times so that at least 
10,000 counts were collected in each channel (giving a coefficient of 
variation of Vfo or less). Statistical errors are more likely to affect
the carbon-14 results since the specific activity is lower than that of 
tritium. In addition, as quenching increases, the energy spectrum is 
shifted to lower energy levels, resulting in fewer counts in channel B 
(carbon-14 mainly), and increased uncertainty in the calculations for 
isotope separation.
An important source of error is the use of a composite set of 
quench curves for toluene and dioxan scintillators, and Instagel. The 
errors introduced by using the composite curves did not exceed ±. 2$, but 
within a given set of samples, the inter-sample variation would be lower. 
The quench curves were plotted using chemically-quenched samples, and a 
further potential source of error is that biological samples, particularly 
urine, are subject to colour quenching. The colour and chemical quenching 
curves are usually very similar, and some experiments comparing urine, 
plasma and water containing labelled tolamolol showed no significant 
difference in isotope ratio.
Another factor possibly contributing to the variability in 
isotope ratio is that for internal historical reasons the counter channels 
were set up so that tritium and carbon-14 counts were observed in both 
channels. The usual procedure in double-isotope counting is to arrange 
one channel to observe only counts from the isotope of higher energy, i.e. 
Egfp = 0 in equation 2.2, thus reducing the uncertainty in separating the 
isotopes.
Of the possible errors discussed above, the most important is 
almost certainly that due to low carbon-14 counts observed when measuring 
low levels of activity. It is not possible to put an absolute value on the 
error expected in the isotope ratio because so many factors contribute to 
the overall error. However, at best, the error is probably ± yfo, and 
increases with increase in isotope ratio.
2.7.4 Combustion of doubly-labelled samples. A method for 
determining tritium and carbon-14 in solid samples such as freeze-dried 
faeces was required. Although each isotope could be determined separately- 
using standard combustion techniques, a method which enabled both isotopes 
to be determined in one sample was felt to be more satisfactory, and a 
procedure based on the Schoniger oxygen flask (Schoniger, 1955)j was 
developed.
First experiments using aqueous ethanolamine added to the flask 
before combustion were unsatisfactory, giving either low recoveries of 
carbon-14 or, with higher concentrations of base, unacceptably low counting 
efficiencies. The method finally adopted used phenylethylamine scintillator 
(Woeller, 196l) added to the fla^k after combustion, to avoid the risk of 
explosion. This scintillator contains sufficient methanol to take up the 
amount of water produced in a.typical combustion. The procedure is as 
follows.
Between 30 and 40 mg of sample is weighed onto a piece of Whatman 
No. 1 filter paper, cut and folded to form a cup with a wick. The size of 
the paper cup is such that it weighs 110 to 120 mg, so that the total weight 
combusted is about 150 mg. The sample is tightly wrapped in the paper and 
placed, with the wick protruding, in a platinum gauze cup sealed to a B24 
stopper. A 500 ml round-bottomed flask with B24 and B19 necks is used for 
combustions. The B19 neck is fitted with a B19 cone modified to accept a 
size 17 Subaseal. After flushing the flask.with oxygen for 30 seconds the 
sample is ignited and inserted in the B24 neck of the flask. When combustion 
is complete, the flask is partially immersed in an acetone/solid carbon 
dioxide bath for 15 minutes, and then 20 ml of phenylethylamine scintillator 
added through the Subaseal using a glass hypodermic syringe. The flask is 
gently swirled periodically to distribute the scintillator over the walls
of the flask. After 15 minutes the flask is opened and the scintillator 
transferred to a 25 ml volumetric flask. The combustion flask is washed 
with two further portions of scintillator, about 2 ml each time, and the 
washings added to the volumetric flask. The volume is made up to 25 ml 
with scintillator, and two 10 ml aliquots taken for counting.
With the weights and volumes used in this procedure a four-fold
excess of oxygen and a :2.5-fold excess of scintillator are present. The • 
recoveries of tritium and carbon-14 after combustion of filter paper 
containing different amounts of carbamolol are given in Table 2.3. The 
mean recovery for tritium is 102$, standard deviation 4«1$> and the mean 
recovery for carbon-14 is 100$, standard deviation 5.2$. A minimum of 25 
minutes is required for each combustion, and for some samples the Packard 
Sample Oxidiser (Packard Instrument Ltd.) was used to determine tritium
only, as this was a much quicker process.
i ,
TABLE 2.5
Recovery of tritium and carbon-14 after combustion
\
The double-label combustion technique described in section 2.7.4 was used. 
The samples combusted contained between 400 and.800 d.p.m. of'carbon-14 
and between 4?000 and 8,000 d.p.m of tritium.
Combustion
2
$ recovery H $ recovery Isotope ratio
1 99 99 100
2 102 92 110
97 100 97
4 102 99 101
5 104 96 108
6 99 97 100
7 100 102 97
8 109 110 99 .
9 108 103
K\OH
2,7*5 Radioactivity on chromatograms. Radioactivity on 
chromatograms was determined either using a Berthold Desaga Scanner 
(Camlah Ltd.), or by liquid scintillation counting.
The Desaga scanner uses a windowless gas flow detector. The
efficiency of this detector for carbon-14 on thin layer chromatograms is
about 17^ (Wood, 1968); the efficiency for tritium has not been determined
but is much lower and likely to vary with R^ value. The low energy of
tritium beta-particles gives a range in silica of about 2 pm (Evans, 1966),
so that only radiation emitted from tritiated. compounds on the surface of
the adsorbent will be detected. When a TLC plate is removed from the
developing solvent, the solvent can only evaporate from the surface of the
adsorbent, so that while the plate is drying there is a net flow of solvent
from the backing material (usually glass) towards the surface of the
adsorbent. Thus compounds of high R^ , will be transported to the surface
of the layer, whereas compounds of low R^ will remain distributed through-i?
out the layer. The apparent efficiency of detection will therefore be 
expected to vary with Rp, being highest for compounds of Rp « 1.0. The 
counting efficiency for tritium quoted by the manufacturers of the Desaga 
scanner is 0.7 to jfo, but in the author’s opinion these values, particularly 
the upper value, are optimistic. For compounds labelled with tritium and 
carbon-14» the scanner is therefore recording essentially carbon-14 only, 
which in the present work is the isotope of lower specific activity.
For semiquantitative work, peak areas were used (determined by 
cutting out the peak and weighing the paper). The accuracy of these 
measurements will vary with total amount of radioactivity present, the 
scanning speed, and also with the contribution from tritium. This method 
was only used to determine the relative proportions of compounds in a 
chromatogram.
When low levels of radioactivity were involved the scanner could 
not he used, and the distribution of radioactivity was then determined by 
liquid scintillation counting. In this technique the thin layer chromato­
gram was divided into strips 5 mm wide (in the direction of solvent flow); 
each strip was transferred to a counting vial, any solid lumps of adsorbent 
crushed, and toluene scintillator added for counting.. Although this method
is time-consuming and lacks resolution (for a solvent run of 10 cm, 21
samples are counted), it is at least ten times more sensitive for carbon- 
14 than the scanner. Paper chromatograms and pherograms were also measured 
in this way, cutting sections of paper 1 cm square (or less) so that the
paper rested flat on the bottom of the counting vial.
When this method was originally used, the adsorbent was suspended 
in toluene scintillator alone. It was felt that this scintillator, being 
non-polar, would be unlikely to elute the separated compounds from the 
silica gel, so that constant counting conditions (i.e. solid-phase counting) 
would apply over the whole Rp range. With a more polar scintillator, there 
is the possibility of variable elution of the separated compounds according 
to their affinity for the adsorbent. Therefore some samples would be . 
counted as solution samples, while strongly adsorbed compounds would be 
counted as solid-phase samples, with an indeterminate loss of counts due 
to absorption of radiation by the adsorbent.
During the course of this work, two identical chromatograms were 
run, and the effect of scintillator polarity investigated. One chromatogram 
was counted using toluene scintillator alone, the other being counted after 
adding 0.5 ml of methanol to the vial, followed by 10' ml of toluene 
scintillator. This comparison showed that addition of methanol gave a 
substantial increase in count rate over the whole chromatogram, and 
addition of methanol is now the standard procedure. The higher counts are
almost certainly due to elution of the adsorbed radioactive compounds from 
the silica, reducing the losses from absorption of radiation by the 
adsorbent.
The counting efficiencies used in the simultaneous equations for 
isotope separation (section 2.7*2) are determined from external standard 
channels ratio measurements, and only apply to radioactivity present in.-... 
solution. Therefore a further cause for speculation was the effectiveness 
of isotope separation when the doubly-labelled samples are adsorbed onto 
a solid suspended in the scintillator. The importance of this factor was 
determined by chromatographing duplicate samples of [^ H, ^ cj-tolamolol and 
[^c]-tolamolol (this singly-labelled material only became available 
towards the end of this work, and was not used in any other experiment). 
After chromatography the UV absorbing areas were removed for counting; one 
sample .of each duplicate was treated with 0.5 ml of methanol before adding 
scintillator; scintillator only was added to the other samples. Tolamolol 
labelled only with tritium was not available, so in a separate experiment 
a structurally similar compound containing tritium (UK-6060) was chromato- 
graphed. In this case the effect of methanol was not investigated. The 
results of this work are given in Table 2.4.
Hie results for doubly-labelled tolamolol in Table 2.4 clearly 
show the increase in recovery of radioactivity caused by adding methanol; 
the isotope ratio is also much closer to its correct value when methanol 
is used..-.‘When tritium only is present, negligible counts appear for 
carbon-14> so that tritium will cause little interference with the 
determination of carbon-14. However, carbon-14 causes considerable 
interference with the tritium count rate; moreover, the sign as well as the 
magnitude of the spurious tritium counts is changed in the presence of 
methanol. This clearly indicates a difference in counting efficiency
TABLE 2.4
Percentage recovery of label from chromatograms
Samples of [^ H, ^ c]-tolamolol, [^c]-tolamolol and j^ Hl]-tJK-6060 were 
chromatographed on silica. The adsorbent containing the radioactive 
compound was counted either by suspension in toluene scintillator alone 
0 silica1) or after adding 0.5 nil methanol followed by scintillator 
('silica + MeOH’). Identical samples of the radioactive compounds were 
counted directly in solution (’solution’)♦ Results for 'silica' and 'silica 
+ MeOH' are expressed as a percentage of the 'solution' results; isotope 
ratio is also expressed as a.percentage of the 'solution' value.
Sample Isotopes % 5h % 14c Isotope ratio
■solution ?h ,14c 100 100 100
silica 5H,1/rC 25 52 - 49
silica + MeOH 5h ,14c 86 -91 95
solution 14C -13 100 «_
silica
O
H
+37 60 —
silica + MeOH 14c - 4 91 -
solution 5H 100 -0.2 _-
silica 3h 12 -0.1 -
between solution and solid phase counting. For [j^H,^cj -tolamolol the 
specific activity of the tritium label is 8-9 times the specific activity 
of the carbon-14 label, so that a contribution to the tritium count rate 
of, say, 12% of the carbon-14 counts will only represent 1.5% of the tritium * 
counts. Therefore, although some interference between the two isotopes 
will occur, the resulting errors are not likely to be of great importance. * 
Ho attempt was made to determine the effect of varying ratios of tritium 
and carbon-14 on the counting results, as the foregoing work effectively 
validated the technique so far as the present study is concerned.
From the various factors considered above, it is clear that the 
results of chromatograms counted in this way cannot be regarded as 
quantitative. Adding methanol to the silica increases the count rate, but 
if, as suggested by the preceding results, this is due to elution o£ 
radioactive material from the adsorbent, then the magnitude of this effect 
will vary with Rp i.e. strongly adsorbed compounds will be less extensively 
eluted, and will be counted at lower efficiency than compounds of higher 
Rp. Thus for tritium particularly, because absorption losses are more 
important than for carbon-14, variability in elution with Rp will probably 
give increased prominence to high Rp materials, nevertheless, when 
plotting tritium and carbon-14 results for chromatograms, it was found 
that there was no significant difference in position of regions of radio­
activity, except in one or two cases (e.g. the rat, section 5*2.3)*
Therefore, for convenience, chromatograms in the following chapters are 
plotted using tritium values only, and any differences between tritium 
and carbon-14 results noted in the text.
2.7*6 Determination of volatile tritium. If hydroxylation of
the beta ring of tolamolol occurs, tritium will be lost from the molecule 
3
as HgO. This will equilibrate with body water. Therefore the detection 
3
of H^O in body fluids will indicate that hydroxylation has taken place 
(the tritium label in tolamolol is stable - section 3*2.1). Volatile 
tritium was determined using a miniature freeze-drying apparatus made from 
two 10 ml Quickfit flasks connected by standard Quickfit bends (SH l/ll and 
RA 3/11 )• One flask was cooled in an acetone/solid carbon dioxide bath, and 
the other flask, containing the pre-frozen sample, joined to'the apparatus 
and the whole assembly connected to a vacuum pump. When drying was 
finished, the condensate was dissolved in NE 250 scintillator, the volume 
made to 25 ml, and two 10 ml aliquots counted.
2.8 ANIMALS, DOSING AND SAMPLE COLLECTION
The mice used in this work were Charles River CD-I strain; the 
-rats were also from Charles River (Sprague-Dawley derived). Guinea pigs 
were Duncan Hartley strain from A. Tuck and Sons Ltd., Essex. Pregnant 
New Zealand White rabbits, supplied by Kingford Conies, Essex, were 
obtained on the tenth day of pregnancy. Dogs were beagles, bred by Pfizer 
Ltd.' All animals were male., except that in two experiments with mice and 
rats, both male and female animals were used (this is indicated in the 
appropriate tables); the rabbits were, of course, female.
Mice and rats were fed Spillers Small Animal Diet (either in 
powder or compressed form) ad libitum. Guinea pigs and rabbits were given 
Spillers Rabbit Diet ad lib., supplemented inthe case of guinea pigs 
with cabbage leaves and hay (although hay was not allowed when the animals 
were in metabolism cages). The dogs were given Coopers Lab Diet A once 
daily. .
'Oral doses were given to mice, rats and guinea pigs as a 
solution of the drug in water, administered by dosing needle (mice, rats), 
or by stomach tube (guinea pigs). In experiments where rats were dosed 
intraduodenally the drug was dissolved or suspended in 25% Cremophor-El 
(the solubility of tolamolol in aqueous 25% Cremophor-El was between 14 
and 20 mg/ml, compared with about 2 mg/ml for water). Rabbits were given 
tolamolol as a suspension prepared in 25% Cremophor-El, administered by 
dosing needle. For dogs, the drug was administered as a powder in hard 
gelatine capsules.
Intravenous doses were prepared in saline, and administered into 
the tail vein for mice, and the brachial vein for dogs. Intravenous 
dosing in the guinea pig was carried out using an animal with an
'•indwelling catheter in the jugular vein. Four weeks were allowed between 
insertion of the catheter and administration of the drug. The surgery 
was performed by Mr. B. Petch.
Oral (capsule) and intravenous doses for human studies were 
prepared using the formulations developed by Pfizer Ltd. for use in 
clinical trials.
Mice, rats and guinea pigs were housed in all-glass ’Metabowls’ 
(jencons Ltd., Herts.). The Metabowls for mice did not work well, and 
cross-contamination of urine and faeces almost certainly occurred.
Rabbits were kept in stainless steel metabolism cages supplied by Alltype 
Tools Ltd., London. Bogs were housed in stainless steel metabolism cages 
about 0.7 m square, made by Thanet Foundry and Engineering Works, Kent.
Urine and faeces were collected separately. Urine from dogs and 
from man was acidified with glacial acetic acid (0.5$ v/v) and stored at 
-20°; urine from other species was stored at -20° without pre-treatment. 
Faeces from dogs were freeze-dried, and then homogenised in a Culatti 
grinding mill. Faeces from other species, including man, were homogenised 
in water and then freeze-dried. Blood was collected in heparinised 
syringes and then centrifuged to obtain plasma. In one or two cases 
serum was used, the blood being allowed to clot overnight at 4°«
Bile-duct cannulations in rats and one guinea pig were carried 
out under urethane anaesthesia (l.75 g/kg subcutaneously); absorption 
studies in the rat, using the method of Boluisio et al., (1969)5 were also 
carried out under urethane anaesthesia.
2.9 HYDROLYTIC PROCEDURES
2.9.1 Glucuronidase hydrolysis. The following basic procedure 
was used. Urine was adjusted to pH 6-7 (using acetic acid or sodium 
carbonate as appropriate), and 1 ml was diluted with 1 ml of 0.2 M 
phosphate buffer, pH 7*0. About 1 mg (l60 units) of bacterial beta- 
glucuronidase Type I (Sigma Chemical Company) was added, followed by 
one drop of chloroform (to prevent bacterial growth; addition of chloroform 
also increases the activity of the enzyme by a factor of 3 according to 
data supplied by Sigma). The mixture was incubated at 37° for 18 to 24 
hours. An identical preparation, but without the enzyme, was incubated 
at the same time to serve as a control. After incubation the samples 
were freeze-dried, 1 ml of methanol added, and after thorough mixing the 
supernatant used for chromatography.
Slight variations of this procedure were used for bile (100 pi 
of bile diluted with 400 pi of 0.12 M buffer) and for metabolites (which 
were dissolved in 0.1 M buffer). No positive control was used, but from
n
the Chromatograms obtained the enzyme preparation was active.
2.9*2 Sulphatase hydrolysis. Hydrolysis of suspected ’ethereal 
sulphate1 conjugates was carried out using aryl sulphatase Type III from 
limpets (Sigma Chemical Company). A solution of the enzyme was prepared 
by dissolving between 1 and 2 mg in 0.5 ml of 0.2$ NaCl solution. The 
metabolite was dissolved in water; 400 pi of this solution was diluted 
with 500 pi of 0.2 M acetate buffer, pH'5*0, and 100 pi of the enzyme 
solution added. A control solution was prepared in a similar way except 
that 100 pi of 0.2$ NaCl solution was added instead of the enzyme solution. 
Control and enzyme solutions were incubated at 37° for 2 to 3 days, then 
freeze-dried, and the residue taken up in 500 pi of methanol for chromato­
graphy.
Enzyme efficacy was checked each time using a solution ofp>- 
nitrocatechol sulphate (potassium salt)(about 0.4 mg/ml) in place of the 
metabolite solution in the above procedure. This, together with an 
appropriate control, was incubated at 37° for 30 minutes, and then both 
solutions basified with 1 M NaOH. The enzyme-treated solution always 
turned deep red, the control solution remaining pale yellow. No quantitative 
measurements were made, the appearance of colour being taken as evidence 
that the enzyme preparation was active. ' ■ , ' •
2.9*5 Acidic hydrolysis. Urine, 1 ml, or a solution of a 
metabolite, was acidified by adding 100 pi of concentrated HC1. In some 
cases, e.g. for the hydrolysis of tolamolol and hydroxy tolamolol (sections 
'2.2 and 2.4.l)» the solid was treated with 1 M HC1. The acidic solution 
was heated oh-a steam-bath-for one hour, cooled, and brought to pH 6-7 
by adding 1 ml of 1 M NaOH followed by solid NaH^PO^. The solution was 
freeze-dried and the residue extracted with 1 ml of methanol. In some 
hydrolyses the solution after heating was treated with an equivalent of 
solid sodium acetate (140 mg for 1 ml of 1 M HCl) before freeze-drying.
A control solution was prepared and stored at 4° while the test solution 
was being heated. On some occasions, e.g. for hydrolysis of metabolites, 
the control solution was treated with sodium acetate immediately after 
preparation.
2.10 THE VITATROH SCANNER
For quantitation of chromatograms the Vitatron TLD 100 Thin 
-Layer Densitometer (Fisons Instruments, Loughborough) was used. In this 
instrument the chromatogram being studied is made to oscillate in a 
horizontal plane. A photomultiplier detector arranged vertically.above the 
plate is moved linearly in a direction at right angles to the direction of 
oscillation, and measures light emitted from the surface, of the plate either 
by transmission (from a light source below the plate) or fluorescence 
(activated by a mercury light source above the plate, inclined at 45° to 
the vertical). The latter mode of operation was used in these studies. 
Filters are available to provide some degree of wavelength selection for 
•incident and emitted light, so that interference from scattered incident 
light is reduced. The amount of light entering the photomultiplier, and 
hence the sensitivity, can be controlled by altering the size of an aperture
The instrument can be used either to detect fluorescent material 
against a dark background, or to detect a decrease in fluorescence, as when 
fluorescent adsorbents are used for chromatograms of UV-absorbing compounds. 
The detector output is processed electronically and a logarithmic output 
fed to a recorder; a chromatographic spot is recorded as a peak. The 
advantage of the so-called ’flying spot’ principle is that variations in 
spot shape do not affect the quantitative nature of the results.
The recorder trace may be quantitated by measurement of peak 
height or peak area. For low plate loadings (e.g. for tolamolol weights 
below 1 pg), linear calibrations are obtained using peak height measurements 
For heavier loadings, peak area measurements give a more reproducible 
calibration curve, but this is not linear, the slope tending to decrease 
with increase in plate loading.
2.11 ASSAYS FOR RADIOACTIVE TOLAMOLOL AND TOLAMOLOL ACID
The following assays were developed to determine tolamolol and 
tolamolol acid in urine and plasma from man after administration of 
radioactive tolamolol. In fact they we re only applied to urine, as the 
specific activity of the administered drug was too low to give reliable 
results with plasma. The results obtained using these assays are given 
in Chapter 9» The development of assays for unlabelled drug is
\
described in Chapter 3»
2.11.1 Assay for tolamolol. To 5»0 ^1 of urine was added 0.50 
ml of an aqueous solution of tolamolol (unlabelled)containing about 
500 pg of the drug. Anhydrous sodium carbonate, 100 mg, was added, and 
the solution extracted once with 5 ml of hexane, using a rotary mixer.
The hexane, containing lipoidal material, was discarded. The urine was 
extracted three times using 5 ml of ethyl acetate each time, and the 
extracts combined and evaporated to dryness under nitrogen at 40° • The 
residue was dissolved in methanol and chromatographed (TLC) using solvent 
VII. The band due to tolamolol, visible under TJV light, was scraped off, 
eluted with methanol, and rechromatographed in solvent VI. The tolamolol 
band was again scraped off, and eluted with methanol into a counting vial. 
After removal of the solvent under nitrogen, the residue was redissolved 
in 1.0 ml of methanol, and counted after adding 10 ml of Instagel.
Recoveries of tolamolol were obtained by using the above 
procedure with control urine to which had been added a known amount of 
radioactive tolamolol. The average recovery of tolamolol from control 
urine was about 60$, which is comparable to values obtained in other 
experiments using extraction techniques (see section 3*2.6).
2.11.2 Assay -for.tolamolol acid. A solution of unlabelled 
tolamolol acid was prepared containing about 2 mg/ml in 50io aqueous 
methanol. A 250 pi aliquot of this solution was added to 1.0 ml of urine 
and the mixture quantitatively applied as a 160 mm band to two TLC plates. 
The plates were developed overnight at 4° using solvent III. The band 
of tolamolol acid, visible under UV light, was removed from both plates, 
the adsorbent combined and eluted with.methanol. The methanol eluate was 
applied to a single plate, developed in solvent VI, and the metabolite 
band eluted into a counting vial. The solvent was evaporated under - 
nitrogen, and the residue redissolved in 1 ml of methanol. This procedure 
was carried out in duplicate for each sample of urine.
To determine the recovery of tolamolol acid in the above method,
two 2 pi aliquots were taken from the solution in each vial and
/
chromatographed using solvent VI. On the same plate 2 pi aliquots of a 
standard solution of tolamolol acid (prepared by pipetting 250 pi 
aliquots of the unlabelled tolamolol acid solution into counting vials, 
evaporating the solvent, and redissolving in 1.0 ml of methanol) we re 
also chromatographed. After development the plate was scanned using the 
Vitatron scanner, and the percentage recovery of tolamolol acid from 
urine calculated. The solution remaining in the vials after taking the 
aliquots for chromatography was mixed with 10 ml of Instagel and the 
radioactivity determined.
The average recovery of tolamolol acid using this procedure
2 .12 INSTRUMENTS, APPARATUS AND MATERIALS
A Perkin-Elmer-Hitachi MPE-2A fluorimeter was used during the 
assay development; infrared (iR) and ultraviolet (UV) spectra were recorded 
with Perkin Elmer model 257 Unicam SP800 spectrometers' respectively. 
Some early mass spectra were obtained with an AEI MS-12 spectrometer using 
a direct insertion probe (DIP), but the majority of the spectra were 
obtained with an LKB-9000S Gas Chromatograph-Mass Spectrometer.> Gas 
chromatography was carried out using Varian 1200/1400 or 2100 instruments; 
column packings are described, in the text.
The pH of solutions was measured using either a Pye Model 79 
pH meter or a Pye Dynacap pHImeter. ' Ereeze-drying of large samples was 
carried out using an Edwards freeze-dryer; small samples were freeze-
i
dried using a Quickfit all-glass apparatus. An MSE top-drive homogeniser 
was used for homogenising faeces from rodents, and also for homogenising 
sections cut from paper chromatograms. Mixing of solutions was carried 
out using either a vortex mixer (’Whirlimixer ’) for small volumes, or a
s.
variable speed rotating wheel-type mixer (made by Pfizer engineers), this 
being used for extracting solutions during assay procedures. A BTL 
’Bench-top' centrifuge was used where appropriate.
All solvents were General Purpose grade unless otherwise stated; 
when Analytical Reagent grades we re used they are prefixed by ’AR’. 
Chemicals were Analytical Reagent grade when available, otherwise 
Laboratory Reagent grades were used. Sephadex products and Amberlite 
XAD-2 resin were obtained from Pharmacia and BDH respectively. Silica 
gel (’made for chromatography') was obtained from Hopkin and Williams.
All temperatures are expressed in degrees Celsius (°C).
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3.1 INTRODUCTION
One of the first requirements at the start of a programme of 
toxicity testing is a method for determining unchanged drug in body 
fluids. This is required initially to check that the drug is absorbed, 
because although absorption may sometimes be demonstrated if a measurable 
pharmacological effect is produced, the effect may be partly or wholly 
due to a metabolite. In later studies, an assay is required for determining 
the pharmacokinetics of the drug (absorption, distribution, metabolism 
and excretion) in different species, and also for correlating plasma levels 
with pharmacological effect (which may be either toxic or therapeutic). 
During clinical trials also, blood levels should be monitored, particularly 
if there is likely to be an inter-subject variation in response to a given 
dose, such as that observed with propranolol (Shand et al., 1970).
Radioactively-labelled drug can be used for some of these studies, 
but the use of labelled drug in man is not practicable for more than a 
few subjects. Difficulties may also arise if radioactive metabolites 
are present, as then the unchanged drug has to be separated from the 
metabolites prior to determination. An assay for unchanged drug is 
therefore of paramount importance, and the demand for such an assay becomes 
greater the nearer the drug comes to marketing.
The assay for unchanged drug must be sensitive, specific, and 
preferably simple. The first use of an assay should be during acute 
toxicity trials. In these trials, where large doses are used, a high 
sensitivity is not usually required, and a relatively crude assay would 
be acceptable. However, as the compound progresses, doses become lower, 
and there is a constant demand for greater sensitivity in the assay.
The assay must be specific in order to differentiate between 
endogenous compounds and the drug, and between the drug and its metabolites, 
if any. If an assay method can be extended to include metabolites, 
determined separately from the parent compound, the usefulness of the assay 
is considerably increased. Simplicity in the assay is desirable because 
for a successful compound the analyses necessary for a large-scale clinical 
investigation must be carried out in hospital laboratories, some of which 
may not have access to sophisticated equipment.
In the early stages of development of tolamolol, attempts were 
made to develop an assay sensitive to about one part per million (p.p.m.) 
using a ninhydrin assay (Troll and Cannan, 1955)* An ion pair extraction 
method (Brodie jet al., 1947; Gupta, 1970) was also investigated. Initial 
results with these methods were not very encouraging.' Meanwhile, labelled 
material became available and various studies, in particular with the dog 
(Chapter 8), indicated that an assay sensitive to at least 0.01 p.p.m., and 
preferably 0.005 p.p.m. was necessary to correlate plasma levels of drug
with biological effect. The following account describes the work carried
\
out in pursuit of these objectives, starting with the determination of the 
stability of tolamolol in serum.
3.2 METHODS AND RESULTS
3.2.1 STABILITY OF TOLAMOLOL IN SERUM
The Analytical Department of Pfizer Ltd. showed that tolamolol 
was stable for at least 48 hours in 0.1 M HCl/methanol, methanol, and 
0.1 M NaOH/methanol; further studies showed the drug to be stable to 
irradiation by UV light (365 nm) for 24 hours. Stability was monitored 
by TLC in three solvent systems. However, it was also necessary to show 
that tolamolol was stable in serum, since any chemical change occurring 
before a sample of serum was assayed would invalidate the analysis. The 
radioactive drug was used in this work, as a. further objective was to
100 pg/ml) was prepared in saline, and 100 pi of this solution diluted to 
5.0 ml with pooled human serum (mixed serum from several volunteers). The 
final solution was therefore 98$ serum and contained about 2 pg/ml. 
Immediately after preparation 1.0 ml of the serum was freeze-dried as 
described in section 2.7.6 to determine volatile tritium. The remaining 
serum was incubated at 37°. After one day, and again after 12 days, further 
1 ml samples were taken for freeze-drying. The lyophilised 12-day serum 
was extracted with 1 ml of methanol, heating briefly on a steam bath to 
ensure adequate extraction. After centrifugation, 100 pi of the supernatant 
was chromatographed in solvent VI with a marker of tolamolol, and the 
radioactivity on the chromatogram determined by scintillation counting.
fteeze-drying was 0.25$, 0.27$ and 0.26$ at time zero, days 1 and 12 
respectively; the chromatogram showed only one region of radioactivity, 
corresponding exactly to tolamolol. The drug, and the tritium label, are
determine the stability of the tritium .label
A solution of pH,^Cj-tolamolol of known concentration (about
The percentage of tritium recovered in the condensate after
therefore stable in serum at 37° for at least twelve days. In practice, 
serum or plasma was stored at -15° so that problems associated with 
stability of the drug were not anticipated. Serum was used in this and 
other preliminary studies because a supply of pooled human serum was always 
available. During experiments with the drug, however, plasma was prepared. 
No difference in the behaviour or stability of the drug was noted when 
plasma was used. -
\
3.2.2 GAS CHROMATOGRAPHY OF TOLAMOLOL
Considerable effort was expended on the gas chromatography of 
tolamolol, and the results are summarised in Table 3*1
In all the chromatograms where a peak attributable to tolamol'ol 
was present other, minor, peaks were also observed. The derivative showing 
most promise was the silyl derivative using bis-(trimethylsilyl)-acetamide 
(BSA), but the retention time of 25 minutes at 230° gave a broad peak 
unsuitable for use in a sensitive assay. The methylene unit value for this 
peak was 29*9* Using a non-polar stationary phase of 5$ 0V-101, the 
retention time was reduced to 16 minutes at 230°, with a methylene unit 
value of 28.2. However, at least three other peaks were observed, 
apparently related to tolamolol, and probably different derivatives of the 
drug. A variety of reaction conditions with BSA were tried, but in each 
case the extra peaks were present, and the yield of the main peak (referred 
to an internal standard of the C-26 alkane) varied by 15$- The relative 
heights of the minor peaks were not consistent, and so attempts to assay 
tolamolol directly by gas chromatography were discontinued in favour of 
other, potentially more promising, methods.
TABLE 3.1
Gas chromatography of tolamolol and derivatives
Solvent/Reagent Column
Temp.-
Retention 
Time (min)
Comments
Py A 40
Py/HMDS/TMCS (18 hours) A 33 Some tailing
Py/BSA A 33 Peak about 4 times 
higher than with
hmds/tmcs
Py/Ac^O (90°, 1 hour) A 54
DMF/PhBA (reflux 18 hours)~ A 16 Peak due to PhBA; no 
other peak.
Py/BSA (80°, 10 min) B 27
Py/BSA (24 hours) B 25 Peak about 2.7 times 
higher than 
previous peak.
The stationary phase was 5$ F-60/HP Chrom W. The code for column temperature 
is: A = start at 150°, programme at 6°/min to 230°, hold at 230°- 
B =230° isothermal.
For derivatisation, about 1 mg of tolamolol was reacted with the reagent 
in a total volume of 300-500 pi, dependent on the solvent/reagent 
proportions. All reactions were carried out at room temperature unless 
stated otherwise. The following abbreviations are used in the table:
= pyridine; BMP = dimethylf ormamide; HMDS = hexamethyldisilazane;
TICS = trimethyl chi or osilane; BSA = bis-(trimethylsilyl)-acetamide;
Ac^O = acetic anydride; PhBA = phenyl boronic acid.
The reagent proportions were:
Py/HMDS/TMCS: - 200 pi Py + 200 pi HMDS + 100 pi TMCS
Py/BSA:- 200 pi Py + 100 pi BSA
Py/Ac^O:- 300 pi acetonitrile + 100 pi Py + 100 pi Ac^O
DMF/PhBA:- 1.6 mg PhBA + 1.8 rag tolamolol + 500 pi DMF (Anthony et al.« 19&9)
3.2.5 GAS CHROMTQGRAPHY OF TOLAMOLOL ACID AND RELATED COMPOUNDS
In an attempt to obtain a less polar compound for gas 
chromatography, hydrolysis of the carbamoyl group of tolamolol was tried, 
using sodium nitrite. The product was N-nitroso-tolamolol acid. This 
could not be chromatographed on 5^ F-60 or 0V-101 after methylation 
followed by silylation, or silylation alone. Fischer-Speier hydrolysis 
of the nitroso group gave the ethyl ester of tolamolol acid; gas >/•
chromatography of this compound after silylation with BSA gave two peaks 
on a 5i° 0V-101 column, the major peak having a retention time at 230° of 
32 minutes (methylene unit value 30.8).
Although at this stage the hydrolysis of tolamolol to tolamolol 
acijl under assay conditions had not been achieved, if tolamolol acid could 
be satisfactorily determined it was a potential assay method. In addition, 
tolamolol acid was a potential metabolite, and assay methods for metabolites 
can be of value in species comparisons.
The results of work on the gas chromatography of tolamolol acid 
t \ 
under various conditions are summarised in Table 3*2. Under all conditions
tried, at least two peaks were obtained, and eventually this approach
also was discontinued.
TABLE 3.2
Gas chromatography of tolamolol acid derivatives
Solvent/Reagent Column
Temp
Retention 
Time (min)
Comments
DM-Py A 24 Broad, low peak.
Py/HMDS/TMCS (18 hours) A 24 Small peak
DM-Py/HMDS/TMCS (18 hours) A 21 ;22 Double peak
DM-Py/BSA (18 hours) A 21;22;24 Three peaks
DM-Py/HMDS/TMCS (J hour) B 5 Shoulder at 4 min
DM-Py/HMDS/TMCS (2j hours)- B 4;5 Major peak 5 min
DM-Py/HMDS/TMCS (6 hours) B ‘ 4;5 Major peak 5 min
D1'l-Py/HMDS/TMCS (3 days) B 4;5 Peak at 4 min higher 
than peak at 5 min.
The stationary phase was Yfo OY-lOl/Gas-Chrom Q, 100/120 mesh. The code 
. for column temperature is:
A = start at 150°, programme at 4°/min to 240°, hold at 240°.
B =240° isothermal.
For derivatisation, about 1 mg of tolamolol acid was reacted with the 
reagents in a total volume of 300-500 pi, dependent on the solvent/ 
reagent proportions. All reactions were carried out at room temperature 
The following abbreviations are used in the table:
DM = ethereal solution of diazomethane, freshly prepared from ’Diazald*. 
Py = pyridine; HMDS = hexamethyldisilazane; TMCS = trimethylchloro- 
silane; BSA = bis-(trimethylsilyl)-acetamide.
The reagent proportions were:
DM-Py:- tolamolol acid + 100 pi methanol + DM; evaporate solvents under 
nitrogen; dissolve in Py (Dalgleish et al., 1966).
Py/HMDS/TIvlCS:- 200 pi Ty + 200 pi HMDS + 100 pi TMCS.'
DM-Py/HMDS/TMCS:- methylate with DM as above, then silylate Py/HMDS/TMCS. 
DM-Py/BSA:- methylate with DM as above, then add 200 pi Py + 100 pi BSA.
5.2:4 GAS CHROMATOGRAPHY OF FISSION PRODUCTS-OF TOLAMOLOL
In view of the lack of success with gas chromatography of 
tolamolol and related compounds, the possibility of chemical degradation 
of tolamolol to give smaller, more volatile compounds was investigated.
These studies, which included permanganate oxidation and heating with 
hydriodic acid, were not successful, multiple products being obtained.
While this work was in progress, the gas chromatography of possible products 
from the degradation process was investigated.
(a) a-cresol and 4-hydroxybenzamide. A mixture of the two 
phenols was silylated (Py/HMDS/TMCS, footnote, Tables 3*1 and 3.2), and 
chromatographed on 5f° F-60, programming from 60° at 6°/min. The first peak, 
due to jo-cresol, had a retention time of 6 minutes; 4-hydroxybenzamide had 
a retention time of about. 21 minutes, but the major peak was preceded by a 
smaller peak. To assess the possibility of developing an assay for 4- 
hydroxybenzamide, weights of the phenol ranging from 7 to 140 pg were 
silylated as above; an internal standard of the C-18 alkane was included.
The ratio of phenol peak height to internal standard peak height was plotted 
against weight of phenol. The points lay on a curve which, however, did 
not pass through the origin; 14 pg of phenol was only just detectable, and 
7 pg could not be detected. Repeat determinations on some samples showed 
a marked lack of reproducibility. A second experiment using Ry/BSA gave 
similar results. In these experiments, at least one other peak was 
observed in addition to the internal standard and major phenol peak.
M  * -acid and ft-lactic acid. The jr-lactic acid, silylated with 
Py/BSA, chromatographed well on 5i° 0V-101, with a retention, time of 2i min 
minutes (temperature start at 150°, programme at 4°/min). Under the same 
conditions, the <x-acid gave two peaks, retention times 6 and 14 minutes. 
Silylation with Fy/HMDS/TMCS also resulted in two peaks, a tailing peak at 
12 minutes, with a major peak at 14 minutes.
5.2.5 DERIVATISATIOF OF TOLAMOLOL WITH LANSYL CHLORIDE
Many compound types can be derivatised with dansyl chloride 
(1-dime thylaminonaphthalene-1-sulphonyl chloride), and the resulting 
fluorescent compound analysed (Seiler, 1970). Kaul et al.t (l970)« have 
used dansyl chloride to assay chlorpromazine and its metabolites, reportedly 
at high sensitivity, although this is difficult to judge from their paper. 
Prei and Lawrence (1971) claimed that less than 1 ng of dansyl derivatives 
of carbamate pesticides could be analysed; Penzes and Oertel (1970) could 
detect 5 ng of steroid dansyl derivatives. The method therefore appeared 
to have the necessary sensitivity, and so was investigated for its 
applicability to tolamolol. A great deal of work was carried out, and 
the following is a summary of that work.
(a) Use of fluorimeter. Some preliminary work showed that at 
least a five-fold excess of dansyl chloride was required for optimum yield 
of derivative, and therefore TLC was necessary to separate the derivative 
from unreacted reagent. The following general procedure was used to 
investigate factors affecting the linearity and reproducibility of the 
method.
Equal volumes of a solution of tolamolol (2.5 mg in 10 ml of 
acetone/0.1 M MaHCO^, 25:75 v/v) and dansyl chloride (5 mg in 5 ml acetone) 
were mixed and allowed to stand at room temperature overnight. Aliquots of 
this solution were applied to a TLC plate prepared from Merck non- 
fluorescent silica gel (nominal layer thickness 250 pm), and developed in 
toluene/acetone/acetic acid (65:50:5)* After drying, the spots of dansyl 
tolamolol were located under UV light, quantitatively transferred to 10 ml 
stoppered tubes, and 5*0 ml methanol added. After mixing, the contents 
were allowed to settle for one horn?, and the fluorescence measured 
in a 10 mm cell at = 550 nm, X^. = 550 nm. After preparation of the
derivatising solution (i.e. tolamolol and dansyl chloride), all operations 
were carried out under safelight conditions in view of the reported light 
sensitivity of the products (Seiler, 1970; Lawrence and Frei, 1972).
A calibration curve using derivative equivalent to 2.4 to 19 pg 
of tolamolol was approximately linear, but intersected the abscissa at a 
point equivalent to about 2 pg of tolamolol. The reproducibility was 
checked by running two plates, each containing eight identical samples; 
a coefficient of variation of 40$ was obtained. This lack of reproducibility 
was almost certainly due to degradation of the spots on the plate, as the 
fluorescence of the spots visibly diminished during the time the plates' 
were drying. • . ( .
(b) Use of cellulose TLC plates and the Vitatron scanner. In an 
attempt to increase the ease of elution of dansyl tolamolol from the 
chromatogram, the use of Merck pre-prepared non-fluorescent cellulose 
plates was investigated. It appeared from this work that dansyl tolamolol 
was more stable on cellulose than on the hand-prepared silica plates. The
stability of the separated dansyl derivatives was increased still further
\
by spraying the plate with triethanolamine/propan-2-ol (20:80) (Seiler and 
Wiechmann, 1966; Frei and Lawrence, 1972). With the improved stability of 
the derivative it was possible to use the Vitatron, operating in the 
fluorescence detection mode, to measure the fluorescence in situ. A 
preliminary test showed that the peak height obtained from a spot of 
dansyl tolamolol, scanned eleven times, decreased by only about 0.6fo for 
each scan. The linearity of the method was assessed by applying different 
volumes of a solution of dansyl tolamolol to a cellulose plate, developing 
in toluene/acetic acid/water (70:20:10, upper phase), spraying with the 
triethanolamine reagent, and scanning. A linear calibration was obtained 
over the range 125-1000 ng tolamolol, plotting peak height against 
concentration.
A further test of linearity was made, using conditions closer to 
those likely to be encountered in an assay procedure. Aliquots of a 
methanol solution of tolamolol base corresponding to 50 to 500 ng were 
evaporated to dryness in conical centrifuge tubes, and 50 pi of an acetone 
solution of dansyl chloride (1.5 mg in 10 ml) added. The molar ratio of 
dansyl chloride to tolamolol was therefore at least 15. After gentle 
shaking to ensure solution of the drug, 25 pi of 0.1 M Na^CO^ was added. 
After hours at room temperature, the solutions were evaporated to dryness 
under a stream of nitrogen, and the residue transferred to a TLC plate 
using two 50 pi portions of methylene chloride. Unfortunately the 
derivative spots tailed badly during chromatography, and the plate was 
therefore not scanned.
Using the above procedure, the effect of different buffer
solutions (0.1 M NaHCO^, 0.1 M Ife^ CO^ , and 0.01 M HaOH, incubating at 57° 
for 2 hours) and the effect of temperature (4°» 22° and 57° for 2 hours,
using 0.1 M Na^CO^ for pH control) was determined. Temperature had little
effect, but the yield of derivative was affected by the buffer salt,
increasing in the order NagCO^, NaHCO^, UaOH. In these chromatograms also
the derivative spots tailed badly, so the chromatograms were assessed
visually.
A similar procedure was used to determine the effect of 
incubation time on derivative formation, using 0.01 M NaOH and incubating 
at 57° • The quality of the chromatogram was sufficient to allow the scanner 
to be used, and no significant difference over the range 1 to 7 hours was 
found, although there was some scatter of results.
The reproducibility of the method was assessed by preparing five 
tubes as above (using 0.01 M UaOH, incubating at 57° for 5 hours) and 
chromatographing. On the basis of peak heights the coefficient of
variation was Q%. In both this experiment and the previous experiment 
the chromatogram scans showed a second peak which ds probably an artefact 
caused by a combination of solvent demixion (giving a second solvent front) 
and a tailing spot of the dansyl derivative. The sensitivity and accuracy 
of this method depends critically on the developing solvent, and although 
eleven other solvents were tried, none was superior to that used above 
(toluene/acetic acid/water, 70:20:10, upper phase). Unfortunately, even 
this solvent often gave chromatograms that were too poor to scan.
(c) Use of silica TLC plates with the Vitatron scanner. The
improvement in stability of the chromatographed derivative obtained by
spraying with triethanolamine, together with the availability of Merck
pre-prepared non-fluorescent silica plates, suggested a re-examination
of silica as an adsorbent. The stabilising effect of the triethanolamine
spray was confirmed, and a calibration curve for the range 50-500 of
tolamolol was attempted. The procedure described in section (b) above was
' 0
used, with 0;01 M UaOH as the buffer. The chromatogram was developed in 
toluene/acetone/acetic acid (65:50:5) and scanned. The 50 ng spot was 
visible as a shoulder on the side of a large interfering peak, due to 
excess reagent. This had not been observed in the earlier work with this 
solvent, described in section (a), because then the molar ratio of dansyl 
chloride to tolamolol was only about 6, compared to about 250 for this 
experiment. The reagent peak did not interfere when toluene/ethyl acetate/ 
acetic acid (65:50:5) was used as the solvent. v
An attempted calibration curve gave poor sensitivity, with a 
lower detection limit of 100 ng, but in this case the derivatising solution 
was allowed 'to stand for a weekend before evaporating for chromatography. 
When this calibration check was repeated, comparing 0.1 M NaHCO^ and 0.01 M 
UaOH as buffers, keeping the derivatising solutions overnight, the
bicarbonate buffer gave peaks for dansyl tolamolol about 10 times higher 
than those obtained from the NaOH solutions. Although this apparently 
contradicts earlier work, the explanation is almost certainly that the 
dansyl derivative is formed and hydrolysed relatively rapidly in the more 
basic solution. In subsequent work, therefore, overnight incubation with 
bicarbonate was used for derivatisation.
: i
A test of this new procedure showed 55 ng to be readily detectable 
visually, but the chromatogram was left overnight before scanning,. and the 
spots faded giving a poor scan. A further problem appeared during this 
work at high sensitivity, namely, the presence of highly fluorescent bands 
at high Rp resulting in a pronounced fluorescent tail which caused a 
steeply sloping background on the recorder trace. In an attempt to overcome 
the problem of fading spots, a chromatographic solvent containing ammonia 
was developed; this solvent (ethyl acetate/methanol/ammonia, 95•2.5*2.5) 
reduced the fluorescent tail, and also made it possible to spray the 
developed plate with triethanolamine as soon as the plate was removed from 
the tank.
\
Under assay conditions, tolamolol would be extracted from basic
solution into ethyl acetate, and for further development the following
procedure, based on the work described above, was followed:
Evaporate the extract containing tolamolol to dryness in a conical 
centrifuge tube, under a stream of nitrogen, washing the sides of the tube 
with methanol and evaporating to concentrate the drug, in the bottom of 
the tube. All subsequent operations should be carried out in subdued 
light so far as possible. Add 50 pi dansyl chloride solution (200 pg/ml 
in acetone) and 50 pi of acetone/aquous 0.1 M NaHCO^ (25:75 v/v).- Stopper 
and allow to stand at room temperature overnight. Evaporate to dryness 
under nitrogen, and add 50 pi of methylene chloride. Allow to stand for 
one hour, and transfer the solvent as completely as possible to a Merck 
non-fluorescent silica TLC plate. Rinse the tube and residue with a 
further 50 pi of methylene chloride, and transfer to the TLC plate.
Develop in ethyl acetate/methanol/ammonia (95*2.5*2.5)> and as soon as 
the plate is removed from the tank, spray well with triethanolamime/ 
propan-2-ol (20:80). Allow to dry, and scan in the direction of 
development using the Vitatron, with filters ’DVB’ and 'U5'. Plot 
peak area against concentration. *"
This procedure was tested, with the results shown in Figure 3.1» which
shows that 12 ng is detectable. At this stage the assay was given to the
Analytical Section for final development.
- FIGURE 5.1
Test of proposed assay for tolamolol by formation of dansyl derivative
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Procedure described in section 3.2.5(c) was followed, except 
that a methanol solution of tolamolol hydrochloride was used 
instead of an ethyl acetate solution of tolamolol base. 
Duplicate samples were not run.
3.2.6 VITATRON PMSITOMETRIC ASSAY FOR TOLAMOLOL
As a means of investigating methods of extraction, a densitometric 
assay for tolamolol on TLC plates was developed. This investigation was 
intended as a preliminary study prior to final development using the 
dansyl assay.
A test of the linearity of the densitometric assay was made by 
chromatographing known amounts of tolamolol in the range 0.1-1.4 pg using 
solvent VI. After scanning with the Vitatron, a plot of peak height against 
concentration gave a straight line, passing through the origin. The 
sensitivity of this assay was therefore adequate for preliminary work.
The general procedure used in this study was as follows.
An aqueous solution of tolamolol (l ml) was basified by the 
addition of 1 ml of an alkaline solution, usually 0.1 M Fa^CO^, and extracted 
for 15 minutes on a rotary shaker with 5 nil of solvent. An aliquot of the 
Extraction solvent’ (4 ml) was transferred to a conical tube and evaporated 
to dryness under nitrogen. The walls of the tube were washed with 30 
drops of a 'rinsing solvent1, and the solvent evaporated to dryness. The 
residue in the tube was transferred to the plate by adding 50 pi of 
’transfer solvent', applying this solution to the plate as a single spot, 
then adding a further 50 pi to the tube, mixing on a vortex mixer, and 
applying this to the plate. After drying, the plate was chromatographed 
and scanned. ' ,
The first extraction solvents-tried were hexane, toluene, 
ethylene dichloride and chloroform, using methylene chloride as transfer 
solvent. The concentration of the aqueous solution was about 0.5 pg/ml.
The results of this work were difficult -to assess. Hexane and toluene, 
extracted nothing, while chloroform extracted more TJV-absorbing material 
than ethylene dichloride. However, the material extracted by. chloroform
was not tolamolol, as judged by Rp value. The nature of this material 
is unknown, but further experiments showed that it is derived from tolamolol 
only appears when halogenated solvents are used, and becomes less important 
as the concentration of drug in the aqueous phase is increased. A further 
solvent tried as extraction and transfer solvent was isopropyl ether, 
redistilled before use. This did not produce any extra spots, but the 
extraction efficiency was low (about 8$). Ethyl acetate gave better, 
although variable recoveries (range 40-80$). The recovery showed a tendency 
to increase with increase in concentration of tolamolol.
In an attempt to increase the recovery of tolamolol, methanol, 
either alone or mixed with ethyl acetate or isopropyl ether, was tried as 
wash and transfer solvent. During the course of this work, which showed 
methanol and methanol mixtures to be superior to ethyl acetate alone, a 
UV-absorbing spot appeared in addition to tolamolol, but different to that 
found with halogenated solvents. This spot was found to be associated with 
the use of ethyl acetate, but the addition of a trace of concentrated HC1 
to the ethyl acetate extract before evaporation reduced the amount of 
unidentified spot, with an increase in overall recovery. In one experiment, 
six identical extractions with ethyl acetate were carried out, and to 
three tubes 50 pi of* concentrated HC1 was added before evaporation. The 
mean recovery was 60$ without acid, and 74$ with acid added. To reduce 
exposure of extracted material to ethyl acetate so far as possible, 
methanol/isopropyl ether (50:50) was used as transfer solvent.
This technique showed promise-as an assay for tolamolol, although 
it was not developed for that purpose. As difficulties were being 
encountered in the dansyl assay, the potential of the Vitatron method for 
determining tolamolol in serum was investigated. A preliminary test showed 
that a cleaner chromatogram was obtained if the serum was first extracted
with hexane. In the light of previous work, the following assay procedure
f  '
was proposed as a basis for further study:
Extract 1.0 ml of serum with 5«0 nil of hexane for 5 minutes using a
rotary mixer. Remove and discard 4*0 ml of the hexane layer, add a 
further 5*0 ml of hexane and again mix for 5 minutes. Remove and
discard 5*0 ml of the hexane. Add 5*0 ml of ethyl acetate and 1 ml of
0.1 M FagCO^ solution; mix for 15 minutes. Pipette 5*0 ml of the upper 
phase into a conical centrifuge tube, and add 2 drops of concentrated 
HC1 as soon as possible. Evaporate to dryness under nitrogen. Rinse, 
the side of the tube tv/ice with 30 drops of methanol, evaporating under 
nitrogen between each rinse. Add 50 pi of methanol/isopropyl ether 
(50:50) to the residue, and transfer to a Merck silica gel TLC plate. 
Add a further 50 pi of transfer solvent, mix on a vortex mixer and 
transfer to the plate, keeping the spot of applied material to a 
diameter of 5-6 mm. Develop the plate in Solvent VI (EtOAc/MeOH/FH^> 
80:15:5)> dry, and scan the chromatogram with the Vitatron scanner in 
the direction of solvent flow.
The results of five experiments to determine the recovery of tolamolol
from serum and plasma are summarised in Table 3*3.
This assay procedure enabled concentrations of tolamolol of at 
least 0.2 pg/ml to be determined. The extraction efficiency of tolamolol 
from plasma was low and tended to vary (Table 3*3)• In use, therefore, 
samples of control plasma containing known amounts of tolamolol were 
extracted simultaneously with the plasma being assayed. All extracts were 
chromatographed on the same TLC plate (to eliminate inter-plate variations), 
and the unknown concentration determined from the standards.
TABLE 5.3
Percentage recovery of tolamolol from human serum or plasm
Serum or plasma was prepared containing different concentrations of tolamolol 
and extracted using the procedure described in section 3*2.6. On the same 
TLC plate were run four standards of 1,2,4 and 6 pg of tolamolol to give 
a calibration curve. C.Y.fo stands for the coefficient of variation.
Serum samples were chromatographed using solvent VI (EtOAc/MeOH/KH^, 80:15:5) 
and plasma samples were chromatographed'in solvent VII (EtOAc/AcOH/HgO,
80:15:5)*
Concentration
(pg/ml) C.V.$0.5 l.o 2.0 Mean
Serum
Plasma
Plasma
Plasma
Mean
Q.Y.fo 12
Overall mean 4^.7^ (C.V. 15f°)
■3.5 BISCUSSIOII
When the analytical work started, a detection limit of about 
1 jug/ml was considered suitable for monitoring the toxicity trials, and 
therefore colorimetric procedures were investigated. Preliminary studies 
with the ninhydrin assay were not very promising, and attention was directed 
to the potentially more sensitive ion-pair extraction technique. Although 
the sensitivity using a dye as counter ion is not very high, using a 
fluorescent anion sensitivities in the ng/ml range should be possible 
(Borg and Westerlund, 1970)* However, initial experiments using bromo- 
thymol blue as the counter ion proved unsatisfactory because tolamolol was 
poorly extracted by solvents suitable for extracting the ion-pair. By 
this time it was becoming apparent from other work that * tolamolol was 
extensively metabolised, and that an assay for the unchanged drug would 
not only need to be sensitive, but also specific. Both the ninhydrin 
assay and ion-pair extraction are inherently non-specific, and so work 
on these methods was discontinued.
Gas chromatography has the advantages of specificity, by virtue 
of the chromatographic process, and high sensitivity, particularly if an 
electron capture detector can be used. In the course of earlier work, not 
reported here, a gas chromatographic assay was developed for a compound 
which differed from tolamolol only in having a 2-methoxy instead of a 
4-carbamoyl substituent in the alpha ring (UK-394* Appendix I). It was 
expected that a similar assay would be suitable for tolamolol. Y/hen 
difficulties were experienced in the gas chromatography of tolamolol, 
therefore, they were thought to be due to the presence of the carbamoyl 
group. Attempts to modify this group by hydrolysis to the acid were not 
entirely successful, although not much work was carried out on this aspect 
because authentic tolamolol acid also proved difficult to chromatograph.
Attention was therefore directed towards methods for chemical degradation 
of the molecule to give simpler compounds more amenable to gas 
chromatography.
Any chemical modification'to the drug is a potential source of 
non-specificity in the assay, and in the case of tolamolol, fission of the 
alkyl chain would result in a very considerable loss in specificity.
However, if the fragments containing each aromatic ring were assayed 
separately, their molar ratio would yield some information about possible 
sites of metabolic attack. In fact, although compounds derived from the 
beta side of the molecule chromatographed well, fragments derived from the 
alpha side gave unsatisfactory chromatograms.
Two possible explanations can be advanced for'the appearance of 
multiple peaks during gas chromatography with this series of compounds. 
First, there is the possibility of multiple derivative formation, since 
secondary amines and alcohols, and amides, can all be silylated under 
certain conditions (Pierce, 1968). A second possibility is thermal 
decomposition. The comparatively low volatility of these compounds makes 
a high column temperature necessary in order to get a reasonable retention 
time, and at the temperatures used (230°-250°) a certain amount of thermal 
decomposition is probably to be expected. At the time this work was 
carried out, GC/MS facilities were not available so that it was not possible 
to determine whether one or other of these alternatives was correct. In 
any case, even at these temperatures, the retention time was sufficiently 
long for the emergent peaks to be broad", with a consequent loss in peak 
height and, therefore, sensitivity.
As the toxicity and clinical trials of tolamolol progressed, so 
the sensitivity demanded of the assay became greater, with determinations 
at levels of 0.005 p.p.m. being required. Apart from electron capture
gas chromatography, the only other methods available for sensitivities of 
this order are fluorescence, radioactive derivative formation (Hammer and 
Brodie, 1967; Kuntzman et al., 1967; Efron et'al., 1971) and the integrated 
'ion current technique of mass spectroscopy (Sweeley .et.al., 1966; Boulton 
and Majer, 1970). Eluorimetry was chosen for further investigation as being 
that method most suitable for routine work.
Derivatisation with dansyl chloride appeared to offer both 
sensitivity and, because of the chromatographic stage, specificity. After 
considerable work, a tentative assay procedure was developed which appeared 
to have reasonable sensitivity. However, the analytical group assigned to 
further develop this procedure were unable to repeat the results shown in 
Figure 3*1» and an attempt by the author to repeat the work was also 
unsatisfactory (perhaps because the assay was .carried out with one of the 
analytical group watching). The lack of reliability is due to instability 
of dansyl tolamolol after chromatography, since the derivative is stable 
for many weeks in solution. This suggests that the stability of- the 
derivative is influenced by the exposed surface area of the derivative, and . 
the surface area of a compound is considerable when it is present as a 
developed spot on a chromatogram. Spraying with triethanolamine probably 
stabilises the spot either by physically covering the derivative, or, more 
likely, by eluting the derivative and forming a solution (Frei and Lawrence, 
1972). Either process would reduce the effective exposed surface area of 
the derivative. Although potentially very sensitive, therefore, this assay 
requires more development before its full sensitivity can be realised.
The extraction of compounds is a common ’clean-up' step in many 
assay procedures. The solvent should be as non-polar as possible, 
consistent with efficient extraction, so that interference from endogenous 
compounds is reduced to a minimum. Tolamolol is not very soluble in non-
polar solvents such as toluene, but appears to be relatively soluble (as 
the base) in some halogenated solvents, including chloroform. Unfortunately, 
at the concentrations employed in this study, there was some interaction 
between solvent and solute, giving rise to an extra spot on the chromatogram; 
these solvents were therefore not investigated further. Of the non- 
halogenated solvents, only ethyl acetate gave a reasonable extraction 
efficiency, but even with ethyl acetate, more than one spot was obtained.
One of the problems associated with developing assays at the low levels
\
attempted in this work is that a small degree of, for example, oxidation, 
will affect proportionately more of a.compound present in nanogram 
quantities than the same compound present in milligram quantities. It is 
possible that tolamolol base has limited stability, particularly when 
evaporation of the extraction solvent distributes the compound'over a - 
large surface area. If the hydrochloride salt is more stable than the base, 
this would explain the higher recovery observed when conversion to the 
salt is included as a step in the assay.
Despite all the effort expended on this work, which lasted for 
nearly two years, the only satisfactory assay for tolamolol is the 
densitometric assay described in section 3-2.6. Although time-consuming, 
it is now being used, with minor changes (transfer, solvent methanol, TLC 
solvent chloroform/methanol/ammonia, 80:10:1) for assaying plasma samples 
on a semi-routine basis. Recoveries tend to be variable, and a calibration 
curve is prepared for each experiment by taking serum or plasma containing 
known amounts of tolamolol through the entire extraction procedure.
For the future, the most promising new approach appears to be 
liquid chromatography, although preliminary results suggest that an 
extensive clean-up procedure is needed before applying the drug-containing 
extract to the column.
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4.1 INTRODUCTION
Toxicity trials of potential drugs are always carried out in 
at least one rodent species, usually either mice or rats, or sometimes 
both. This is because the small size and cheapness of these species 
allows the use of a statistically significant number-of animals.
Mice are not often used for long-term toxicity trials because 
their life-span is comparatively short, and they show a natural incidence 
of spontaneous tumours. However, the first beta-blocking drug to undergo 
extensive clinical investigation, pronethalol,.was shown during toxicity 
trials to be a moderate carcinogen in mice, although in rats, guinea pigs 
and dogs there was no evidence of carcinogenicity (Paget, 19^5? Howe, 1-965) 
The nature of the proximate carcinogen has not been established (Bond and 
Howe, 1967), and therefore any drug structurally related to pronethalol, 
such as other beta-blocking drugs, could also have carcinogenic potential. 
As.the carcinogenic action of pronethalol is species specific, the only 
way to demonstrate the absence of a similar activity in a new beta- 
blocking drug is to carry out toxicity trials in mice; this species was 
therefore used for the toxicity trials of tolamolol.
Mice on the sub-acute toxicity trials received tolamolol as a 
component of the diet. In support of these trials an experiment was 
carried out to determine whether the drug was absorbed when administered 
in this way. In addition, studies on blood level, tissue distribution 
and excretion we re carried out, and metabolite patterns determined. The 
results of these studies are presented in this chapter.
4.2 METHODS AUD RESULTS
4.2.1 BLOOD-LEVEL ADD TISSUE DISTRIBUTION STUDIES
Eighteen mice were dosed intravenously by way of the tail vein 
with a solution of radioactive tolamolol in saline, using a dose-level 
of 2 mg/kg. The mice were killed in groups of three at intervals up to 
24 hours, exsanguinated, and the major organs removed. Radioactivity in 
blood and freeze-dried tissues was determined by combustion, and in 
plasma by solubilisation (toluene scintillat.or/5/^  NE5.20) and combustion. 
Samples of plasma were also freeze-dried for determination of volatile’ 
tritium.
The results for radioactivity in tissues are plotted in Figure 
4.1. The observed counts were low, particularly for carbon-14, and there 
was some scatter in the results. For all tissues the levels of radioactivity 
at 24 hours were too low to be reliably measured. The isotope ratio 
was close to the calculated, value for all tissues except the brain, which 
appeared to have a higher proportion of carbon-14 than expected.
Figure 4«1 shows that the kidney, lung and liver contain a 
higher concentration of radioactivity than the blood, while the ......
concentration in brain is less than that in blood. The high concentration 
of radioactivity in kidney and liver is not unexpected in view of their 
role as excretory organs, but the high levels of radioactivity in the 
lung, about six times the blood concentration, was not anticipated.
There is therefore some drug localisation in the lung.
FIGURE 4.1
Variation of tissue radioactivity with time in mice 
dosed with radioactive tolamolol
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Mice were dosed3 with radioactive tolamolol at 2 mg/kg i.v. Three were 
killed at each time interval, and the individual organs combined. The 
concentration of radioactivity is expressed as parts of tolamolol base 
per million, i.e. , jxg/ml or pg/g. The experimental points are the mean 
of tritium and carbon-14 results.
Radioactivity in the plasma was determined by solubilisation, 
which measures all radioactivity, and by combustion, which only measures 
the non-volatile radioactivity (aliquots of plasma were allowed to dry on 
filter paper which was then combusted). Volatile tritium (almost ~ 
certainly ^H^O) was determined by freeze-drying. The results are given in 
Table 4.1. At the dose-level used in this experiment, which gives a good 
level of beta blockade, the concentration of radioactivity is low and falls 
rapidly, although the proportion of volatile tritium increases with time.
An assay for unchanged drug would therefore need to be sensitive to at 
least 50 ng/ml to give useful results under these conditions, even 
assuming all the radioactivity to be due to tolamolol.
% *
TABLE 4.1
Radioactivity in plasma from mice dosed with
radioactive tolamolol
Mice were dosed intravenously with tolamolol at a dose-level of 2 mg/kg. 
Concentrations are expressed as jig equivalents of tolamolol base per ml 
of plasma. The isotope ratio is calculated (section 2.7.3). Volatile 
tritium is expressed as a percentage of the tritium value determined . 
by combustion. ^
Time 
(hours )
Solubilisation Combustion Volatile 
3H (/»)5r Ratio V 14c Ratio
1 0.49 0.38 130 0.41 0.38 105 14
2 0.24 0.17 140 - - - -
3 0.16 0.09 180 0.08 0.09 85 35
5 0.15 0.06 240 - - - 54
7 0.12 0.03 400 0.03 ■O'. 04 75 64
24 0.08 - - - - - 78
4.2.2 EXCRETION OF RADIOACTIVITY
The excretion of radioactivity hy mice was determined in three 
experiments. In the first experiment a group of six mice was. dosed intra 
venously at 2 mg/kg, and urine and faeces collected for 24 hours. About 
one hour prior to urinecollection the mice were given a ’loading dose' 
of water to ensure adequate urine excretion. The urine from all animals 
was combined, volatile tritium determined, and the freeze-dried urine 
extracted with methanol for chromatography (section 4«2.4)« Faeces from 
all animals were also combined and homogenised in water. Part of the 
homogenate was centrifuged and an aliquot of the^supernatant freeze-dried 
for determination of volatile tritium. The remainder of the suspension
was returned to the bulk for freeze-drying.
In a second experiment, five mice were dosed orally at 50 mg/kg 
using a suspension of the drug in 25$ Cremophor-El, and collecting urine 
and faeces for two days. A third experiment used four mice dosed orally 
at 20 mg/kg with a solution of the drug in 33$ PEG-200/water; excreta were 
collected for three days. ^
The results of these experiments, together with the results of 
the drug absorption study (next section) are given in Table 4*2. From 
this table it is clear that the major route for excretion of radioactivity 
after both oral and intravenous dosing is the faeces. This suggests that 
extensive biliary excretion can occur, and therefore the low urinary 
excretion of radioactivity after oral dosing need not be due to poor 
absorption. In the first experiment, the percentage of the dose recovered 
from urine and faeces as volatile tritium was 0.48$ and 0.22$ respectively 
When expressed as a percentage of the excreted activity the figures are 
1.6$ and 0.47$» so that urine is the more important route for excretion 
of volatile tritium.
TABLE 4.2
Excretion of radioactivity by mice after administration of
radioactive tolamolol
Mice were dosed with radioactive tolamolol at the dose-levels indicated. 
Urine and faeces samples in each experiment were pooled for determination 
of radioactivity. Results are expressed as percentage of the dose; 
values are the mean of tritium and carbon-14 results except when only 
tritium was determined, i.e. faeces in 10 mg/kg experiment, and urine and 
faeces for the 240 mg/kg experiment. Total excretion for the 10 mg/kg 
experiment is based on tritium results. Isotope ratio calculated (2.7*3) 
for 2mg/kg and 50 mg/kg experiments, and measured for 10 mg/kg experiment.
Bose 2 mg/kg i.v. (n = 6<f)
10 mg/kg p.o. 
(n = 4<?)
50 mg/kg p.o. 
(n = 5(f)
240 mg/kg p.o. 
(n « 2d5,2?)
Time 
(hours) 1o Ratio
of/° Ratio * Ratio
URINE
3 14*7 85 - ' - - - •-
8 5.4 85 - - - - - -
24 9.5 85 13.3 95 25.3 75 15.1. 22.7
48 - - 1.4 105 5.6 85 0.6 0.8
72 - - 0.4 140 - - - -
Total 2 9.6 15.1 30.9
>
15.7 . 25.5
FAECES
8 18.2 105 — — — . — — — ■
24 29.0 105 52.0 - 9.2 95 40.7 34.2
48 - - .. 7.5 - 56.7 115 3.8 1.9
•72 - - 4.1 - - - -
Total 47.2 65.6 65.9 44.5 56.1
URINE
+
FAECES
76.8 78.7 96.8 60.2 59.6
4.2.5 DRUG ABSORPTION STUDY
Powdered diet containing radioactive tolamolol was prepared as 
follows. The labelled drug was weighed into aFlorentine flask and 
unlabelled tolamolol added to make a total weight of 180,mg. The mixture 
was dissolved in a small quantity of methanol, 180 mg ’Avi'cel* micro­
crystalline cellulose added and the solvent removed underv vacuum (rotary 
evaporator). A supply of the powdered diet used in rodent toxicity trials 
was obtained from the Department of Toxicology, and 100 g weighed out.
A small portion of this (about 0.5 g) was added to a pestle and mortar, 
the dry mixture of “tolamolol and Avicel added, and the components thoroughly 
mixed. A small quantity of the diet was added to the flask in which.the 
Avicel/tolamolol mixture had been prepared, shaken to remove traces of 
adhering drug mixture, and added to the material in the mortar. This 
procedure was repeated several times, mixing and grinding the diet 
thoroughly with each addition. After a total of about 4 g of the diet 
had been mixed in this way, the diet mixture in the mortar was added to 
the bulk of the diet, contained in a 250 ml jar, and mixed thoroughly on a 
tumble-mixer. The diet so prepared contained 161 mg of tolamolol base 
per 100 g of diet. For a 20 g mouse consuming 2.5 g of diet per day, the 
dose-level would be 200 mg/kg.
Contamination of excreta with the radioactive diet would 
prejudice the experiment, and so the following procedure was used. Mice 
were housed in stainless steel cages, about 25 cm square, fitted with a 
wire mesh floor. The diet was contained in hoppers designed to prevent 
diet being transferred into the cage, but they were not very efficient in 
this respect. Just below the floor of the cage was fixed a piece of 
filter paper the same size as the floor. At the end of a collection 
period the filter paper was removed, faeces transferred to a separate
container, and contaminating diet removed from the paper by brushing. The 
filter paper, impregnated with dry urine, was homogenised in water, the 
homogenate filtered, evaporated to a small volume on a rotary evaporator, 
and then made up to 25 ml for counting. Although some contamination of 
urine and faeces with diet almost certainly occurred, a visual assessment 
of the contamination suggested that it would not have been sufficient to 
invalidate the results.
The experiment was carried out using two male and two female 
mice, housed by sex, two mice per cage. They were allowed free access to 
powdered diet (which did not'contain the drug) for two days to familiarise 
the animals with the cages, and to check the functioning of the modifications 
described above. The radioactive diet was presented to the mice for 24 
hours, and then replaced by diet containing non-radioactive drug at the 
same concentration for a further 24 hours. The dose received by the mice 
was calculated from the weight of labelled diet consumed, and was about 
240 mg of tolamolol base per kg. Aliquots of the urine extract were 
applied to filter paper, allowed to dry, and tritium determined by 
combustion; tritium activity in freeze-dried faeces was also determined 
by combustion. These results appear in Table 4*2.
The urinary excretion of radioactivity found in the absorption 
experiments is within the range found in the other two experiments using
1
oral dosing. The absorption of tolamolol when mixed with the diet is 
therefore at least as good as that found by dosing with the drug in 
solution or suspension.
4.2.4 METABOLITE PATTERNS
The methanol extract of freeze-dried plasma from mice dosed 
intravenously at 2 mg/kg (section 4*2.2) was chromatographed in solvent 
VI. At least three metabolites were present, but little unchanged drug 
was detected. To investigate the pattern of plasma metabolites in more 
detail, a mouse was dosed intravenously at 50 mg/kg, killed after one hour 
and the blood removed. The plasma was separated and the proteins 
precipitated by adding three volumes of methanol. The supernatant was 
used for low voltage electrophoresis and chromatography.
Electrophoresis at pH 6 caused the radioactive material to 
separate into two main bands, one acidic and the other basic. Chromatography 
in solvents I, III and VI showed two major compounds, one being identified 
as unchanged tolamolol by co-chromatography. In addition other minor 
metabolites were present.
Urine from the 2 mg/kg intravenous study was subjected to low 
voltage electrophoresis at pH 2, 6 and 10. The urine contained one major 
band which behaved as a base at pH 2 and 6, and as antacid at pH 10. 
Chromatography of a methanol' extract of the freeze-dried urine (section
4.2.2), using solvent III, showed one major and one minor metabolite, with 
traces of other material; there was little tolamolol acid present.
Chromatograms of plasma (50 mg/kg i.v.) and urine (2mg/kg i.v.) 
are compared in Figure 4*2. Tolamolol is still present in the plasma one 
hour after a (large) intravenous dose. In urine, however, there is little 
unchanged drug. The marker of tolamolol in Figure 4*2 (urine) does not 
coincide with the main region of radioactivity, and this was confirmed 
using solvents I and VI which give better separations of the metabolite 
from unchanged drug.
FIGURE 4.2
Chromatograms of plasma and urine from mice dosed with
radioactive tolamolol
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Solvent III (Bun0H/Ac0H/H20, 60:15:25). . •
Markers: T » tolamolol, TA = tolamolol acid.
Plasma obtained from a mouse one hour after an intravenous dose of 50 mg/kg 
was. deproteinised with methanol, and the supernatant chromatographed. 
Combined urine from six mice obtained three hours after an intravenous dose 
of 2 mg/kg was freeze-dried and the residue extracted with methanol. The 
methanol extract was chromatographed.
Urine from the mice dosed at 10 mg/kg p.o. gave a similar pattern 
on chromatography (solvent IV, cellulose plate), except that a significant 
quantity of unchanged drug was present together with a small quantity of a 
compound (or compounds) containing only tritium. A radioactive region 
containing a single isotope had not been observed in previous chromatograms 
of mouse urine, but different solvent systems had been used. With the 
solvent IV/cellulose plate system, tritium-only compounds were also found 
in rat urine; this observation is discussed in detail in section 5«2.5*
The presence of unchanged drug in the urine is believed to be an 
artefact. One mouse in this experiment proved difficult to dose, and part 
of the administered drug solution was seen to trickle from his mouth. This 
would be recovered in the urine when the Metabowl was rinsed with water.
As the radioactivity excreted in the urine was low (about \yfo of the dose), 
contamination of the urine with a small amount of the dosing solution would 
result in a comparatively large increase in the proportion of tolamolol 
present.
The polar metabolite in urine was hydrolysed by bacterial (i- 
glucuronidase, and is therefore almost certainly a glucuronide conjugate.
As the conjugate was only a minor component of the urine, the aglycone 
could not be differentiated by chromatography from the other, more 
abundant, radioactive metabolites.
In a preliminary study of the metabolite pattern in faeces, a 
sample of faeces from the 2 mg/kg i.v. experiment was extracted with hot 
methanol in a test tube, and the supernatant used for chromatography and 
electrophoresis. The extract contained one major component, a base at 
pH 6, and of similar, but not identical, R^ , to tolamolol in solvents 
I and VI.
A sample of Day 1 (24 hour) faeces from the 10 mg/kg p.o. study 
was extracted with methanol in a Soxhlet extraction apparatus. The faeces 
contained 52$ of the dose, and 80$ of the faecal radioactivity was 
recovered in the solvent. Chromatography of this extract using solvents 
III and VI showed one major metabolite, identical to hydroxy tolamolol by 
co-chromatography. Traces of tolamolol acid and other metabolites were 
also present (Figure 4*3)*
Authentic hydroxy tolamolol had not been prepared when the urine 
and plasma chromatograms were run. When it became available, chromatography 
showed it to have similar, but rather lower, values than tolamolol (Table
2.2). It is therefore almost certain that hydroxy tolamolol is the major 
urinary metabolite.
FIGURE 4.5
j
Chromatogram of faeces extract from mice dosed orally 
with radioactive tolamolol
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Solvent III (Bun0H/Ac0H/H20, 60:15:25).
Markers: T = tolamolol, HT » hydroxy tolamolol, TA'= tolamolol acid.
Methanol extract of Day 1 faeces from mice dosed at 10 mg/kg p.o.
4.3 DISCUSSION
Tolamolol, when administered orally or intravenously to mice, is 
-rapidly and extensively metabolised. A semi-log. plot of the concentration 
of plasma radioactivity against time shows a biphasic decline in 
concentration, with half-lives for the two phases, determined graphically, 
of about 0.5 h and 5*5 h. These half-lives relate to total radioactivity 
and hot to a single chemical species. Therefore, as chromatography showed 
that plasma contained several radioactive metabolites, the half-lives have 
little or no physiological significance. They are, however, a useful means 
of describing the results.
The tissue distribution studies showed no evidence of significant 
accumulation of radioactivity. The high concentration of radioactivity in 
the lungs, about six times the blood concentration, was unexpected in view 
of the cardioselectivity of tolamolol. Although the important factor in 
eliciting a pharmacological response is the concentration of the drug 
at the receptor site, and not the gross tissue concentration, it is 
interesting that tolamolol shows an affinity for lung tissue. Propranolol 
also shows a high concentration of radioactivity in the lungs, with a 
lung to blood ratio of about four after intravenous dosing in the dog 
(Hayes and Cooper, 1971). For practolol, this ratio is about three after 
oral dosing in the dog. Tolamolol is therefore similar to propranolol and 
practolol in this respect, and follows the general observation that basic 
drugs tend to be localised in tissues, particularly lung (Burns, 1971).
The feasibility of determining the uptake of tolamolol by heart 
and lung tissue under the conditions of the pharmacological test for 
tissue selectivity was investigated, but the specific activity of the 
radioactive drug was too low for this to be done. - '
The major route for excretion of radioactivity after both oral 
and intravenous dosing is the faeces. Faecal excretion after oral dosing 
can mean poor absorption, but faecal excretion after intravenous dosing 
must mean that gastric or biliary excretion has taken place. If the 
stomach contents are acidic, gastric secretion of basic compounds can occur 
in accordance with the pH-partition hypothesis (Shore et al., 1957). As 
the pK of tolamolol is about 8, a pH in the stomach of 6 or lower will 
favour gastric secretion; indeed, gastric secretion of propranolol, a basic 
drug similar to tolamolol, has been observed in the dog (Hayes and Cooper, 
1971)* However, gastric secretion is a passive diffusion process, whereas 
secretion of many substances into the bile is an active process, as 
indicated by the high bile to plasma concentration ratios often found.
There appear to be at least three systems for the active transfer of 
compounds from the blood to the bile - one for organic acids, one for 
bases, and one for nonionic substances (Plaa, 1971). When biliary 
excretion occurs, therefore, it is likely to be a more important route 
for elimination of drug related material than gastric secretion. The 
extent of faecal excretion after intravenous dosing in the mouse suggests 
that, although gastric secretion may occur, biliary excretion is the 
most important factor.
Biliary excretion of radioactive material may explain the 
observation in the tissue distribution studies that the total radioactivity 
recovered in the tissues assayed, including blood, is less than 6$ of the 
dose one hour after dosing. It is possible that the bulk of the radio­
active dose unaccounted for was present in the intestine as a result of 
biliary excretion; the intestine was the only major organ not assayed for 
radioactivity.
The metabolite pattern of tolamolol in mice is basically simple, 
with only one major metabolite in ■urine and faeces, although a number of 
minor and trace metabolites are present. The major urinary metabolite . 
shows the electrophoretic behaviour expected of a compound containing a 
phenolic hydroxyl group and a basic function. The major faecal metabolite 
was tentatively identified by co-chromatography as hydroxy tolamolol.
These two facts, together with the similarity of R^ values relative to 
tolamolol, suggest that the major urinary and faecal metabolites are 
identical, so that the bulk of the excreted radioactivity in the mouse is 
hydroxy tolamolol.
Hydroxylation of the ring of |^ H, ^ cj-tolamolol will result in 
3
the formation of HgO, and this would then enter the general pool of body
water. The biological half-life for tritiated water in the rat has been
determined by Griffith (1968), who obtained values of 4 and 16 days. The
half-life of a hydroxylated metabolite, however, would probably be only
a few hours because of the generally rapid excretion of polar compounds
from the body. Furthermore, a metabolite hydroxylated in the ring, since
it contains less tritium than the parent compound, will have a low isotope
ratio. Therefore, if the  ^ring is hydroxylated the isotope ratio of
blood and excreta will be low during the initial stages of elimination,
but will increase with time as the proportion of excreted radioactivity due 
3
to H^O increases. The results in Tables 4*1 and 4-2 demonstrate a 
tendency for the isotope ratio, or the proportion of volatile tritium, to 
increase with time, providing further evidence for the presence of a 
hydroxylated ^ ring.
The minor urinary metabolite is a glucuronide, probably of 
hydroxy tolamolol. This conjugate will have a molecular weight of 
and being anionic and polar would satisfy the criteria of Abou-el-Makarem
'jal* t (1967)) for biliary excretion in the rat and many other species.
From a comparison of R^ , values in Figure 4*2, the polar acidic plasma 
metabolite is almost certainly hydroxy tolamolol glucuronide. It is
• 'is '”'
-therefore probable that in the mouse the phase I metabolite is hydroxy 
tolamolol, which is either excreted in urine or conjugated with glucuronic 
acid and excreted in urine or bile. The biliary-excreted glucuronide can 
be hydrolysed by the gut bacteria to give hydroxy tolamolol which therefore 
appears in the faeces. There is also the possibility of an enterohepatic 
circulation, which may account for the second phase of the plasma radio­
activity levels. Additional evidence for the above sequence of events has 
been obtained for the rat (Chapter 5)«
Little unchanged drug was excreted in urine or faeces, suggesting 
that absorption of the drug after oral administration is essentially 
complete, although an alternative explanation for the absence of unchanged 
drug in the excreta could be metabolism by the gut bacteria before 
absorption or excretion. However, as the major metabolite appears to be 
hydroxy tolamolol, and aromatic hydroxylation is not a reaction normally 
performed by the gut microflora (Scheline, 1968), this possibility seems 
unlikely. The experiment to test for absorption of tolamolol from diet 
containing the drug gave results that apparently suggest poor absorption,
i.e., low urinary and high faecal excretion of radioactivity. However, the 
preceding discussion provides an explanation for high faecal excretion of 
radioactivity, and by comparing the figures from the diet experiment and the 
oral dosing experiments, it is almost certain that satisfactory absorption 
is occurring under the conditions of the toxicity trial.
The results of this work in the mouse, therefore, indicate good 
absorption of tolamolol, and extensive metabolism, primarily by aromatic 
hydroxylation.
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5.1 INTRODUCTION
Some factors favouring the use of rodent species for acute and 
sub-acute toxicity trials were briefly’mentioned in the Introduction to 
Chapter 4* Although, for reasons discussed there, toxicity trials of 
tolamolol were carried out in mice, toxicity trials were also carried out 
in rats. Rats are the preferred toxicity trial species because their 
longer life-span means less wastage towards the end of the trial, and in 
addition there is a considerable literature on the pathology of the rat.
During the toxicity trials, tolamolol was given in admixture 
with diet, and so a test for absorption was carried out similar to that 
described for the mouse (Chapter 4)> to show whether or not tolamolol was 
absorbed when administered in this way. The results were not conclusive. 
As tolamolol had shown a lack of activity in blocking isoprenaline-induced 
tachycardia in the rat (although in the mouse it was effective), this 
suggested that the drug v/as poorly absorbed. A detailed study of this 
aspect of the disposition of tolamolol was therefore carried out, in 
addition to determining metabolite patterns.
5.2 METHODS AND RESULTS
5.2.1 EXCRETION OF RADIOACTIVITY IN URINE AND FAECES
Radioactive tolamolol was • given to rats in four experiments.
In the first experiment radioactive drug was administered orally to two 
rats at a dose-level of 10 mg/kg. For the following-six days unlabelled 
drug was given at the same dose-level. On the eighth day a second radio­
active dose was given to the same animals, again at 10. mg/kg; this.is 
regarded as the second experiment. Unlabelled drug was given for a further 
six days. The two rats were-individually housed in Metabowis, and the 
daily urine and faeces collections for each animal stored separately.
One -of the rats from the previous experiments was later used*
1 A
to determine whether 00 ^ was excreted. A single oral dose of radioactive 
tolamolol was given as before, at a dose-level of 10 mg/kg. The animal 
had not received any tolamolol for three weeks at the time of this, 
experiment.
The rat was housed in a Metabcwl arranged for the collection of 
carbon dioxide. Air was passed through a drying tube containing CaCl^, 
followed by a tube containing soda lime to remove carbon dioxide, and entered 
the Metabowl through the glass lid. The expired air was taken from the 
bottom of the apparatus and drawn through a trap containing a solution of 
80 g of NaOH in 450 of water. The air pump was attached to the exhaust 
of the carbon dioxide trap, so that there was a slight negative pressure 
throughout the apparatus - this eliminated loss of expired air due to leaks 
in the numerous joints and connections. The experiment was continued for 
two days, changing the caustic soda solution after 24 hours, and collecting 
urine and faeces daily as before. The caustic soda solution from the trap 
was made up to 500 ml. For counting, aliquots of 500 p.1 were diluted with
500 pi of water, and 10 ml of NE 250 scintillator added. A precipitate 
formed, and was allowed to settle before counting.
The fourth experiment was primarily designed to determine whether 
tolamolol, when administered with the diet, was absorbed., by rats. The 
diet containing radioactive drug was the same batch as that prepared for 
the experiment with mice (section 4.2.3)* The rats were housed individually 
in Metabowls which had food containers designed to hold powdered diet.
To prevent the animals scooping the radioactive diet into the Metabowl and 
thus contaminating the excreta, a wire frame was inserted in the entrance 
to the food container. This-frame allowed only the head to enter the 
food vessel, and also prevented any scooping action by the rat. Urine and 
faeces were collected as in the previous experiments.
In each experiment the urine volume was made up to 25 ml with 
aqueous washings from the Metabowl, and counted using toluene/NE 520 
scintillator. Only tritium activity was determined in faeces, using the 
Sample Oxidiser. The counting results for these four experiments are 
given in Table 5*1. The isotope ratio was measured (section 2.7•3)* but 
after two days the counts for carbon-14 became too low for reliable isotope 
ratio determination.
The Table shows that most of the radioactivity is excreted in the 
faeces. The isotope ratio for urine increases rapidly with time, and 
although in the first two experiments carbon-14 could not be detected in 
urine after 5 days, significant quantities of tritium (about 0.15^ of the 
dose) were being excreted on Days 7 and 14. The excretion results for 
experiment 4 show that tolamolol is absorbed from the diet at least as 
well as when given as a solution.
TABLE 5.1
Excretion of radioactivity by rats after oral administration
of radioactive tolamolol
Rats were dosed with radioactive tolamolol at the dose-levels indicated.
In experiment 4 the drug was mixed with the diet. Results are expressed as 
percentage of the dose, and are the mean of tritium and carbon-14 values for 
Bay 1 and 2 urines from experiments 1, 2 and 3* All other results are 
tritium only. Total excretion in all cases is based on tritium figures.
The isotope ratio was measured (section 2.7*3). The rats in experiment 2 
had been dosed for one week before receiving the radioactive dose (see text)
Experiment 1 Experiment 2 Exp.3 Experiment 4
10 mg/kg 10 mg/kg 10mg/kg.
235
mg/kg-
230
mg/kg
110
mg/kg
125
mg/kg
Rat A Rat B Rat A Rat B Rat A Rat C<T Rat B<? Rat L£ Rat m
URINE - -
Bay 1 26.4 24.4 18.3 22.2 20.4 25.2 17.6 19.8 11.8
Bay 2 1.5 1.3 0.4 0.6 0.8 6.3 6.3 6.0 11.0
Bay 3 0.3 0.3 0.3 0.2 - - - - -
Bay 4 0.3 0.2 0.3 0.2 - - - -
Total 
Bays 1+2 27-5 25.1 18.4 22.6 21.2 31.5 25.9 25.8 22.8
FAECES
Bay 1 *29* 22.1 59.9 57.7 55.4 I3.4 22.4 15.4 13.0
Bay 2 23.1 24.6 1.4 0.8 4.2 15.8 38.1 50.8 43.8
Bay 3 0.2 0.1 0.1 <0.1 - - - - . -
Bay 4 <0.1 <0.1 <0.1 <0.1 - - - - -
Total 
Bays 1+2 ~52 46.7 61.3 58.5 59.6 29.2 60.5 66.2 56.8
Urine + 
Faeces: 
Bays 1+2
~80 71.8 79.7 81.1 80.8 60.7 84-4 92.0 79.6
URINE ISOTOPE RATIO
Bay 1 95 90 90 95 95 - - - -
Bay 2 115 120 300 300 160 - - - -
Bay 3 650 550 700 450 - - - - -
'* Low faeces yield; experimental difficulties in determining radioactivity.
Volatile tritium in the Day 1 urine from experiment 1 v/as 
determined (section 2.7*6) for both rats, but accounted for less than 0.02% 
of the dose. In experiment 3 the carbon-14 activity recovered in the 
caustic soda solution accounted for less than 0.1% of the dose on either 
Day 1 or Day 2, so that excretion of ^COg is not a significant route for 
elimination of radioactivity.
3.2.2 EXCRETION OF RADIOACTIVITY IN THE BILE
\
Some preliminary experiments with three bile-fistula rats, using 
unlabelled tolamolol, had shown that after intraperitoneal doses of 
tolamolol at dose-levels of 24-28 mg/kg, four UV-absorbing bands were 
fouid oh chromatograms using solvent IV with cellulose plates. The bile 
was collected hourly, and judging solely by the intensity of TJV absorption, 
excretion of metabolites was nearly constant for two hours, but thereafter 
started to decrease.
A single experiment v/as performed v/ith radioactive drug using 
Rat A from the excretion experiments described in section 5*2.1. At the
V-
time of this work the animal had not received any tolamolol for three v/eeks. 
The labelled drug was given intraperitoneally at 26.5 mg/kg, and bile 
collected hourly in 5 nil volumetric flasks for four hours. The flasks 
were made to volume with water, and aliquots taken for counting. The 
counting results showed an almost constant ra/te of excretion of radioactivity 
over the four-hour period, with between 4*1 and 5*2% of the dose being 
excreted per hour. Over the four-hour period, total excretion in the bile 
was 19%. The isotope ratio (measured) for all samples v/as 99%.
5.2.5 METABOLITE-PATTERNS IN URINE
Metabolite patterns in urine for rats A and B, experiment 1, 
were established by chromatography using cellulose plates and solvent IV. 
The patterns obtained for both animals, were essentially identical, and 
only the patterns for Rat A will be given in the following work.
The Day 1 urines from experiment 1 were subjected to enzymic 
(glucuronidase) and acidic hydrolysis (section 2.9.1 and 2.9.3)* The 
results for glucuronidase hydrolysis in Figure 5*1 show that the low R^ 
metabolite is probably a glucuronide. Acidic hydrolysis appears to result 
in an increase in tolamolol (Figure 5*2).
The chromatograms of control urine in Figures 5 * 1 and 5•2 show 
two major areas of radioactivity, but the major peak at the solvent front 
is due to tritium alone, the carbon-14 counts showing only a trace of 
radioactivity in this region, corresponding to tolamolol acid. The 
importance of the tritium-containing metabolite(s) is probably exaggerated 
in Figures 5*1 and 5.2 for the reasons given in section 2,7*5 (i.e. 
elution by scintillator, giving high-efficiency counting and negligible 
absorption losses). Therefore, in rats, there is only one major "urinary 
metabolite which contains both isotopes.
As a region of radioactivity containing only tritium was found, 
fission of the albyl chain must have occurred, and therefore a fragment 
or fragments containing only carbon-14 should also be observed, since 
excretion of ^COg is not significant. The chromatograms did not show any 
evidence for such a compound, probably because the likely fragments are
fairly polar (Appendix II) and generally have low R^ values (Table 2.1).
J?
Therefore, by the arguments used in section 2.7*5» if chain fission is a 
minor metabolic route, it is not surprising that fragments containing 
carbon-14 are not observed in the presence of other metabolites
FIGURE 5.1
Glucuronidase hydrolysis of urine from a rat after oral
administration of radioactive tolamolol
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Solvent IV (EtOAc/AcOH/H 0, 60:20:20), cellulose plate.
Markers:- T = tolamolol, TA = tolamolol acid.
Day 1 urine from Rat A, experiment 1 (10 mg/kg p.o.), hydrolysed 
according to procedure in section 2.9*1»
FIGURE 5.2
Acidic hydrolysis of urine from a rat after oral
administration of radioactive tolamolol .
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Markers: T = tolamolol, TA *= tolamolol acid.
Lay 1 urine from Rat A, experiment 1 (10 mg/kg p.o.), hydrolysed 
according to procedure in section 2.9.3*
■5.2.4 METABOLITE PATTERNS IN FAECES AM) BILE
Samples of the Day 2 faeces from Rats A and B (experiment l) 
were extracted with methanol in a Soxhlet extraction apparatus. (The 
weight of faeces excreted on Day 1 was so low that it was expected that 
the amount of radioactivity excreted would also be low; at this time the 
faecal radioactivity had not been determined). The methanol extracts 
contained virtually all the faecal radioactivity, and had an isotope ratio 
of 9 in both cases. A similar result was obtained for the extraction 
of Day 1 faeces from experiment 2.
The faeces extracts were chromatographed on cellulose plates 
using solvent IV, and all showed one major region of radioactivity. The 
radioactive bile (section 5*2.2, 1 hour collection) was also chromatographed 
using the same solvent system, and showed one' major region of radioactivity. 
The results of these two chromatograms are compared in Figure 5*3*
Enzymic hydrolysis was used to determine whether the major
biliary metabolite was a glucuronide conjugate of the major faecal
metabolite. After glucuronidase hydrolysis (section 2.9.1), of the bile,
chromatography using solvent IV (cellulose plate) showed that the biliary
metabolite had been hydrolysed to give an aglycone having the same R_i)
as the major faecal metabolite. .
The relationship between the major faecal metabolite and the 
prime (dually-labelled) urinary metabolite was determined by co-chromato­
graphy as follows. A portion of the faecal extract was preparatively 
chromatographed on a cellulose plate (solvent IV), and the metabolite band 
removed and eluted with methanol. This crude metabolite extract was 
applied to a second cellulose plate as a band partly overlapping a band of 
an extract of urine (’Band 1’, section 5*2.5)» The chromatogram was
FIGURE 5.5
Comparison of biliary and faecal metabolite patterns after
administration of radioactive tolamolol
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Solvent IV (Et0Ac/Ac0H/H20, 60:20:20), cellulose plates.
Markers: T « tolamolol; TA = tolamolol acid.
Bile (l hour) from rat A after 26.5 mg/kg intraperitoneal dose of 
radioactive tolamolol. Faeces (Bay 2) extract from Rat A, experiment 
1 (10 mg/kg p.o.) prepared by Soxhlet extraction"with methanol.
developed in solvent IV, and the plate scanned. The faecal metabolite 
corresponded to the major urinary metabolite.
The conclusion to be drawn from this study is that the rat 
metabolises tolamolol primarily to one compound, excreted as such in the 
urine, and excreted as a glucuronide in the bile. The conjugate is 
hydrolysed by the gut microflora to give the aglycone, which is excreted 
in the faeces.
5.2.5 CHARACTERISATION OF URINARY METABOLITES
A preliminary examination of the metabolites in the Day 1 
urine from Rats A and B (experiment l) v/as carried out as follows:
Urine (3 ml) adjusted to pH 6 with NaHgPO^
Apply to 9 x 70 mm-column of XAD-2 resin’
i1
(i) Wash with water (25 ml)-----—
(ii) Elute with methanol (25 ml)
’Methanol eluate' 
Contained 67$ of urine 
- radioactivity.
1
V
’Water wash' 
Contained 33$ of urine 
radioactivity; 
■not examined further.
Paper chromatography in 
solvent YIII
Pour main radioactive 
regions, each cut out 
and eluted with methanol
1
Bands 1-4
The isotope ratio for the 'water wash' was 70$, and for the 'methanol 
eluate' 105$. TLC examination of the 'methanol eluate' showed that the 
glucuronide metabolites had not been retained by the resin. The extracts 
derived from Bands 1 to 4 were separately examined to obtain some information 
about the nature of the metabolites.
Band 1: Contained compounds remaining at or near the origin.
TLC showed the extract to be a complex mixture with at least four metabolites 
The two major radioactive components, which were also the most polar (low 
Rp), were separated by preparative TLC on cellulose using solvent IV.
The crude metabolite extracts were examined by high voltage electrophoresis 
at pH 6, and in both cases the major radioactive peak had no net charge 
at this pH. The most likely explanation is that the metabolites each 
contain both an acidic and a basic group ionised at pH 6. Attempts to 
determine the isotope ratio of these metabolites" was unsuccessful due to 
an instrumental fault in the counter which gave a high and variable 
background count for tritium.
The minor components in this extract, which included the 
metabolite present in Band 2, were not investigated.
Band 2: TLC showed this extract to contain the major urinary
metabolite. A preparative chromatogram was run to remove some non-radio­
active material, and the resultant extract examined" by high voltage 
electrophoresis at pH 6. The main metabolite'migrated in the same 
direction and to the same distance as tolamolol; the metabolite is therefore 
a base, and probably of a similar molecular size to tolamolol. The 
determination of isotope ratio, as for the metabolites from Band 1, did 
not give meaningful results. As this metabolite is also present in faeces
v
(section 5*2*4), and in larger quantities, no further work was done with 
the urinary material.
Band 3: This band contained mainly carbon-14, but as the level
of radioactivity v/as low, it was not studied further.
Band 4: This band included the solvent front, and contained
mainly tritium compounds. Chromatography using solvent XI, with markers 
of the p-acid and f-lactic acid, provided evidence for the presence of both 
these acids, and at least two other tritium-only compounds (Figure 5*4)*
High voltage electrophoresis of the metabolite extract at pH 6 showed the 
majority of the tritium activity to be due to acidic compounds.
Tritiated metabolites from rat -urine after oral administration
of radioactive tolamolol •
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Solvent XI (Et20/Ac0H, 95:5).
Markers: pA = f-acid; ^LA = f-lactic acid.
Extract from Band 4 after paper chromatography of a urine extract 
(methanol eluate from XAD-2 treatment of Bay 1 urine from Rats A and 
B, experiment 1, 10 mg/kg p.o.).
Confirmatory evidence for the presence of the fr-acid and ^-lactic 
acid was sought from gas chromatography. The two authentic acids were 
silylated using Py/HMBS/TMCS (section 3.2.2). Sharp, well-defined peaks 
were obtained with a 5 0V-101 column, programming the temperature from 
80° at 2° per minute. (Varian 2100 chromatograph). Methylene unit values 
for the two acids were 14• 7 (f-acid) and 17.8 (f>-lactic acid).
The Bay 1 urine from experiment 3 (10 mg/kg p.o.), 10 ml, was 
acidified with 2 M HC1 to give a pH of about 2 (pH paper), and v/as then 
extracted with four 20 ml aliquots of ether. Control urine was treated 
similarly. The ether extracts were dried over anhydrous H a ^  and
evaporated to dryness. The residue was dissolved in methanol (l ml) and 
100 jil aliquots, equivalent to 1 ml of urine, evaporated to dryness in 
conical centrifuge tubes using a stream of nitrogen. The residues were 
silylated as described above and chromatographed.
There were considerable differences in relative peak heights 
and in peak positions between the chromatograms for control urine and 
urine after dosing. The chromatograms provided no evidence for the JS-acid 
in the urine after dosing, and although a peak corresponding to ^-lactic 
acid was present, this corresponded to a (smaller) peak in the control 
urine, so that identification could at best be described as equivocal.
TLC of the ether extract showed tritium peaks corresponding to.both acids.
5.2.6 IDENTIFICATION OF THE MAJOR FAECAL METABOLITE
The methanol extracts of faeces from rats A and B (section 5*2.4) 
were combined and subjected to preparative chromatography using solvent 
VII. The major radioactive band was eluted, and re-chromatographed in 
solvent II, giving three radioactive bands. These bands were separately 
eluted and re-chromatographed in solvents II and VII, but gave a rather 
confusing picture. After several chromatograms it was apparent that the 
major faecal metabolite was unstable, particularly when a basic chromato­
graphic solvent was used, being converted to a yellow compound, together 
with a number of other minor compounds. A sample of the yellow material 
was chromatographed using solvent IV on a plate which had been pre-washed 
with methanol. The radioactive band was eluted with methanol, and the 
residue, after evaporation of the solvent, submitted for mass spectroscopy. 
A complex spectrum was obtained, the most notable feature being a peak at 
m/e 368. The yellow material is probably an oxidation product of the 
metabolite, but it is difficult to assign a structure to this peak (the
molecular weight of tolamolol is 344? and hydroxy tolamolol has a molecular 
weight of 360). For various reasons the preceding work was spread over 
several weeks, and in view of the instability of the metabolite, a fresh 
attempt at isolation was made, reducing delays between different stages 
to a minimum.
Faeces from the rat diet experiment (experiment 4) were extracted 
with methanol in a Soxhlet apparatus, and the methanol extract, after 
concentration, chromatographed on preparative TLC plates using solvent VII. 
The radioactive band detected by scanning was removed, eluted with methanol 
and re-chromatographed in solvent II. This gave one radioactive band; 
the centre region of this band was removed, eluted with methanol, and the 
eluate acidified with glacial acetic acid. Evaporation of the solvent 
under a stream of nitrogen yielded a solid' product. About 500 pg of the 
solid was chromatographed on a TLC plate which had been pre-washed with 
methanol. The plate was developed in solvent VII, and the UV-absorbing 
band eluted with methanol. After evaporation of the solvent (nitrogen) 
the residue was sent for mass spectroscopy.
v.
At the time this work was in progress a small amount of hydroxy 
tolamolol, prepared by an unambiguous synthesis (section 2.4*1)* but' 
contaminated with about 30$ of the o(-amine, became available. This was 
chromatographed exactly as described above for the metabolite, and sent 
for mass spectroscopy. The mass spectra of the two chromatographic eluates 
are given in Figure 5»5» together with a spectrum of authentic hydroxy 
tolamolol uncontaminated with the ot-amine (this was obtained from the 
chemists about two days after the TLC clean-up of contaminated material 
described above). As noted in Figure 5»5? the chromatographic eluates 
required a much higher temperature of the DIP than did the authentic 
compound before a spectrum could be obtained.
FIGURE '5.5
Hass spectra of the ma.jor rat metabolite and hydroxy tolamolol
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Metabolite isolated from rat faeces, and authentic hydroxy tolamolol, 
subjected to TLC (solvent VII), eluted with methanol, and solvent 
evaporated. Spectrum of residue obtained by DIP at 250° (rat metabolite) 
and 260° (hydroxy tolamolol). Spectrum of authentic hydroxy tolamolol, 
without prior TLC, obtained by DIP at 120°.
The spectra from TLC plates are essentially identical, suggesting 
that the metabolite is hydroxy tolamolol. These spectra differ from the 
Spectrum of the authentic compound obtained without a prior TLC clean-up. 
-The reason for this difference is almost certainly that the use of higher 
probe temperatures for the chromatographic eluates gave rise to greater 
fragmentation and hence more complex spectra; some peaks are probably also 
due to background from the TLC plate.
A plausible interpretation of the three spectra is as follows.
The base peak at m/e 124, and peaks at m/e 107, 137 and 210, due to the ^ 
side, are present in all spectra, and show that the mass of the  ^ring is 
increased by 16 compared to tolamolol. Peaks due to the side are m/e 137, 
150, 193 and 236. In the spectra from TLC plates these peaks are usually 
present, but more abundant peaks occur at m/e - 18, corresponding to loss 
of water from the carbamoyl group. No molecular ion is observed in the 
spectra of the chromatographic eluates, but the highest peak at m/e 324 
could be accounted for by the loss of two molecules of water, probably 
from the carbamoyl group and the secondary alcohol.
5.2.7 OTHER EXPERIMENTS
Most of the work described in this section, primarily concerned 
with factors relating to the absorption of tolamolol, was done at the 
University of Surrey, and relied on the densitometric assay for tolamolol 
(section 3*2.6).
5.2.7.1 Incubation with rat caecal contents. The method used
was essentially that of Scheline (1966), but using a buffer of different •
\
pH (H. Walker, private communication).
An incubation medium was prepared containing 2 g of yeast extract 
(assumed to be equivalent to 1 g of the dry powder), 1 g of proteose peptone, 
and 1 g of D-glucose, dissolved in 100 ml of 0.2 M pH 6.4 phosphate buffer;
10 ml of this medium was pipetted into each of six tubes (about 16 ml 
volume). A solution of tolamolol, about 9 mg/ml, was prepared using hot 
water, and 1 ml of this solution added, while still hot, to the tubes 
containing medium (if the solution of tolamolol was allowed to cool, the 
drug crystallised). Buffer, 1 ml, was added to three of these tubes, which 
were to serve as controls, and to the other three tubes was added 1 ml of 
the caecal extract (see below). A seventh tube was prepared with 10 ml of 
medium, 1 ml of water, and. 1 ml of the caecal extract, to serve as a blank 
for chromatography.
The ’caecal extract’ was prepared as follows. The caecal contents 
from a rat were transferred to a tared sterilised (flamed) beaker, weighed, 
and 5 volumes of the phosphate buffer, which had been sterilised by heating 
at 100°, added. The mixture was stirred and quickly filtered through a 
loose wad of cotton wool to give a suspension of the gut bacteria, the 
’caecal extract'. All tubes were sterilised by heating at 100° before 
adding the caecal extract. After flushing vigorously with nitrogen, the 
tubes were stoppered (rubber bungs) and incubated at 37°•
Two tubes, one control and the other containing the caecal extract 
were removed from the incubator after four hours, and frozen; the remaining 
tubes were removed after 24 hours. A chromatogram was prepared with 4 P-l 
each of the medium blank, 24 hour control, 24 hour test (containing 
tolamolol), and 4 hour test solutions. Markers of tolamolol and tolamolol 
acid were applied and the chromatogram developed at 4° in solvent III 
(overnight run). The developed chromatogram showed that no significant 
metabolism of tolamolol had occurred, even after 24 hours. The weight of 
tolamolol applied to the chromatogram was 3.1 pg over a 1 cm band; under 
these conditions, 0.15 pg is visible under TJY light, so that a metabolite 
corresponding to 5f° of the tolamolol would have been detected. A positive 
control was not used, and this result is therefore regarded as tentative.
No further work was done with these samples, and no additional experiments 
have since been carried out.
5.2.7.2 Absorption of tolamolol from the intestine. A rat, 
anaesthetised with Nembutal, was prepared by cannulating the intestine at 
the duodenum and the caecum, and connecting each cannula to a three-way 
tap fitted with a 10 ml and a 50 ml syringe. The arrangement was identical 
to that of Doluisio et _al., (19&9) • I1*16 intestine was flushed through
from the proximal end first with saline, and then with air. Ten ml of a 
solution of tolamolol (containing 5.47 nig of the drug) in 0.05 M pH 6.4 
phosphate buffer/75/^ saline was introduced into the intestine from the 
proximal end, using the 10 ml syringe. After three minutes the solution 
in the intestine was displaced by air into the 10 ml syringe attached to 
the distal cannula, the volume of solution measured using the syringe 
graduations, and a 100 }il sample taken for assay. The solution was then 
re-introduced into the intestine and sampled every 3 minutes for a period 
of 27 minutes. To ensure reasonable mixing, samples were taken from 
distal and proximal cannulae in turn.
The samples of drug solution were assayed by diluting with 9 ml 
of saline, and pipetting 1 ml of the diluted solution into a second tube 
containing 1 ml of 0.2 M Ife^ CO,, solution. The basified solution was 
extracted twice with 2 ml of ethyl acetate, and the combined ethyl acetate 
extracts concentrated and assayed using the densitometric assay. A 
calibration curve was prepared by making dilutions of the original drug 
solution with the pH 6.4 buffer, and extracting as above. The results, 
plotted on a logarithmic scale, showed a rapid initial decline in 
concentration followed, after about six minutes, by a linear portion lasting 
for the remainder of the experiment.
The experiment was repeated' using the radioactive drug dissolved 
in saline, proceding exactly as described above, except that urethane 
anaesthesia was used, the experiment was continued for 40 minutes, and 
the bile duct was ligated before cannulating the intestine. The 
concentration of the drug solution was determined by liquid scintillation 
counting, and the results are given in Figure 5*6. This shows a rapid 
fall in concentration, as observed in the first experiment, followed by 
a slower first-order decline. Possible reasons for the initial portion of 
the curve are discussed in section 5*5 •
The half-life for absorption, calculated from the slope of the 
linear portion of the curve, was 34 minutes for the first experiment (dose- 
level 22.4 mg/kg), and 35 minutes for the second experiment (dose-level 
19.8 mg/kg).
FIGURE 5.6
Absorption of radioactive tolamolol by the rat in situ 
intestinal preparation
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Concentration of initial solution 0.451 mg/ml, equivalent to
19.4 x 10 d.p.m./ml. Intercept of regression line on concentration 
axis equivalent to 0.253 mg/ml, i.e. $6% of initial concentration. 
Half-life for absorption, calculated from slope of regression line 
is 55.46 minutes (55 minutes). Regression line calculated for 
points between 6 and 40 minutes.
5.2.7*5 Bile-duct cannulation. Previous experiments (section 
5.2.2) had shown extensive biliary excretion of metabolites after intra- 
peritoneal administration of tolamolol. Similar biliary excretion after 
intraduodenal administration would provide additional evidence for absorption 
of the drug from the intestine.
The bile-duct of a rat under urethane anaesthesia was cannulated, 
and while control bile was collected a single cannula was inserted into 
the proximal end of the duodenum. A solution of tolamolol (2.5.mlf 
equivalent to a dose-level of 20.6 mg/kg) was’added through the duodenal 
cannula. The addition was made over 5 minutes to avoid any distortion of 
the intestine which might have interfered,with the mesenteric blood flow 
or the excretion of bile. Bile was collected at intervals up to four hours 
after dosing, and aliquots chromatographed in solvent III together with 
a marker of hydroxy tolamolol glucuronide (isolated from rabbit urine,
Chapter 7)•
At least three UV-absorbing bands were present in the bile after 
dosing, but not in the control bile; the major biliary metabolite had the 
same R^ as hydroxy tolamolol glucuronide. Most of the drug-related 
material appeared in the bile between 0.5 and 1 hour, but quantitation 
could not be carried out as assays for the biliary metabolites we re not 
available. ‘
5.2.7*4 Liver perfusion experiments. Two experiments using 
a perfused liver preparation were carried out at the University of Surrey 
in conjunction with Mr. R. Jones. The set-up, essentially that described 
by Nagashima et al., (1968), was enclosed in a perspex-fronted cabinet • 
maintained at 37° with a humid atmosphere.
The total volume of perfusion fluid required for the apparatus 
is 105 ml, hut only 40 ml of heparinised blood was available, so this was 
diluted to 105 ml with Krebs-Ringer original bicarbonate buffer. The 
perfusion fluid was therefore only 38$ blood; normally 50$ blood is used. 
The liver from a male rat was quickly removed and connected into the 
apparatus. After 45 minutes, during which time control bile was collected,
1.5 ml of a solution of tolamolol was added to the perfusion fluid 
reservoir; the final concentration of tolamolol in the perfusion fluid 
was 7.4 jag/ml. Three 2 ml samples were taken during the course of the 
experiment, which only lasted 71 minutes because some clotting of the .blood 
occurred, partially blocking the ’lung*. At the end of the experiment the 
blopd flow through the liver was measured by a timed collection of venous 
bloDd; the flow rate was 5*5 ml/min.
The 2 ml samples of perfusion fluid were centrifuged, and the 
supernatant ’plasma1 separated. Considerable haemolysis had occurred.
The ’plasma1 was assayed by densitometry, using a solution of tolamolol in 
saline, extracted at the same time and chromatographed on the same plate, 
to provide a calibration curve for the 'plasma' samples. (Some preliminary 
work comparing the recovery of tolamolol from saline with that from 
heparinised blood which had been diluted with an equal volume of Krebs- 
Ringer buffer, showed the overall recovery from diluted blood to be 85$ of 
that from saline). The results of the assay, allowing for this recovery 
factor, are given in Figure 5»7» The experimental points lie on a straight 
line, and from the slope, the half-life of tolamolol in this system is
24.5 minutes.
FIGURE 5.7
Plasma levels of tolamolol in an isolated perfused rat liver system
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Data from first liver perfusion experiment (see text). Tolamolol 
added to perfusion fluid at time zero. Concentration of tolamolol 
in plasma determined by densitometric assay .(section 3.2.6). Half- 
life calculated from slope of regression line: 24.5 minutes.
At the end of the experiment, the blood from the reservoir was 
centrifuged and the ’plasma’ separated. A 4 eiI sample of this 'plasma1 
was applied to a 60 x 10 mm column of XAD-2 resin, the resin washed with 
12 ml of water, and eluted with 12 ml of methanol. The water wash was 
discarded, and the methanol eluate evaporated to dryness under nitrogen.
The residue was taken up in 200 pi of methanol for chromatography.
Extract equivalent to 500 pi of plasma was chromatographed using 
solvent III, together with a sample of bile from the bile-duct cannulation 
experiment (5-2.7-3) and a marker of hydroxy tolamolol glucuronide. The 
Rp values of the UV-absorbing bands were as follows:
Plasma 0.19 0.31
Bile 0.10 0.-17. 0.51
HT glucuronide 0.18
The leading edge of the band at Rp 0.18 was continuous for all three samples 
but the trailing edge was not - probably indicative of different loadings 
and salt concentrations for the three samples. The band at Rp 0.31 was 
continuous in bile and plasma and this, together with'the presence of 
hydroxy tolamolol glucuronide, means that two metabolites occur in both 
bile and plasma. v
Bile flow in this experiment was lower than that found in vivo, 
less than 250 pi being collected during the 71 minutes the experiment 
lasted. Chromatography of this bile (solvent III), showed three, possibly 
four, W-absorbing compounds that were not present in the control bile.
The Rp values were 0.13, 0.22 (main), 0.29 (very faint), and 0.39*
Hydroxy tolamolol glucuronide had an Rp value of 0.22, and formed a 
continuous band with the major biliary metabolite.
For the second experiment, the perfusion apparatus was modified
by incorporating 3-way taps in the liver arterial supply and venous
return tubes, so that the arterial and venous blood could be sampled. In
•this experiment, the total volume of perfusion fluid was only 94 nil of
45% blood; tolamolol was added to give a concentration of 11 pg/ml. The
blood flow through the liver, which started at about 2 ml/min, became
slower with time, and was less than 1 ml/min after 1 hour. Bile flow was
*
also'negligible. The viability of this liver preparation is therefore 
doubtful. . -
Assays of the arterial and venous blood collected 5 and 10 
minutes after adding tolamolol to the perfusion fluid showed that the 
tolamolol concentration in venous blood was less than 20% of that in the 
arterial blood, i.e. a hepatic extraction ratio of greater than 80% 
applied in this experiment. Arterial blood was sampled at intervals during 
the experiment, and a logarithmic plot of the arterial blood concentration 
of tolamolol-against time showed two distinct phases. The first phase, 
lasting for 15 minutes, was characterised by a half-life of about 16 
minutes; the half-life for the second phase was about 220 minutes. These 
results presumably indicate a sudden deterioration of the liver about 
15 minutes after ’dosing1.
5.5 DISCUSSION
The work described in this chapter had two main objectives.
These were to determine whether tolamolol was absorbed in the rat, and to 
determine the routes of excretion and pattern of metabolites after 
administration of tolamolol, for comparison with other species. .
Preliminary pharmacological studies in* rats had suggested that 
tolamolol was not active as a beta-blocking drug in this species. As 
mentioned in the introduction to this chapter, one interpretation is that 
tolamolol is poorly absorbed in the rat. However, studies with the beta- 
blocking drug pronethalol had shown that this drug did not effectively 
antagonise isoprenaline-induced +achycardia in the rat (Alcock and Bond, 
1964), although it was active in many other laboratory a n i m a l s . . . .
(Black, 1967). Lack of pharmacological activity is therefore not a 
satisfactory indication of lack of absorption in this species, and some 
alternative evidence for absorption was sought.
The figures for urinary excretion of radioactivity after oral 
dosing of labelled tolamolol suggest that the drug is not well-absorbed, 
although the low urinary excretion. of radioactivity can be readily 
explained by postulating high biliary excretion, as discussed in Chapter 4* 
'The bile-duct cannulation experiments confirmed that extensive biliary 
excretion occurred, but further experiments were carried out in an 
attempt to determine the extent of absorption.
Two experiments to determine the intestinal absorption of tolamolol 
were carried out, and both gave similar results, with an absorption half- 
life of about 35 minutes. This is regarded as slow absorption by Doluisio 
et al., (1969), but as a first-order process will be essentially complete
(9T/°) within'five half-lives, the drug should be well-absorbed in the rat. 
The experimental data from these experiments indicated a rapid initial 
fall in concentration of the lumenal solution (Figure 5*6), but the reason 
for this is not known; results published by Doluisio et al., (1969) n0^
show similar behaviour. Studies with hypotonic, hypertonic and isotonic 
solutions (Kojima et al., 1972) show that volume changes of non-isotonic 
solutions in the rat intestine are smaller, and occur over a longer period
4
of time, than would be necessary to account for the observed fall in 
concentration of tolamolol. Moreover, to give a decrease in concentration 
the volume of the lumenal solution would have to increase, whereas in fact 
the volume of the solution decreased with time. As the results were 
.corrected for volume change, the most likely explanation for the initial 
fall in concentration is either that tissue binding of the drug occurred, 
or that the effective area of the intestine was increased in the early 
stages of the experiment as a result of the distension caused by forcing 
10 ml of solution into the intestine.
Another factor which could affect the amount of drug available 
for absorption is the possibility of metabolism of tolamolol by the gut 
bacteria before absorption has taken place. This was investigated in one 
experiment, and negligible metabolism occurred. Less than 1 mg of drug 
was incubated with the bacterial suspension, at a concentration of less 
-than 100 jig/ml. Since a dose of 10 mg/kg to a 250 g rat would give a much 
higher concentration of drug in the intestine than that used in this 
experiment, it may be concluded that bacterial metabolism of tolamolol 
does not occur to a significant extent in vivo. However, more experiments 
should be done to confirm this result.
After oral dosing of labelled tolamolol, the major route for 
excretion of radioactivity by the rat is the faeces. The foregoing 
discussion has considered the evidence for absorption, and it is clear that 
oral doses of tolamolol are well-absorbed, the high faecal excretion being 
due to extensive biliary excretion of metabolites. Therefore, if tolamolol 
stimulated the microsomal enzyme system, the proportions of the dose 
appearing in urine and faeces might be altered.
t
When the first experiments were planned, the dosage regimen 
provided an opportunity to compare excretion patterns after the first dose 
of tolamolol (experiment l), 'and after continuous administration of the 
drug for seven days (experiment s). Only two animals were studied, and 
it would be unwise to draw detailed conclusions from the results. However, 
urinary excretion seems to be lower during continuous administration of 
the drug, and the radioactivity appears to be excreted more rapidly. This 
suggests that tolamolol does have a weak inducing effect on the microsomal 
enzymes, and is in agreement with the results of enzyme assays (e.g. amino- 
pyrine demethylation) carried out by the Department of Toxicology on livers, 
from animals on toxicity trial. These tests showed that continuous 
administration of tolamolol caused a slight increase in enzyme activity, 
but the effect was too small to be of practical consequence.
One major metabolite was found in both the urine and faeces, and 
this appears to be hydroxy tolamolol. The identification is based on co­
chromatography with authentic hydroxy tolamolol, and mass spectroscopy 
(although this latter evidence is less satisfactory than was hoped). The 
mass spectrum showed that it is the ^ ring and not the crt ring that is 
hydroxylated. From the discussion in Chapter 1 the 4-hydroxy isomer would 
be expected, but it is by no means certain that chromatography and mass' 
spectroscopy would be able to differentiate between this and the other 
three possible isomers.
In a molecule as large as tolamolol, it would be difficult to 
unequivocally determine the position of substitution without the appropriate 
model compounds. An alternative approach is to degrade the molecule to 
simpler compounds. During work on the assay of tolamolol, methods for 
cleaving the alkyl chain were briefly investigated. Oxidation with 
permanganate gave a complex mixture, as did the use of constant-boiling 
hydriodic acid for cleavage of the ether functions. Recently, the use of 
boron tribromide for cleaving the aromatic ether linkages (McOmie et al., 
1968) has been investigated, and smooth production of £-cresol from - 
tolamolol, jo-cresol and p-hydroxybenzoic acid from tolamolol acid, and 
toluhydroquinone from hydroxy tolamolol has been demonstrated. It is 
intended to isolate a sample of the major faecal metabolite in order to 
carry out this reaction, and if toluhydroquinone can be identified, then 
4-hydroxylation of the ^ ring will be confirmed.
If the  ^ring was uniformly labelled with tritium, hydroxylation
would give an(l 511 isotope ratio for the metabolite of 75$* • Tritium
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present as H^O has a half-life of several days, whereas other non- 
endogenous metabolites are likely to have half-lives of a few hours. 
Therefore, as discussed in Chapter 4> a significant metabolic conversion 
of tritium into tritiated water should result in a low initial isotope 
ratio for excreta. However, the isotope ratios for urine (about 93/05 
XAD-2 urine extract- (1055°), ~faeces-extract (93/0 an& bile (99?0» samples 
•which all contain substantial quantities of the major metabolite or its 
glucuronide, are higher than might be expected if the major metabolite 
had lost 25$ of its tritium label.
At the start of this work it was assumed that the tritiated 
starting material, p-cresol, was uniformly labelled, and therefore when 
isotope ratios of about lOOfo were obtained for rat excreta, it was concluded
that hydroxylation of the ^ ring was only a minor metabolic pathway.
However, as evidence for the major metabolite being hydroxy tolamolol began 
to accumulate, the assumption of uniform labelling was questioned.
ThefPR.l process for tritium labelling involves tritium exchange 
between the unlabelled compound and a tritiated solvent, in the presence 
of a heterogeneous catalyst such as palladium or platinum. The labelling 
is general, but rarely uniform, and the method is regarded as ’unpredictable 
probably due to variations in activity of the catalyst (Wilson, 1966).
The distribution of tritium in compounds labelled by this process has not 
been investigated in detail, and it is not possible to generalise from the 
few examples where the distribution of tritium is known (Evans, 1966).
From the results obtained with tolamolol, it is concluded that the 4- 
position is very lightly labelled, although the appearance of small amounts 
cf tritiated water in urine indicates some labelling of this position.
A major metabolic reaction of phenols is glucuronide conjugation, 
and the evidence of enzymic hydrolysis of urine and bile, and co­
chromatography of bile with the rabbit metabolite (identified as hydroxy 
tolamolol glucuronide), shows that in the rat hydroxy tolamolol is 
conjugated with glucuronic acid. The properties of hydroxy tolamolol 
glucuronide, particularly its molecular weight of 536, explain its 
predominance in bile (Hirom et al., 1972a). The aglycone is excreted in 
the faeces, so that hydrolysis of the glucuronide is evidently occurring 
in the gut to give free hydroxy tolamolol, which will then be available for 
re-absorption. There is, however, no evidence for or against an entero- 
hepatic circulation of hydroxy tolamolol. The nearly constant rate of 
biliary elimination of radioactivity suggests that the excretion of 
hydroxy tolamolol glucuronide is near to saturation at a dose-level of 
27 mg/kg, and it would be interesting to determine the effect of dose-level 
on biliary excretion of radioactivity.
There are a number of minor metabolites which have not been 
identified, and one of these, present in the urine, is acid-labile giving 
a compound having an Rp value similar to tolamolol. Only one chromato­
graphic system was used, so that identification of the hydrolysis product 
as tolamolol would not be justified. As the metabolite is acid-labile, 
but not hydrolysed by glucuronidase (Figures-. 5«1» 5*2), it could be the 
ethereal sulphate conjugate of hydroxy tolamolol, since' sulphate conjugation
f
is a common Phase II reaction of phenols. During the hydrolytic 
procedure some hydrolysis of the carbamoyl group would occur (section 2.4»l) 
to give an acid which might be expected to have an Rp similar to tolamolol. 
At the time of writing, however, this is only speculation.
The finding of metabolites labelled only with tritium shows that 
chain fission must occur to some extent. Of these metabolites, ^-acid and 
p-lactic acid have been tentatively identified by co-chromatography. The 
other major regions of radioactivity on the chromatogram (Figure 5*4) have ■ 
not been identified. However, ^-toloxylactic acid ('^-lactic acid') is 
metabolised in vivo by rats to give 4-hydroxy-2-methylphenoxy lactic acid 
(Riley, 1950) > and chain cleavage of the major metabolite, hydroxy tolamolol 
could also occur to give the hydroxylated acids. It is therefore probable 
that these acids are also present in the extract.
The.experiments with an isolated perfused liver system showed that 
tolamolol is readily metabolised by the liver. Unfortunately, no tests 
were made to check the viability of the liver preparations, and in both 
experiments the blood flow rate was well below the 1.5 - 2.5 ml/min per 
gram of liver used by other workers (Nagashima et al. i 1968; Yon Bahr et al. 
1970)* The results of this work, particularly the second experiment where 
there was definite evidence of liver degeneration, must therefore be • 
treated with caution.
An analysis of the results illustrated in Figure 5*7 using the 
equations of Nagashima and Levy (1968) gives a hepatic extraction ratio of 
45/^ j i.e. 4bi° of the tolamolol entering the liver is lost by metabolism or 
excretion (there was no evidence of significant tissue uptake). An 
alternative approach, using the clearance concept of Rowland (1972), gave a 
hepatic extraction ratio of 5 4 Both these values are significantly lower 
than the figure obtained by analysis of arterial and venous blood from the 
second perfusion experiment (extraction ratio greater than 80fo).
Bata from the second experiment for the period 0 to 15 minutes, 
analysed according to Nagashima and Levy (1968), gives an extraction ratio 
of 86$. This is an approximate value'as the initial flow rate was not 
accurately measured, but is of the same order as the value based on assay 
of ’plasma’. From these two perfusion experiments, therefore, the hepatic 
extraction ratio appears to depend on hepatic blood flow rate. This is in 
conflict with the conclusions of Nagashima and Levy (1968), who show that 
flow rate of perfusate has essentially no effect on drug elimination rate 
constants. The conclusion from this work is therefore that, although 
metabolism occurs in the liver, as shown by the disappearance of drug from 
perfusate and the appearance of metabolites in the bile and ’plasma’ , 
reliable information on the extent of metabolism requires further work 
using liver preparations of confirmed viability. The results obtained from 
liver perfusion studies with propranolol (Shand et al., 1971; Rangno and 
Shand, 1971) , "the clinical implications of a high hepatic extraction 
ratio (Shand and Rangno, 1972), indicate the importance of repeating this 
work.
Summarising, tolamolol is well-absorbed in the rat, and is 
extensively metabolised, mainly to hydroxy tolamolol which is excreted as 
such, or conjugated with glucuronic acid. Other minor metabolites, perhaps 
including hydroxy tolamolol sulphate, are also formed.
5.4 ADDENDUM TO CHAPTER 5
5.4.1 BILIARY EXCRETION IN THE RAT
Additional biliary excretion experiments have been carried out. 
Radioactive tolamolol was administered intraduodenally to four bile-duct- 
cannulated rats at the dose-levels given in Table 5*2. Bile was collected 
at intervals up to four hours, at which time the animals were exsanguinated 
(ficom the vena cava, using a heparinised syringe). Radioactivity in bile 
and plasma was determined, and the results are summarised in Table 5•2.
TABLE 5.2
• R a d i o a c t i v i t y  in bile and plasma after intraduodenal administration of
radioactive tolamolol to rats
Rat E Rat P Rat G • Rat H
Bose-level (mg/kg) 9 10 45 47
Biliary excretion, 0-1 hour (fo dose) 14 17 25 ' 26
Biliary excretion, 0-4 hour (fo dose) 42 28 58 -
Plasma radioactivity (pg/ml) 0.72 0.25 2.7 22
Plasma concentration expressed as pg equivalents of tolamolol base 
per ml. Plasma result for Rat H is for 1.5 hours after dosing; all 
other values are for 4 hours after dosing.
Bile samples were chromatographed in solvents I and III to 
obtain metabolite patterns. In the case of Rat H, the experiment was 
terminated after 1.5 hours, and the pattern of metabolites in a methanol 
extract of plasma also determined.
Prom the results in Table 5«2, tolamolol is well-absorbed after 
intraduodenal dosing, and the bile is the major route for excretion of 
radioactivity. Bile from Rat H was collected every 15 minutes, and over
the period 15 to 90 minutes the biliary excretion process was close to 
saturation as shown by the almost constant specific activity (expressed as 
d.p.m./mg) of .the bile. At the maximum rate of excretion, this rat was 
excreting radioactivity equivalent to 5*2 mg of tolamolol per hour, or
■-J '
8.1 mg of hydroxy tolamolol glucuronide per hour.
The metabolite pattern of the bile was similar to that shown in 
Figure 5*5 for all animals, regardless of dose-level or amount of radio- • 
activity excreted. The major component (about 65$ of the bile radioactivity) 
was hydroxy tolamolol glucuronide, as shown by co-chromatography with the 
rabbit metabolite (see Chapter 7)* About 12$ of the radioactivity was 
present as a material chromatographically identical in solvents I and III 
to a rabbit urinary metabolite which has been tentatively identified as 
hydroxy tolamolol sulphate (see Addendum, Chapter 7)» The minor metabolite, 
of lower Up than hydroxy tolamolol glucuronide, was shown to be a glucuronide 
by enzymic hydrolysis, but insufficient material was available to 
characterise the aglycone, although it did not correspond to tolamolol, 
hydroxy tolamolol, tolamolol acid, or hydroxy tolamolol acid (see Addendum, 
Chapter 7)« Chromatography of plasma obtained 1.5 hours after dosing 
showed hydroxy tolamolol glucuronide to be the main component. Unchanged 
drug was also present, and there was some evidence for the presence of 
hydroxy tolamolol sulphate.
The results of this work confirm the findings and conclusions 
reported in the main part of this chapter.
5.4.2 DEGRADATION OF THE FAECAL METABOLITE
Boron tribromide degradation of the faecal metabolite has been 
carried out by Dr. D. Stopher. Toluhydroquinone was identified by TLC, and 
confirms that the beta ring of hydroxy tolamolol is substituted with 
hydroxyl in the 4 position (Chapter 1, p. 20).
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6.1 INTRODUCTION
The guinea pig is a species often used by the pharmacologist, 
mainly because surgical techniques are easier than with mice and rats, 
and also because it is cheaper to house and feed than the larger animals 
such as cats and dogs.
During the development of tolamolol the guinea pig was used in 
several tests. Beta-blocking potency was determined in vivo and in vitro 
(using an isolated atria preparation); tests for tissue selectivity were 
made in vivo and in vitro (using a tracheal chain preparation); and 
cardiac depressant activity was measured in vitro using a driven atria 
preparation* A comparison of the metabolic pattern of tolamolol in the. 
guinea pig with that in other species was therefore relevant in connection 
with mode of action studies and also the general pharmacological profile 
of the drug, particularly since the major rat metabolite, hydroxy tolamolol, 
showed both beta-blocking activity and tissue selectivity.
6.2 METHODS AND RESULTS
6.2.1 EXCRETION OF RADIOACTIVITY
Radioactive tolamolol was given to two guinea pigs. One was 
dosed orally with an aqueous solution of tolamolol, and the other was 
dosed intravenously (by way of a catheter in the jugular vein) with a 
solution of the drug in saline, sterilised before administration. The 
nominal dose-levels were 20 mg/kg p.o., and 2 mg/kg i.v., but the actual 
dose-levels received were 21 mg/kg and 2.1 mg/kg respectively.
Urine and faeces were collected daily for four days after dosing. 
The urine as voided was alkaline (about pH 9 by pH paper), and a 
precipitate settled out on standing. Each daily collection of urine was 
made up to 50 ml with washings from the Metabowl, care being taken to 
recover all the precipitate. To determine radioactivity in the urine, the 
flask was shaken vigorously to bring the precipitate into suspension, and 
100 jil aliquots of the turbid urine pipetted into counting vials. The 
precipitate was soluble (with effervescence) in acetic acid, therefore 
0.5 ml of 0.1 M acetic acid was added to the vial to dissolve the 
precipitate, and then 10 ml of Instagel scintillator added. x
Faeces were homogenised in water, freeze-dried, and tritium 
determined by combustion using the Sample Oxidiser.
The results for radioactivity in urine and faeces are given in 
Table 6.1, and suggest a difference in excretory routes between the two 
methods of dosing. However, as only two animals were used, and only one 
experiment performed in each animal, little significance can be attached to 
this observation. Nevertheless, with nearly 70i° of an intravenous dose 
appearing in the faeces, the bile is clearly an important route of 
excretion in the guinea pig.
TABLE 6.1
Excretion of radioactivity “by the guinea pig after administration
of radioactive tolamolol
Animals were dosed as described in the text. Brine was counted using
Instagel, and isotope ratios were measured (section 2.7*3)• Results are
3expressed as percentage of dose. Values for urine are the mean of H and
results, but only tritium was determined for faeces. Total recovery
3
for urine + faeces is therefore calculated using. Revalues for urine.
21 mg/kg p.o. 2.1 mg/kg i,,v.
Brine IsotopeRatio Faeces Brine
Isotope
Ratio
Faeces
Day 1 20.5 110 72.1 36.0 95 41.6
Day 2 1.0 130 12.6 1.6 110 19*7
Day 3 0.2 430 2.2 0.6 140 5*4
Day 4 0.2 230 0.3 0.3 210 1*9
Total Days 1-4 21.7 . — 87.2 38*5. — 68.6
Total recovery, 
Brine + Faeces 110$ 106$
■Two weeks after the excretion study, the catheterised guinea pig 
was used to determine biliary excretion. The animal was anaesthetised with 
urethane and the bile duct cannulated. The gall bladder was not ligated.
A 2 mg/kg intravenous dose of radioactive tolamolol was given, and the bile 
collected. After 50 minutes the guinea pig began to have difficulty with its 
breathing, and eventually stopped breathing 70 minutes after dosing. The 
peritoneal cavity was then opened, and the contents of the gall bladder 
removed by hypodermic syringe. Both samples of bile were counted using 
Instagel scintillator.
• The total radioactivity in bile from the bile duct and gall 
bladder was 15*8$,of the dose, with a measured isotope ratio of 95* This 
radioactivity was excreted within 'JO minutes, and confirms the importance 
of biliary excretion in the guinea pig.
6.2.2 METABOLITE PATTERNS
The ■urinary metabolite patterns were determined by TLC using 
solvent III. The urine was applied directly to the plate with no prior 
treatment other than the addition of sufficient glacial acetic acid to 
dissolve the precipitate and give a homogeneous solution. A comparison 
of metabolite patterns in urine after intravenous and oral dosing is given 
in Figure 6.1, and shows that there is ho significant difference in 
metabolite pattern after either method of dosing. Both tolamolol and 
tolamolol acid appear to be present as shown by co-chromatography.
Enzymic hydrolysis of the urine using bacterial ^-glucuronidase 
showed that the polar metabolite (R^ , about 0.25 in Figure 6.1) is the 
glucuronide of the major urinary metabolite. This was shown by co­
chromatography to be hydroxy tolamolol.
Day 1 faeces from both the orally- and intravenously-dosed 
animals were•extracted with methanol in a Soxhlet apparatus; the methanol 
extract contained at least SOfo of the faecal radioactivity in each case. 
The extracts were chromatographed using solvents III and VI; the 
chromatograms obtained with solvent VI, which gives a good separation of 
the less polar, i.e. unconjugated, metabolites, are given in Figure 6.2 
As found for urine, there is no significant difference in the metabolite 
patterns after intravenous or oral dosing. The major radioactive 
components in the faeces extracts appear to be tolamolol and hydroxy 
tolamolol, with very little, if any, tolamolol acid.
FIGURE 6.1
Chromatograms of -urine from guinea pigs dosed with
radioactive tolamolol
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Solvent III (Bun0H/Ac0H/H20, 60:15:25).
Markers: T = tolamolol, TA = tolamolol acid.
Day 1 "urine from two guinea pigs, one dosed at 2.1 mg/kg i.v., the 
other dosed at 21 mg/kg p.o. Urine applied directly to plates-with 
no pretreatment.
FIGURE 6.2
Chromatograms of faeces extracts from guinea pigs dosed with
radioactive tolamolol
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Markers: T = tolamolol, TA = tolamolol acid, HT *= hydroxy tolamolol. 
Methanol extracts of Day 1 faeces from two guinea pigs, one dosed 
at 2.1 mg/kg i.v., the other dosed at 21 mg/kg p.o.
Samples of the gall bladder bile and the excreted bile were 
chromatographed using solvent III; a marker of hydroxy tolamolol glucuronide 
(isolated from rabbit urine, Chapter 7) was used. The pattern for both 
bile samples was identical, the major radioactive component corresponding 
to the marker. Thus the major urinary metabolite, hydroxy tolamolol, is 
excreted in the bile as a glucuronide.
This was confirmed by glucuronidase hydrolysis of the bile. The 
extracts from control and enzyme-treated bile were chromatographed using
.a
solvents IV (cellulose plate), and VI; the results for solvent VI are 
given in Figure 6.5. Although the main biliary metabolite is the 
glucuronide of hydroxy tolamolol, the bile contains traces of unconjugated 
hydroxy tolamolol, tolamolol and tolamolol acid. After hydrolysis, 
apart from the considerable increase in hydroxy tolamolol, there was 
also a slight increase in the radioactivity in the region of tolamolol, 
indicating that tolamolol may be excreted in the bile partly as a 
glucuronide conjugate.
FIGURE 6.5
Glucuronidase- hydrolysis of bile from a guinea pig dosed with
radioactive tolamolol
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Markers: T = tolamolol, TA = tolamolol acid, HT = hydroxy tolamolol 
Bile from a guinea pig dosed at 2 mg/kg i.v. was hydrolysed with 
bacterial ^-glucuronidase, freeze-dried, and the residue extracted 
with methanol for chromatography.
6.5 DISCUSSION
At the dose-levels employed in this study the pattern of 
metabolites in the guinea pig appears to be independent of the route of 
administration. This suggests that, notwithstanding a considerable faecal 
excretion of radioactivity after oral.dosing, the drug is well-absorbed 
from the intestine. The proportion of apparent unchanged drug in the 
faecal extract is similar for both dosage routes, and it. is therefore 
unlikely that lack of absorption is the main reason for the appearance of 
tolamolol in faeces after oral dosing. Even if this was the explanation, 
it could not account for the tolamolol in faeces after intravenous dosing.
For the intravenously-dosed guinea pig a considerable proportion, 
perhaps 50/6 of the extracted faecal radioactivity (Figure 6.2), was 
present as unchanged drug. However, the bile, which is probably the main 
source of faecal radioactivity after intravenous dosing, contains 
relatively little tolamolol, either free or conjugated with glucuronic 
acid (Figure 6.5). The major biliary metabolite is the glucuronide of 
hydroxy tolamolol, so that the major faecal metabolite would be expected 
to be hydroxy tolamolol, as it is for the mouse (Chapter 4) and the rat 
(Chapter 5). Neither the mouse nor the rat excrete significant quantities 
of unchanged drug.
There are at least two possible explanations, apart from biliary 
excretion, for the presence of tolamolol in the faecal extracts. The 
first possibility is excretion into the stomach: if the stomach contents 
are acidic, excretion of bases of pK greater than 5 across the gastric •SL
epithelium is blood-flow limited (Shore _et al., 1956). This has been 
considered in Chapter 4» with the conclusion that when appreciable biliary 
excretion occurs, as it does in the guinea pig, gastric secretion is
relatively less important. To account for the quantity of unchanged drug 
in the faeces a particularly effective gastric secretion process must occur, 
particularly when account is taken of the possibility of reabsorption of 
the drug on reaching the intestine. Gastric secretion does not therefore 
seem adequate to explain the presence of considerable quantities of 
tolamolol in the faeces.
The second possibility is that the radioactivity attributed to 
tolamolol is due to another metabolite, since the only evidence.for the 
identity of the radioactive compound has been co-chromatography with 
tolamolol in two solvent systems (one acidic and one basic). As there was 
no obvious precursor in the bile for 'a major metabolite other than 
hydroxy tolamolol, any additional metabolite must arise from the action 
of gut bacteria on hydroxy tolamolol. The most likely product of 
bacterial action would be hydrolysis of the carbamoyl group to give 
hydroxy tolamolol acid. However, this compound would be expected to have 
an Rp in solvent VI lower than tolamolol acid (see marker compounds in 
Figure 6.5), so that the radioactivity corresponding to tolamolol is 
unlikely to be due to this compound. A third possibility, bacterial 
dehydroxylation (which would give tolamolol from hydroxy tolamolol) seems 
unlikely because the gut microflora normally only dehydroxylate aromatic 
rings containing two or more hydroxyl groups (Smith et al.. 1964; Parke, 
1968). At the time of writing, no further work on this problem has taken 
place, and since only two experiments have been carried out it is perhaps 
unwise to draw too many conclusions from such limited data.
Apart from the excretion of unchanged drug in faeces, the guinea 
pig handles tolamolol in a similar way to mice and rats. Excretion is 
similar, with most radioactivity appearing in the faeces, and the major 
metabolite in all three rodent species is hydroxy tolamolol, either free 
or conjugated with glucuronic acid.
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7.1 INTRODUCTION
\
The responsibility of manufacturers to ensure the safety of 
a new drug includes testing for any teratogenic effects. One of the 
species generally used for teratology studies is the rabbit, which is 
especially suitable because ovulation is non-spontaneous (requiring the 
stimulus of mating for its induction), there is no seasonal anoestrum, 
and gestation is short, the length of pregnancy being 51 to 52 days.
The rabbit was used for teratology studies of tolamolol, and it 
was therefore necessary to determine routes of excretion and metabolite 
patterns in the rabbit for comparison with other species. In order to 
reproduce the teratology trial conditions as closely as possible, pregnant 
rabbits and high dose-levels were used. The opportunity was also taken 
to isolate metabolites for identification, although this was not the 
primary objective of the work.
This chapter therefore describes not only the absorption, pattern 
of metabolites and excretion of tolamolol after oral dosing in the rabbit, 
but also some studies on the isolation and identification of metabolites.
: 7.2 METHODS AND RESULTS
7.2.1 DOSING, AND PLASMA LEVELS OF RADIOACTIVITY
Two mated female rabbits were dosed on.the sixteenth day of 
pregnancy with radioactive tolamolol, administered as a suspension in 
25^ 6 Cremophor-El. Due to the difficulties of administering a thick 
suspension, the actual dose received by the rabbits (determined by 
measuring the amount of radioactivity recovered from the syringe and tube 
used for preparing the dose) corresponded to dose-levels of 230 and 250 
Kg/kg, although the nominal dose-level was 300 mg/kg. Unlabelled drug 
was given on subsequent days at the same nominal dose-level.
Blood was taken from the ear vein at intervals after dosing, 
and the plasma dissolved in Instagel scintillator for counting. The 
results are given in Table 7»1> and show that the drug is well-absorbed, 
maximum levels of radioactivity being reached about two hours after dosing. 
At this time the isotope ratio is significantly lower than that of the 
drug, but the nature of the plasma radioactivity could not be determined
V.
as the specific activity of the administered drug (0.07 pCi/mg for tritium, 
0.008 pCi/mg for carbon-14)' was too low.
Four days after dosing the animals were sacrificed, the foetuses 
removed, and samples of blood obtained from the vena cava. The foetuses 
'were homogenised in water using a top-drive homogeniser, and the 
suspension freeze-dried; the blood was also freeze-dried. The lyophilised 
samples were combusted for tritium using the Sample Oxidiser, but the 
levels of radioactivity were too low for reliable counting. However, there 
appeared to be little difference in the levels of radioactivity between 
blood and foetuses, the values for both tissues corresponding to between 
0.4 and 0.6 p.p.m. of wet tissue.
TABLE 7.1
Radioactivity in rabbit plasma after oral administration of
radioactive tolamolol
The radioactive drug was administered 'as a suspension in Cremophor-El at 
the dose-level indicated. Concentration is expressed as jug equivalents 
of tolamolol base per ml of plasma. Results are the mean of tritium and 
carbon-14♦ The isotope ratio was measured (section 2.7.3).
Rabbit 1 (250 mg/kg) Rabbit 2 [250 mg/kg)
Hours 
after dose pg/ml
Isotope
ratio jig/ml
Isotope
ratio
0.5 - - 25 100
1 50 95 48 90
2 77 90 94 9°
3 68 95 ' 91 95
5 51 100 62 100
7.2.2 EXCRETION OF RADIOACTIVITY
Urine and faeces were collected daily. Urine was dissolved in 
Instagel scintillator for counting, and the tritium activity in lyophilised 
faeces was determined by combustion (Sample Oxidiser). The results in 
Table 7.2 confirm that tolamolol is well-absorbed, since about 7 0 of 
the administered radioactivity is excreted in the urine. The isotope ratio 
for urine shows a tendency to increase with time, as observed in other 
species.
TABLE 7.2
Excretion of radioactivity by the rabbit after oral administration
of radioactive tolamolol . \
The radioactive drug was administered as a suspension in Cremophor-El at 
the dose-levels indicated. The results, expressed as percentage of dose, 
are the mean of tritium and carbon-14 values for urine; the isotope ratio 
was measured (section 2.7*3)* Only tritium-was determined for faeces; 
the total excretion of radioactivity is therefore based on the tritium 
values. For rabbit number 2, negligible excretion of faeces occurred on 
Bay 1, and the samples for Days 1 and 2 were therefore combined.
Rabbit 1 (250 mg/kg) Rabbit 2 (250 rQg/kg)
Bays 
after dose Urine Faeces
Isotope
ratio Urine Faeces
Isotope
ratio
1
2
64.6
3.5
18.0
4*4
95
100
54.4 v
14.2
'3.1
95
100
3 1.1 0.8 105 2.6 5.4 120
4 0.5 0.7 105 0.9 1.3 140
Total:
Bays 1 to 4 69.5 23.9
- 72.1 9.8 -
Total:
Urine+Faeces 91.9- - 81.0 -
7.2,5 METABOLITE PATTERNS IN URINE AND FAECES .
The metabolite patterns in urine were obtained by chromatographing 
the urine after the addition of sufficient glacial acetic acid to give 
a homogeneous solution (as for the guinea pig, section 6.2.1). Solvents 
III hnd IV were used, cellulose plates being employed with the latter 
solvent. The metabolite patterns for both animals were similar, and the 
result for urine from rabbit 1 (solvent IV) is given in Figure 7*l(A).
A moderately complex pattern of metabolites is found, and for ease of 
reference these have been numbered 1 to 6 in order of increasing R^, as 
shown. There is little unchanged drug (5), but there are considerable 
quantities of tolamolol acid (6) and other, more polar metabolites. 
Hydrolysis of the urine with ^-glucuronidase (section 2.9*1) showed that 
metabolite 1 was a .glucuronide conjugate, the.aglycone having an value 
lower than tolamolol in solvents III and IV.
lay 1 faeces from rabbit 1 were extracted with methanol in a . 
Soxhlet apparatus, and the extract, v/hich contained 82$ of the faecal 
radioactivity (14$  of the dose), chromatographed in the same solvent 
systems as used for urine. The results for solvent IV are given in 
Figure 7*l(B) for comparison with the urinary metabolite patterns. From 
the similarity in Rp values for the two chromatograms, the faecal 
metabolites have been numbered to correspond with the urinary chromatogram. 
Evidently hydroxy tolamolol is excreted in the faeces (and also in the 
urine), together with unchanged drug, but tolamolol acid is not excreted. 
There is, by comparison with the urine, a complete absence of the polar 
metabolites.
FIGURE 7.1
Chromatograms of rabbit urine and faeces extract after oral
administration of radioactive tolamolol
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Solvent IV (Et0Ac/Ac0H/H20, 60:20:20); cellulose plate 
Markers: T = tolamolol; TA = tolamolol acid; HT = hydroxy tolamolol. 
Radioactive tolamolol administered orally at 250 mg/kg (rabbit l). 
Day 1 urine chromatographed with no pre-treatment; Day 1 faeces 
extracted with methanol (Soxhlet), arid extract chromatographed.
7.2.4' ISOLATION, CHARACTERISATION AND IDENTIFICATION OF METABOLITES
Samples of metabolites 1, 2 and 6 (using the numbering given in 
Figure 7»l) were isolated for characterisation and identification. A 
summary of the various steps used in the isolation of these metabolites 
is given on page 165, which folds out for reference during the following 
descriptions.
7.2.4*1 Metabolite 1. Glucuronidase hydrolysis of urine had 
shown that metabolite 1 was a glucuronide. A sample of this metabolite 
was isolated as follows.
Day 1 urine from rabbit 2 (80 ml) was acidified with acetic acid 
to give a homogeneous solution, and parsed down a 20 x 190 mm column of 
XAD-2 resin. The resin was washed with water, collecting 25 ml fractions. 
These were counted for radioactivity, and showed a peak containing about 
of the urinary activity, which was eluted within 150 ml (column volume 
+ urine volume). This material was evidently not retarded by the resin.
After this peak, a slow elution of radioactivity (about 0.3/^  per 25 ml) 
occurred, probably due to the gradual elution of a polar material which 
was not strongly adsorbed by the resin. The column was washed with a 
total of five column volumes of water, and then eluted with three column 
volumes of methanol. The water wash, containing inorganic salts and urea, 
together with traces of metabolites (about 7»5^ of the applied radioactivity) 
was discarded.
The methanol eluate was concentrated (rotary evaporator), applied 
to Whatman 3MM paper, and developed in solvent III (ascending). The 
chromatograms we re scanned, and showed three main regions of radioactivity. 
The region corresponding to the most polar metabolite was cut out, 
homogenised in methanol, and filtered. Evaporation of the methanol 
filtrate gave a solid which was redissolved in a small quantity of
methanol and applied to a 20 x 320 mm column of Sephadex LH 20. The 
column was eluted with methanol, and fractions of 10 ml collected. A 
broad region of radioactivity was eluted between 50 and 80 ml. The 
radioactive fractions were combined and evaporated to dryness (rotary 
evaporator). The resultant solid was not readily soluble in methanol, but 
was soluble in acetic acid; the metabolite was therefore transferred to a 
centrifuge tube using MeOH/AcOH (50:50), and concentrated to about 1 ml 
under nitrogen. Addition of about 10 ml of methanol to the brown solution 
gave a whitish precipitate which was centrifuged, washed with about 2 ml 
of methanol, centrifuged, and finally dried in a vacuum desiccator over 
PgOf. and NaOHl The buff-coloured product was submitted for mass 
spectroscopy, together with a sample of hydroxy tolamolol for comparison.
The mass spectra, shown in Figure 7*2, are. complex, but have 
many common features. Peaks at m/e 107, 1.24j and 210 are almost certainly 
derived from the side with the mass increased by 16 (see page 120), 
and these peaks, together with the ion at J60, suggest that the metabolite 
is related to hydroxy tolamolol. Hydrolysis of the metabolite with 
bacterial ^-glucuronidase gave a compound Identical to hydroxy tolamolol 
by chromatography in solvents VI and VII. Reaction with carbazole (Bitter 
and Muir, 1962) gave the characteristic purple colour obtained with 
glucuronic acid. The metabolite is therefore the glucuronide conjugate 
of hydroxy tolamolol. It has repeatedly been observed in these 
laboratories that glucuronide conjugates give the mass spectra of the 
aglycone, so that the mass spectrum of the metabolite is consistent with 
the proposed structure. ' ,
All attempts to recrystallise the metabolite have been 
unsuccessful. .
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FIGURE 7.2
Mass spectra of metabolite 1 and hydroxy tolamolol
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Spectrum of metabolite 1 obtained by DIP at 180°; spectrum of 
hydroxy tolamolol obtained by DIP at 120°. Metabolite isolated 
from rabbit urine by method described in section 7»2*4*1.
7.2.4*2. Metabolite 6. This metabolite was isolated from the 
■urine of rabbit 1 following the same XAD-2/paper chromatography procedure 
described in section 7*2.4.1. The radioactive band of highest Rp was 
eluted with methanol, and the eluate subjected to preparative TLG on silica, 
developing the plate twice in solvent IX. The major radioactive band was 
eluted with methanol, and yielded a solid on evaporation of the solvent.
To remove contaminating silica and traces of fluorescent material eluted 
from the TLC plate, the solid was redissolved in methanol and applied to a 
10 x 320 mm column of Sephadex LH 20. The column was eluted with methanol 
and the eluate passed through a Uvicord to monitor the UV absorbance of the 
eluate. Two approximately equal W-abs orbing peaks we re obtained. 
Chromatography of fractions corresponding to these two peaks (solvent IX) 
showed them to have the same R^ as tolamolol acid. • The mass spectra of 
these two fractions were also similar, with a-base peak at m/e 108. There 
were only minor peaks at higher m/e values (147, 1495 1&3t 1^7, 207), an& 
it was not possible to assign a structure from these spectra. The most 
likely explanation for the appearance of two TJV-absorbing peaks after LH 20 
chromatography, both containing the same compound, is as follows.
1 - V
Solvent IX contains acetic acid, and if the metabolite has a 
basic nitrogen, it will be present as the acetate salt. There is almost 
certainly some dissociation in methanol, and therefore, on passage down 
the column, there will be a separation of acetic acid from the base (either 
by a sieving action, or by selective adsorption of the metabolite)/ 
Therefore one of the two peaks could be due to the salt form of' the 
metabolite, and the other to the free base.
The two fractions were combined, dissolved in about 0.5 ml of 
methanol, and about 5 ml of ethereal HC1 added. A white precipitate formed 
immediately, and was separated by centrifugation. The precipitate was 
washed with about 2 ml of a methanol/ether mixture, and dried in a vacuum
desiccator. The solid was extracted 'with hot ethanol, and the solvent 
evaporated to yield a white solid (The nature of the ethanol-insoluble 
material was not investigated beyond an attempt at TLC, when it was 
apparent that it had negligible UT absorbance, and was therefore unlikely 
to be drug-related). A sample of the ethanol-soluble material (1.8 mg) 
was ‘silylated with Py/BSA (section 3*2.2), and subjected to GC/MS; for 
comparison an authentic sample of tolamolol acid was similarly treated.
Both the metabolite and the authentic compound had the same 
retention time (24 minutes at 240° on a 10$ 0V 101 column), and gave 
identical mass spectra (Figure 7*3)* Interpretation of the mass spectra 
is difficult because many fragments, although originating from different 
sides of the molecule, have the same mass. 'For example, cleavage at A or 
B (diagram below), with the addition of one silyl group would give m/e 266, 
and with two silyly groups, m/e 338* A peak at 193 could arise from 
cleavage at C, with one silyl group, i.e. the silyl ester, although the 
non-silylated fragments resulting from cleavage at A or B would have 
m/e 194* It is therefore not possible to determine the number of silyl 
groups which have been introduced into the molecule, although there are 
probably at least two. The base peak at 73 is due to the trimethyl silyl 
group.
From chromatographic evidence (both TLC and GC), and mass 
spectroscopy, this metabolite is identified as tolamolol acid.
FIGURE 7*5
Mass spectra of metabolite 6 and tolamolol acid
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Metabolite 6 isolated by the method described in section 7*2.4*2, 
and silylated with pyridine (100 ul) and bis -trimethylsily 1 acetamide 
(200 ul). Authentic tolamolol acid treated similarly. Samples 
submitted to GC/MS at 240° on 10$ 0V-101. Peaks of m/e greater 
than 100 plotted as relative abundance x 4*
7*2.4*3* Metabolite 2. Day 1 urine (50 ml) from rabbit 1 was
treated with XAD-2 resin to remove salts and urea, as described above.
The methanol eluate was concentrated and adsorbed on silica gel (10 g).
After allowing to dry, the silica gel was added to the top of a 30 x 185
mm column of silica gel prepared in EtOAc/AcOH (90:10). Gradient elution
of the column was carried out, increasing the methanol and water content
so that after 300 ml the eluting solvent was EtOAc/MeOH/H^O/AcOH
(40:30:20:10). Most of the radioactivity was eluted between 250 and 450 nil*
These fractions were combined, concentrated, and subjected to preparative
TLC using solvent III. Two radioactive bands were obtained. The lower
band was eluted with MeOH/AcOH (50:50) and shown by TLC to be metabolite 1
(hydroxy tolamolol glucuronide); the second band was eluted with methanol,
and chromatography in solvents III or IV (both silica -and cellulose layers)
showed this extract to contain three radioactive components. The major
component, of lowest Rp, corresponded to metabolite 2, while the other two
components, which had very similar R~ values, corresponded to metabolite 3*J?
At-present, no information is available concerning the two components 
constituting metabolite 3* The following work on the characterisation of 
metabolite 2 has been carried out using an impure sample of the metabolite 
eluted from chromatograms using the cellulose/solvent IV system.
High voltage electrophoresis at pH 2, 6 and 10 showed the 
metabolite to have no net charge at pH 2 and 6, but to migrate as an acid 
at pH 10. This suggests the presence of a strongly acidic group, ionised 
at pH 2, together with a basic group of pK between 6 and 10. (The 
alternative explanation of one acidic group, pK between 6 and 10, but no 
other ionisable groups, seems unlikely when the structure of the original 
drug is considered).
The only acidic function having a pK less than 2, and likely 
to occur as a result of metabolism, is a sulphate ester. Ho estimate of 
the pK of these esters, appears to have been published, although they are 
-known to be very strong acids (Burkhardt et al., 1936). Sulphatase 
hydrolysis (section 2.9*2) followed by chromatography in solvents III and 
VII showed partial conversion of the metabolite to a compound having the 
same Rp as hydroxy tolamolol. The hydrolysis was repeated, and again 
only partial conversion of the metabolite was observed. % TLC in solvent 
VII showed the hydrolysis product to co-chromatograph with hydroxy 
tolamolol, and to react with diazotised_o-dianisidine in the same way. as 
hydroxy tolamolol.
Acidic hydrolysis of the metabolite (section 2.9*3) gave two 
products, as shown by TLC in solvents III and VII. Both products reacted 
with Gibb's reagent to give a blue colour, and with diazotised o-dianisidine 
to give a brown colour. One product co-chromatographed with hydroxy 
tolamolol; the other product had an R^ in solvent VII greater thanX
tolamolol, but less than tolamolol acid. This unidentified phenolic 
compound was also found when hydroxy tolamolol was hydrolysed with acid 
(section 2.4*1) and is probably hydroxy tolamolol acid, i.e. tolamolol 
acid with a 4-hydroxy group.
The evidence from these experiments strongly suggests that 
metabolite 2 is hydroxy tolamolol sulphate.
SUMMARY OF METABOLITE ISOLATION
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7.5 DISCUSSION
Tolamolol is well-absorbed in the rabbit, even when administered 
in gram quantities, as in this experiment. However, the presence of 
unchanged drug in the faeces suggests that not all the dose was absorbed, 
although it is perhaps significant that unchanged tolamolol was apparently 
found in the faeces from a guinea pig afber intravenous dosing (section
6.2.2 and Figure 6.2). ' . -
In contrast to the species so far-considered (i,e. , the mouse, 
rat and guinea pig), the urine is the major route for excretion of 
radioactivity, even after oral dosing. In the rat, and in the guinea pig, 
biliary excretion has been shown to be a prominent feature in the 
disposition of tolamolol, and probably accounts for the high faecal 
excretion in these species. The rabbit, on the other hand, is generally 
considered to be a ’poor* biliary excretor (Abou-el-Makarem et al., 1967; 
Hirom et al.,' 1972b), and this probably accounts for the observed species 
difference in excretory routes.
The major metabolites of tolamolol in the rabbit have been 
identified as hydroxy tolamolol glucuronide, hydroxy tolamolol sulphate 
(tentative identification), and tolamolol acid. From Figure 7*l(A) it is 
probable that hydroxy tolamolol is excreted in the urine unchanged, and 
although this has not been proved by isolation,, it would not be unexpected 
The presence of hydroxy tolamolol in the faeces is almost certainly the 
result of biliary excretion of hydroxy tolamolol glucuronide which, with 
a molecular weight of 536, is above the threshold molecular weight of 
475 + 50 required for biliary excretion (of anions) in the rabbit (Hirom > 
et al., 1972b). Hydroxy tolamolol sulphate, molecular weight 440, is near 
the lower limit of this threshold, and is therefore unlikely to be 
excreted in the bile.
A further difference between the three species studied so far 
and the rabbit is the appearance of significant quantities of tolamolol 
acid in the rabbit urine. One explanation is that there might be a more 
active amidase in the rabbit than in the other species - from the work of 
Bray et al., (l950)» the hydrolytic activity of rabbit liver and kidney 
for aromatic amides is greater than that of several other species-, 
including the guinea pig and rat. Another explanation is' that, although 
aromatic hydroxylation is the preferred metabolic route, as in the other 
three species, the massive dose of tolamolol administered to the rabbits 
in these experiments saturated the microsomal hydroxylating system so that 
an. alternative, but less favourable, metabolic route (hydrolysis) was 
called into operation. Of course, this argument could be applied in the 
opposite sense, hydrolysis being the favoured reaction, with hydroxylation 
a second choice.
Quantitative results for the relative proportions of hydroxy 
tolamolol and tolamolol acid were not obtained in this work, although from, 
the chromatographic data it is probable that hydroxy tolamolol is the major 
Phase I metabolite. However, the possibility of a change in metabolite 
pattern with dose (as suggested above) should be investigated by determining 
the ratio of hydroxy tolamolol (free and conjugated) to tolamolol acid 
(including conjugates if any) for different dose-levels. This will show 
whether there is a favoured route, and give some indication of its capacity. 
A dose-related variation in metabolism could be important both in 
assessing the validity of the toxicity trials, and also if it is necessary 
to use widely varying dose-levels of tolamolol in man.
7.4 ADDENDUM TO CHAPTER 7
Authentic hydroxy tolamolol was treated with acid under the 
same conditions used for metabolite 2 (section 2.9*3)- Chromatography 
of the hydrolysis solution showed two products: unchanged hydroxy tolamolol 
and a second phenol at higher R^ ,. About 5 4 of the hydroxy tolamolol 
had been converted to this second product. High voltage electrophoresis 
of the hydrolysis product at pH! 10 and 12 indicated the presence of both 
a phenolic and a carboxylic acid group. Comparison of values of the 
hydrolysis product with tolamolol, tolamolol acid and hydroxy tolamolol in 
solvents I, III and VII showed that the compound was equivalent to
i .
tolamolol acid with one phenolic group, or to hydroxy tolamolol with the 
carbamoyl group replaced by a carboxyl group. The data are consistent 
with the product of acid treatment of hydroxy tolamolol being the acid 
resulting from hydrolysis of the carbamoyl group, i.e., hydroxy tolamolol 
acid (see below). Since this-product was also obtained after acidic 
hydrolysis of metabolite 2, the above work provides additional evidence 
for metabolite 2 being ah acid-labile conjugate of hydroxy tolamolol.
0.CH2CH(OH)CH2HH.CHgCHg.0
HO'^s^'CH, ^^'COOH
Hydrolysis product of hydroxy tolamolol
Chromatography of the crude metabolite extract obtained by 
preparative TLC resolved the radioactivity into three components, the major 
component being metabolite 2., The other two components (representing 
metabolite 5) were together eluted with methanol, and subjected to 
glucuronidase hydrolysis. One metabolite was hydrolysed to give tolamolol, 
identified by co-chromatography in solvents I, III, VI and VII. Thus in 
the rabbit, tolamolol is probably conjugated with glucuronic acid; biliary 
excretion of this conjugate could account for the presence of tolamolol 
in rabbit faeces.
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8.1 INTRODUCTION
In assessing the safety of a new drug, regulatory authorities 
require toxicity data from a non-rodent species. The dog is commonly 
used in this role as it is readily available in defined breeds, its 
temperament makes for easy handling for dosing and sample collection, and 
there is an extensive literature covering its physiology, pathology and 
anatomy. Dogs were used in the toxicity trials of tolamolol, and so 
routes of excretion and metabolite patterns were investigated. The 
primary objective for this work was to determine the suitability of the 
dog as a toxicity trial species by comparison with similar 'data from other 
species and man.
The dog was also used in pharmacological studies to assess the 
beta-blocking potency of tolamolol. It was therefore of interest to 
obtain information about drug-related compounds in plasma, and some work 
on this aspect was carried out.
8.2 METHODS-AMD RESULTS
8.2.1 DOSING, AM) PLASM LEVELS OF RADIOACTIVITY
Six experiments were carried out in which radioactive tolamolol 
was administered to dogs either orally or intravenously. One dog, 
reference number 8G01, was dosed orally at 100 mg/kg, but vomited soon 
after the two-hour blood sample had been taken. Chromatography of the 
vomit showed that the only radioactive material present was unchanged 
drug. Determination of radioactivity, and UV assay for total tolamolol, 
gave identical results. Therefore, two hours after dosing, the drug had 
not been completely absorbed. The actual dose received by this animal, 
callulated from the recovery of drug in the vomit, v/as 48 nig/kg.
! Dog 9JZ2 v/as dosed at 25 mg/kg v/ith radioactive drug, and was
given a second dose of unlabelled drug at a dose-level of 50 mg/kg six 
hours later. Although the total dose of tolamolol was equivalent to 75 
mg/kg, in terms of radioactivity the dose v/as only equivalent to 25 mg/kg.
Aliquots of plasma were counted by solubilisation using toluene/ 
NE 520 scintillator; the results are given in Table 8.1. Plasma samples 
from dog 6DB2, after both routes of administration, were obtained at more 
frequent time intervals than indicated in Table.-8.1, and the full results 
have been plotted in Figure 8.1.
• In two of the’ orally-dosed dogs absorption of the drug was 
delayed: in the case of 8G01 it is possible that rapid absorption of the 
drug soon after the 2-hour blood sample had been taken was the cause of 
vomiting. Possible reasons for the delayed absorption, which is clearly 
illustrated for dog 6DB2 in Figure 8.1, are considered in the Discussion, 
section 8.5.
TABLE 8.1
Plasma levels of radioactivity in dogs dosed with
radioactive tolamolol
Bogs were dosed with radioactive tolamolol at the dose-levels indicated.
All concentrations are expressed as pg equivalents of tolamolol base per ml 
of plasma. : Results are the mean of tritium and carbon-14 values; isotope 
ratios are calculated (section 2.7.5)* The dose-level for dog 8G01 was 
calculated from the recovery of tolamolol in vomit (see text). The 25 mg/kg 
dose of labelled tolamolol given to dog 9JZ2 was followed six hours later 
by a further.50 mg/kg dose of unlabelled drug. The total dose of tolamolol 
was therefore equivalent to a dose-level of 75 mg/kg.
Hours
after
dose
8G01
48mg/kg
p.o.
9JZ2
25mg/kg
p.o.
6BB2
20mg/kg
p.o.
9JZ2
2mg/kg
p.o.
9JZ2' 
2mg/kg 
i. v.
6BB2
2mg/kg
i.v.
PLASM RABIOACTBriTY (pg/mlL)
1 1.4 19 0.1 0.65 0.52 0.39
2 1.6 25 ii 0.54 0.46 0.35
4 18 17 8 0.51 0.34 0.36
6 .  - 6 - - 0.28
7 • 6 18 - 0.53 0.25 . -
24 4 4 2 0.15 0.09 0.08
ISOTOPE RATIO
-
1 110 120 - 120 110 115
2 105 115 115 150 125 115
4 115 130 120 135 125 115
6 - - 150 — - 125
7 135 130 - 130 145 -
24 150 205 180 160 560 195
FIGURE 8.1
Plasma radioactivity after oral and intravenous administration
of radioactive tolamolol to a dog
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Hours after administration
Log 6LB2 dosed with radioactive tolamolol at 20 mg/kg p.o. or 
2 mg/kg i.v. Concentration is expressed as jig equivalents of 
tolamolol base per ml of plasma. Values plotted are the mean 
of tritium and carbon-14 results.
The plasma levels of radioactivity for dog JJZ2 dosed orally 
and intravenously at 2 mg/kg correspond closely, suggesting that absorption 
of the drug after oral administration is virtually complete. The 
increase in plasma radioactivity with dose is also indicative of good 
absorption.
The isotope ratios in Table 8.1 are calculated values, andt 
therefore the absolute value is of doubtful significance (section 2.7*5)* 
During each experiment, however, the ratio increased with time, suggesting 
the presence of tritiated water as discussed in section 4-3« Volatile 
tritium was determined for plasma from dog JJZ2 after intravenous and 
oral doses of 2 mg/kg, and was equivalent to 3-4$ of the tritium activity 
one hour after dosing, rising to about 35$ at 24 hours. • This confirms 
the trend shown by the' isotope ratio.
The levels of radioactivity do not show a steady decline - in 
two dogs the .concentration at 7 hours is higher than it is at 4 hours. 
Figure 8.1 shows this effect for dog 6DB2 after intravenous dosing, the 
plasma radioactivity/time curve showing a slight maximum about three 
hours after dosing. The non-first-order decline in plasma radioactivity 
is due to the presence of metabolites in the plasma, as described in the 
next section.
8.2.2 METABOLITES IN PLASM FROM BOG 6DB2
The pattern of metabolites in a methanol extract of plasma was 
determined as follows. Plasma, 0.5 ml, was mixed with 4*5 nil of AR methanol 
and centrifuged. The supernatant was transferred to a separate tube, and 
the protein pellet washed with a further 2 ml of methanol. After 
centrifugation the methanol wash was added to the first extract, and the 
resultant solution evaporated to dryness using a rotary evaporator. The 
residue was extracted three times with a total of 0.5 ml of methanol, and 
the methanol evaporated to dryness under nitrogen. The residue was re­
dissolved in 0.25 ml of methanol and this extract used for chromatography.
The plasma protein precipitates from the orally-dosed dog were combusted to 
determine tritium; the maximum recovery of radioactivity occurred for the 
5-hour sample and was equivalent to 2.1$ of the total activity. In the 
following work, no correction for this loss of radioactivity was made.
For chromatography, 0.05 ml of the methanol extract, equivalent 
to 0.1 ml of plasma, was applied to a Merck pre-prepared cellulose plate 
as a 3 cm band. .To reduce interference from lipids, the plate was first 
developed in hexane/acetic acid (90:10) to a height of 11 cm, allowed to 
dry at room temperature, and then re-developed in solvent IV. To 
standardise conditions, the second development was started 4 hours after 
the start of the first development, and care was taken to ensure that the 
chromatography tanks were well-saturated with solvent.
Each plasma sample was run in duplicate, with markers of tolamolol 
and tolamolol acid superimposed on the extract. One chromatogram was 
divided into 5 mm wide strips for counting, and after establishing the 
pattern of radioactivity, regions on the duplicate chromatogram corresponding 
to radioactive regions on the first chromatogram were marked out. The 
cellulose from these areas was transferred to filter paper discs, which 
were folded and combusted to determine tritium (Packard Sample Oxidiser).
Typical metabolite patterns are shown in Figure 8.2, and show
the decrease in tolamolol with time, the increase in tolamolol acid with
time, and also the appearance of a band corresponding in R^ , to an acid-
labile urinary metabolite (see section 8.2.4)» which represents an
increasing proportion of the total plasma radioactivity with time. After
oral dosing there is a metabolite at the solvent front which does not
correspond to the marker of tolamolol acid. Despite attempts to keep the
chromatographic conditions the same for all samples, chromatograms showing
this activity at the solvent front gave a lower R„ value for tolamolol1?
acid than previous chromatograms, including all those obtained for the 
intravenous dose samples. Thus it may be that in other chromatograms where 
tolamolol acid is near the solvent front, a second radioactive component 
.is also present. However, this appears to be a relatively minor component, 
and should not affect the results to a significant extent.
The variation in concentration of plasma metabolites with time 
is shown in Figures 8.3 and 8.4. The major metabolite after oral and 
intravenous dosing is tolamolol acid, as expected from its predominance
V.
in urine. After intravenous dosing, tolamolol shows an apparently biphasic 
decline in radioactivity, with a half-life for the second phase of about
2.5 hours; this compares with a half-life for propranolol in the dog of 
about 45 minutes (Hayes and Cooper, 1971). The metabolite provisionally 
identified as the acid-labile urinary metabolite reaches its maximum 
concentration later than tolamolol acid. Although not shown in Figure 
8.4? the concentration of this metabolite, also of tolamolol and tolamolol 
acid, was determined for the 24-hour plasma, giving concentrations of
0.53, 0.11 and 0.47 pg/ml respectively. Thus, 24 hours after dosing, the 
acid-labile metabolite is present in higher concentration than tolamolol 
acid, and may therefore be a secondary metabolite occurring as a result 
of enterohepatic circulation (see Discussion, section 8.3).
FIGURE 8.2
Plasma metabolite patterns after intravenous and oral administration
of radioactive tolamolol to a dog
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Markers: T = tolamolol; TA = tolamolol acid.
Log 6LB2 received radioactive tolamolol at either 2 mg/kg i.v. or 
20 mg/kg p.o. Methanol extracts of plasma prepared as described in text,
: . ' FIGURE 8,5
Plasma metabolites in dog 6UB2 after intravenous administration of
radioactive tolamolol
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Hog 6HB2 received radioactive tolamolol at a dose-level of 2 mg/kg i.v. 
Radioactive compounds in plasma assayed as described in the text.
FIGURE 8.4
Plasma metabolites in dog 6DB2 after oral administration of
. radioactive tolamolol
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Hog 6BB2 received radioactive tolamolol at a dose-level of 20 mg/kg 
Radioactive compounds in plasma assayed as described in the text.
The advantage of a chromatographic assay using radioactive drug, 
as compared to a chemical assay, is that not only can unchanged drug be 
measured, but also metabolites whose structure is unknown. The disadvantage 
is that there is no way of ensuring that only one compound is being 
measured, the success of the method depending entirely on the efficiency 
of the chromatographic system in separating the different components.
The solvent system used in this work (solvent IV, cellulose plate) 
gave an adequate separation of tolamolol and tolamolol. acid, and. provided 
a reasonable separation of the other, more polar metabolites. By 
comparison with silica gel as adsorbent, however, the separated bands on 
cellulose tended to be broader and less well-defined. Using markers of 
tolamolol and tolamolol acid applied over the plasma extract, the areas 
containing these compounds after chromatography'were sufficiently well 
delineated to enable removal of the bands to be carried out apparently 
without cross-contamination. The data in Figures 8.5 and 8.4 must 
neverthelessbe treated with caution. ^
8.2.5 EXCRETION OF RADIOACTIVITY IN URINE AND FAECES '
Urine and faeces from the dogs described in section 8.2.1 were 
collected daily; urine was counted using NE 250 scintillator, and faecal 
radioactivity was determined by combustion.
The results, which are given-in Table 8.2, suggest that the dog 
has no preferential route of excretion for doses of tolamolol. In three 
experiments urinary and faecal excretion was comparable; in one experiment 
(oral dose) urinary excretion was about double the faecal excretion, while 
in another experiment (intravenous dose) faecal excretion was nearly double 
the urinary excretion. The isotope ratio was calculated, and no significant 
conclusions can be drawn from the available data.
TABLE 8.2
Excretion of radioactivity by dogs after administration of
radioactive tolamolol
Bogs were dosed with radioactive tolamolol at the dose-levels indicated. 
All results are expressed as percentage of the administered dose, values 
being-the mean of tritium and carbon-14 figures. Isotope ratios are 
calculated (2.7-3). See legend to Table 8.1 for details of the doses 
received by 8G01 (48 mg/kg) and JJZ2 (25 mg/kg).
Bay-
8G01
48mg/kg
p.o.
9JZ2
25mg/kg
p.o.
6BB2 
20mg/kg 
- p.o.
9JZ2
2mg/kg
p.o.
9JZ2 
' 2mg/kg 
i.v.
6BB2
2mg/kg
i.v.
IJRINE
1 15.9 * 22.9 16.2 17.0 8.4
2 24.0 51.4 12.8 11.2 7.8 1.1
3 5.2 9.4 - 4.1 1.1 0.2 '
1-3 45.1 60.8 35.7 . 31.5 25.9 9.7
FAECES
1 20.8 * 21.0 9.8 34.9 *
2 • 11.7 18.6 17.5 18.0 7.O . 0.6
3 7.9 10.5 . - 3.6 1.1 0.1
1-3 ' 40.4 29.1 38.5 31.4 ' 43.0 0.7
BRINE
+
FAECES
85.5 89.9. 74.2 62.9 68.9 10.4
ISOTOPE RATIO - BRINE
1 100 - 95 90 90 95
2 100 100 95 95 90 100
3 100 100 - 95 90 150
ISOTOPE RATIO - FAECES
1 110 - 120 115 110 —
2 105 115 120 105 110 x 115
3 105 110 - 105 105 110
* indicates that no sample was excreted during the collection 
period.
The results for dog 6DB2, dosed intravenously at 2 mg/kg, are 
clearly atypical. This dog was used for pharmacological studies, and 
sample collection was carried out by someone not familiar with the use 
of radioactivity to determine excretion patterns. It is probable that 
incomplete sample collections were made. The second experiment carried 
out in this dog gave results comparable to previous experiments; in this 
case the importance of complete sample collection was stressed.
\
e.2.4 METABOLITE PATTERNS IE URINE
The initial studies of metabolite patterns in dogs involved the 
use of extraction and hydrolysis techniques. For example, 10 ml of Day 
2 urine from dog 9JZ2 (25 mg/kg p.o.) was basified by the addition of 1.5 " 
ml of 1 M NaOH, and extracted three times with 12 ml of di chi or o ethane.
The urine was then acidified by adding 1.5 ml of concentrated HC1, and 
extracted three times with 15 ml of ethyl acetate. The aqueous phase was 
heated on a steam-bath for one hour, cooled, and re-extracted as before 
with ethyl acetate. The radioactivity in the extracts, expressed as a 
percentage of the urine radioactivity was as follows:
basic extract 1.9$ 
acidic extract 48• 8$ 
hydrolysate extract 14.5$ '
extracted aqueous phase 54*8$
Chromatographic examination of the acidic and hydrolysate extracts 
in solvents I and III showed one major radioactive compound, chromato-" 
graphically identical to tolamolol acid. Traces of other metabolites were 
present in the acidic extract. As the urine from this animal contained 
51$ of the dose, and the extracts of acidified and hydrolysed urine 
contained mainly tolamolol acid, this compound, perhaps together with an 
acid-hydrolysable precursor, accounts for over 50$ of the dose.
Similar extraction results were obtained for dog 8G01 (48 mg/kg 
p.o.) and dog 9JZ2 (2 mg/kg p.o. and 2 mg/kg i.v.). The acidic and 
hydrolysate extracts from these experiments also contained one major radio­
active component, identical to tolamolol acid by co-chromatography in 
solvents I, III, VI and VIII. A crude sample of' this metabolite was 
obtained by preparative TLC of the hydrolysate extract from dog 8G01, using 
solvents I and III; high voltage electrophoresis of this crude metabolite 
showed it to be amphoteric (see section 2.6). Taken together, the results 
of TLC and electrophoresis suggest that the major urinary metabolite, 
which accounts for at least half the urinary radioactivity,: is tolamolol 
acid.
In the extraction experiments, a considerable proportion of the - 
radioactivity remained in the aqueous phase. To investigate the nature 
of the non-extractable radioactivity, Day 1 urine from dog 6DB2 (2 mg/kg
i.v.) was chromatographed without any pretreatment, applying 15 pi over a 
2 cm origin band on a cellulose plate, and developing in solvent IV. The 
chromatogram was sectioned and counted, and showed tolamolol acid to be 
the main component. However, a second, more polar compound was also 
present, together with a number of minor metabolites.
The effect of ^-glucuronidase and acidic hydrolysis on the 
metabolites was determined using the procedures described in section 2.9* 
Extracts from .these, experiments were chromatographed on cellulose using 
solvent IV; the results are shown in Figure 8.5« The major polar metabolite 
is not hydrolysed with glucuronidase, but is acid labile, yielding a 
compound having an. R_ similar to, but lower than, tolamolol. Glucuronides 
are present, but only as minor metabolites. The major urinary metabolite 
is tolamolol acid, and the minor metabolite present at the solvent front 
contains only tritium, indicating a certain degree of alkyl chain cleavage.
FIGURE 8.5 
Hydrolysis of dog urine
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Day 1 urine from dog 6DB2 (2 mg/kg i.v.) hydrolysed with glucuronidase 
(section 2.9.1) and with acid (section 2.9*3)•
The results for the Day 1 and Day 2 urine from dog 6DB2 after 
oral dosing were similar to those obtained after intravenous dosing, except 
that the Day 1 urine contained more of the glucuronides and less of the 
acid-labile metabolite than Day 2 urine. Thus it seems that changing the 
route of administration does not qualitatively affect the pattern of 
metabolites.
A further comparison of urines after oral and intravenous dosing 
was obtained using the following extraction procedure. Samples of urine 
(10 ml) from dog 6DB2 (Day 1, i.v. and p.o. doses; Day 2 p.o. dose) were 
-treated with anhydrous to give a pH of 11, and extracted three times
with 10 ml of dichioroethane. The aqueous phases were then adjusted to 
pH 1 with concentrated HC1, and extracted three times with 10 ml of ethyl 
acetate. The pH of the aqueous phase was increased to about 3 hy the 
addition of solid HagHPO^, residual ethyl acetate removed by bubbling 
nitrogen through the solution for 15 minutes, and the urine then passed 
down a 9 x 85 mm column of XAD-2 resin. The column was washed with 9 
column volumes of water, and eluted with 5 column volumes of methanol. 
Counting was carried out at each stage; the results are given in Table 8.3 
The essential similarity of the extraction pattern is clear; chromatography 
of the acidic extracts, and the XAD-2 methanol eluates gave similar 
results, both in the number of metabolites and their relative abundances.
TABLE 8.5
Extraction of urine from dog 6DB2 after intravenous and oral
doses of radioactive tolamolol
The results are the percentage of the total urinary radioactivity appearing 
in each extract, and are the mean of the tritium and carbon-14 values.
Extract 2 mg/kg i.v. Day 1
20 mg/kg p.o. 
Day 1
20 mg/kg p.o. 
Day 2
Basic extract 3 3 2
Acidic extract 49 59 65
XAD-2 water wash 6 5 3
XAD-2 methanol eluate 43 34 30
XAD-2 resin was used to isolate small quantities of the major 
polar metabolite. Urine samples from dog 6DB2 (Day 1, both dose levels,
Day 2, oral dose; approximately equal volumes) were combined to give a
total volume of about 50 ml. Solid NaHSO^ was added (2.6 g) to bring the
pH to about 1, and the acidified urine extracted three times with a total 
of 250 ml of ethyl acetate. The aqueous phase was brought to pH 4 by the 
addition of 1 ml of 1 M NaOH and 2.6 g of Ha^HPO^, and applied to a 
20 x‘120 mm column of XAD-2 resin. After washing with water (8 column 
volumes), the column was eluted with methanol (4 column volumes). Counting 
showed that the acidic ethyl acetate extract contained 44i° of the urinary 
radioactivity, the XAD-2 methanol eluate 43/W and the water wash 15$>.
The methanol eluate was’concentrated and chromatographed on Whatman 
paper using solvent TV; radioactive bands were located by scanning. A 
radioactive band at R^ , about 0.5, judged by its position relative to the 
other bands to be the acid-labile metabolite, was removed and eluted with 
methanol. This crude extract was used to determine the electrophoretic 
behaviour of the metabolite at pH 2, 6 and 10, comparing its migration
with markers of tolamolol, tolamolol acid, and p>-nitrobenzenesulphonic acid.'
The migrations of the markers and the major radioactive metabolite relative 
to jD-nitrobenzenesulphonic acid are shown diagramma-tically in Figure 8.6.
Urea was used to correct for electroendosmotic flow. The 
displacement of uncharged compounds from the zero line is almost, certainly 
due to the large difference in molecular size between urea and the drug- 
related compounds, with the result that urea is able to follow the net flow 
of water more rapidly than the larger compounds. The true zero line for 
these experiments should therefore be about +10 in the diagram.
Tolamolol and tolamolol acid behave as expected on electrophoresis 
(section 2.6), and it is interesting to note that the relative migration 
appears to increase by about 40 units for each group ionised. The behaviour
FIGURE 8.6
High voltage electrophoresis of the acid-labile metabolite
from dog urine
Tolamolol acid
Buffer
pH
Tolamolol Metabolite
10-1
2 -
- 100. “50 0 50 100
Migration relative to £-nitrobenzenesulphonic acidp
(x 100)
of the metabolite suggests two possibilities: either it is non-basic and 
contains an acidic group of pK less than 6, and a second acidic group of 
pK greater than 6 but less than 10, or it retains the basic function and 
has two acidic groups, one of pK less than 2 and the other of pK between 
2 and 6. These alternatives are considered in the discussion.
•A further sample of this metabolite was isolated from about 10 ml 
of urine by the same basic procedure as that described above, except that the
extraction step was omitted. The crude metabolite was purified by electro­
phoresis at pH 6, the major, acidic, component being eluted with methanol. 
After evaporation of solvent, the residue was taken up in pH 7 buffer, 
the solution divided into two portions, and one portion treated with 
glucuronidase (section 2.9*l)» the other serving as control. Chromatography 
showed that no hydrolysis had occurred; the metabolite is therefore
unlikely to be a glucuronide conjugate.
8.2.5 METABOLITE PATTERNS IN FAECES
Faeces from dog 9JZ2 at all three dose-levels (see Table 8.4) 
were extracted in a Soxhlet extraction apparatus first with dichioroethane, 
then-with ethyl acetate, and finally with methanol. The percentage of 
the faecal radioactivity recovered in each extract is given in Table 8.4*
• table 8.4
Extraction of faeces from dog 9JZ2 after administration of
radioactive tolamolol
Bose-level and 25 mg/kg p.o. 2 mg/kg p.o. 2 mg/kg i.v.
samples extracted Bays 2 + 3 Bays 1 + 2 Bays 1 + 2
Faecal activity ($> dose) 29 28 42 .
fo faecal dichloroethane 25 11 26
activity * ethyl acetate 8 8 53
extracted kmethanol 45 39 11
Faeces were extracted in a Soxhlet apparatus. Each daily sample of faeces 
was extracted separately, but for convenience the sum of results for each 
dose level is reported. The results are the mean of tritium and carbon-14 
values. The dog excreted no faeces on Bay 1 after the 25 mg/kg dose..
The distribution of radioactivity between the extracts apparently 
varies with the route of administration, but no valid conclusions can be 
drawn from so few experiments. Chromatography of the dichloroethane extracts 
showed one main radioactive component, having a similar to tolamolol in 
solvents I, III, VI, and VIII. Thus, after intravenous dosing, for 
example, about 10fo of the dose appears in the faeces,' apparently as 
unchanged drug. Chromatography of the other extracts was less informative, 
but tolamolol acid was tentatively identified in the ethyl acetate 
extracts.
In a further experiment, Day 2 faeces from dog 9JZ2 (25 mg/kg p. 
were extracted with methanol in a Soxhlet apparatus. Virtually complete 
extraction of radioactivity was obtained, and chromatography of the 
extract in solvents VI and VII showed the presence of tolamolol and 
tolamolol acid in addition to a third major component (Figure 8.7). 
Authentic hydroxy tolamolol was not available at the time'this work was 
in progress, but on the basis of R^ value relative to tolamolol, the 
unidentified region of radioactivity could be due to hydroxy tolamolol.
FIGURE 8.7 :
Chromatogram of methanol extract of faeces after oral administration 
of radioactive tolamolol to a dog
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Markers: T = tolamolol, TA = tolamolol acid.
Day 2 faeces from dog 9JZ2, 25 mg/kg p.o., containing 18.6$ of 
the dose, extracted in a Soxhlet apparatus with methanol.
8.3 DISCUSSION
It is important that a drug such as tolamolol, which acts on
receptors in the heart (either directly, or indirectly through a metabolite),
be well absorbed after oral administration. In this work, the similarity
of plasma levels after oral and intravenous administration of the same
dose-level (dog 9JZ2, 2 mg/kg, Table 8.1), together with the approximately
dose-related levels of radioactivity in plasma after different dose-levels,
indicate that tolamolol is well absorbed in the dog. The delay in
achieving significant plasma levels of radioactivity in two of the orally-
dosed dogs must therefore be due to the absence of tolamolol at the
intestinal mucosa. This could be the result either of delayed gastric
■ - ? 
-emptying, or of delayed disintegration of the capsule. '
Tolamolol, being a weak base, is unlikely to be well absorbed in • 
the stomach (Shore et al., 1957)> so that if the stomach contents were not 
emptied into the intestine immediately after dosing, absorption would be 
delayed. As the dogs were not starved before dosing, the volume of the 
stomach contents, which is a major factor determining the gastric emptying 
rate (Gibaldi, 1971) > is not known. Another factor is that many amines 
have, been found to delay gastric emptying in the rat (Dr. J. V. Bridges, 
personal communication, 1973)> so that this might also contribute to the 
delayed^absorption of tolamolol.
The second possible explanation for delayed absorption is non- 
disintegration of the capsule in which the drug v/as administered. Under 
stomach or intestinal conditions, the gelatin capsule could have softened 
and collapsed around the drug - as no excipient was added, the drug would 
not be released until the gelatin had finally dissolved. (At the time 
these experiments were carried out the first explanation was considered
most reasonable, but since then it has become standard practice to include 
an excipient with capsule doses to eliminate any possibility of non­
disintegration of the capsule).
For the small number of experiments carried out there is no 
obvious pattern in the excretion of radioactivity. The high urinary 
excretion in one orally-dosed dog is additional evidence for good absorption, 
while the high faecal excretion after intravenous dosing demonstrates the 
likely occurrence, and importance, of biliary excretion in the disposition 
of tolamolol.
As found for the other species studied, tolamolol is extensively 
metabolised in the dog, with only small amounts of unchanged drug appearing 
in urine, plasma (Figure 8.2) or, probably, faeces. Although no quantitative 
data has been obtained, apart from the extraction experiments, tolamolol 
acid is undoubtedly the major biotransformation product of tolamolol - it 
is the most abundant single compound in urine, and is extensively excreted 
in faeces. The acid-labile metabolite is next in order of importance, 
although representing a much smaller proportion of the dose than tolamolol 
acid, as judged by chromatographic evidence (Figure 8.5). Of the remaining 
metabolites, the two most polar are glucuronide conjugates, as shown by 
enzymic hydrolysis, and there is at least one metabolite present of similar 
Rp to tolamolol. In addition, there is a relatively non-polar metabolite 
which only contains tritium.
The presence in plasma of volatile tritium, representing an 
increasing proportion of the total tritium activity with time after dosing, 
shows that hydroxylation of the £ ring has occurred. Authentic hydroxy 
tolamolol was not available at the time this work was carried out so that 
it is not possible to say with certainty whether it was present or not.
As hydroxy tolamolol is a major metabolite in the other species examined,
it is to be expected as a metabolite, even if only a minor metabolite, in
the dog. On the basis of relative IL, values, one of the glucuronidei?
conjugates is probably the glucuronide of hydroxy tolamolol.
Ho serious attempts were made to isolate and identify the acid- 
labile metabolite. However, the electrophoresis data obtained for a crude 
extract of the metabolite allows two interpretations, as noted in section 
8.2.4. The first possibility would be satisfied by a compound such as 
tolamolol acid, hydroxylated. in the ring, with the basic nitrogen masked 
in some way, e.g. by acetylation. This is unlikely since secondary 
aliphatic amines are not aoetylated in vivo (Mandel, 1971); furthermore, 
a phenolic hydroxyl group in the (> ring will probably not be sufficiently 
ionised at pH 10 to markedly affect the migration of the compound on
eleotrophoresis.
The second possibility would be satisfied by proposing a sulphate 
ester of hydroxylated tolamolol acid. Sulphate esters are very strong acids 
acids (Burkhardt et al., 1936), and would be ionised at pH 2. At this 
pH the basic nitrogen would be protonated, but the carboxylic acid would
not be ionised; the net charge on the molecule would therefore be zero.
At pH 6 all three groups would be ionised, leaving a net charge equivalent
to one acidic function. At pH 10 the nitrogen would not be protonated and
the molecule would therefore have two ionised acidic functions, and would 
be expected to migrate twice the distance it migrated at pH 6. The 
proposed structure for this metabolite, which will be called 'hydroxy 
tolamolol acid sulphate' (the aglycone being 'hydroxy tolamolol acid') is:-
?H
0. CH^CH. CH^NH. CH„CH«.
HSO-j. 0 CH2
3 3
Hydroxy tolamolol acid sulphate
A possible sequence of events leading- to the formation of hydroxy 
tolamolol acid sulphate is as follows. Hydroxy tolamolol is expected as 
a metabolite (as mentioned above), the hydroxylation probably occurring 
in the endoplasmic reticulum, mediated by cytochrome P-450» The glucuronyl 
transferases are also associated with the endoplasmic reticulum, and it 
is suggested that conjugation occurs almost immediately after hydroxylation 
to give hydroxy tolamolol glucuronide. From molecular weight considerations, 
and the classification of the dog as a ’good' biliary excretor of foreign 
compounds (Abou-El-Makarem et al., 1967), hydroxy tolamolol glucuronide 
will almost certainly be extensively excreted in the bile. In the 
intestine, hydrolysis by the gut microflora will liberate the aglycone.
This will be reabs'orbed because although hydroxy tolamolol is more polar 
than tolamolol, it is still comparatively lipid soluble•(calculated 
log P is 0.81). '
In dogs, there is some site, probably the liver (see section 1.5)» 
which contains a potent amidase, sjnce the major metabolite of tolamolol 
in the dog is formed by hydrolysis of the carbamoyl group. _ Thus hydroxy 
tolamolol, after absorption, will be exposed to this amidase, giving 
hydroxy tolamolol acid. As the bulk of the sulphotransferase activity is 
in the cytoplasm (Dodgson and Rose, 1970)> it might be expected that the 
more polar the compound, the more likely it is that sulphate conjugation 
will occur in preference to glucuronide conjugation. This would explain 
why it is that a sulphate conjugate is excreted in the urine, but that 
significant amounts of a glucuronide conjugate are not found (see, for 
example, glucuronidase hydrolysis of urine, Figure 8.1).
A diagrammatic representation of the proposed routes for the 
formation of hydroxy tolamolol acid sulphate is given on the next page.
T = tolamolol
HT « hydroxy tolamolol 
TA a tolamolol acid 
HTA a hydroxy tolamolol acid
K/I
Reabsorption
LIVER
P-450 k Amidase'
Glucuronic
acid
HTA TAHT
HT
Sulphate
Intestinal
hydrolysis HT-Gluc HTA-SO
UrineBile
Proposed metabolic scheme for tolamolol in the dog
The above scheme is oversimplified; for example, some hydroxy 
tolamolol will be conjugated with sulphate and will appear in the urine, 
and hydroxy tolamolol glucuronide will almost certainly be excreted to 
some extent in the urine.
One of the consequences of this hypothesis is that hydroxy 
tolamolol acid sulphate, being a secondary metabolite formed after entero- 
hepatic circulation, will have a prolonged excretion. It was noted that 
the-acid labile metabolite formed a higher proportion of the urinary radio- 
activity on Bay 2 than on Bay 1 (dog 6BB2, 20 mg/kg p.o.; section 8.2.4)• 
Furthermore, there is a metabolite in plasma having a similar R^ , to the 
acid labile urinary metabolite (section-8i2.2), and the concentration 
of this metabolite lags behind the concentration of the other radioactive
components in plasma. For example, the maximum concentration of tolamolol 
acid occurs between 2 and 3 hours after intravenous dosing, whereas the 
maximum concentration of the polar metabolite occurs between 5 and 6 hours 
.after dosing (Figure 8.6). If the polar plasma metabolite and the urinary 
metabolite are the same (and a prominent urinary metabolite might be 
expected to be present as a significant metabolite in plasma), then the 
delayed appearance of the plasma metabolite would be consistent with 
hydroxy tolamolol acid sulphate formed according to the scheme above.
To check this hypothesis it would be necessary to prepare a 
crude extract of the metabolite (for example, by chromatography), determine 
whether or not it was a sulphate by enzymic hydrolysis, and then determineS'
the nature of the aglycone, perhaps by high voltage electrophoresis. These 
experiments would provide good circumstantial evidence for the proposed 
structure of the acid-labile metabolite.
■8.4 ADDENDUM TO CHAPTER 8
The polar dog metabolite was isolated in crude form by XAD-2 
-treatment of urine followed by TLC of the methanol eluate in solvent III. 
High voltage electrophoresis at pH 2, 6 and 10 confirmed the results 
shown in Figure 8.6. Sulphatase hydrolysis (section 2.9.2) gave partial 
conversion to a compound with an Rp intermediate between tolamolol and. 
tolamolol acid in solvent III. , High voltage electrophoresis of the 
control and enzyme-treated solutions at pH 10 and 12 indicated that the 
hydrolysis product was a phenol.
This evidence suggests that the metabolite is a sulphate 
conjugate of hydroxylated tolamolol acid, as suggested on page 192. 
Insufficient material was available for a direct comparison of the 
aglycone of the dog metabolite with the hydrolysis product of hydroxy 
tolamolol (Addendum, Chapter 7)> but values and relative R^ values 
were consistent with the proposed structure.
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9.1 INTRODUCTION
Although a compound may show activity in animals, it must also 
show useful activity in man compared to existing drugs if it is to he 
marketed as a new drug. Tolamolol had shown potency and cardioselectivity 
as a beta-blocker in.animals, and it was important that this spectrum 
of activity should be demonstrated in man. However, while it is relatively 
easy' to determine the efficacy of a drug as a beta-adrenoceptor antagonist 
in man, for example, by measuring inhibition of exercise tachycardia, it 
is much more difficult to test for selective blockade of the cardiac beta-
receptors in man (Barrett, 1971)*
r
The methodology for determining cardioselectivity in man was 
available at the Royal Postgraduate Medical School, Hammersmith Hospital. 
Professor C. T. Dollery and his colleagues agreed to evaluate tolamolol 
as'a cardioselective beta-adrenoceptor antagonist in suitable volunteers, 
and their studies showed that tolamolol did have a greater effect on 
cardiac beta-adrenoceptors than on those in vascular smooth muscle 
(George et al., to be published).
Radioactive tolamolol was administered to two of the subjects 
on this trial so that blood levels, routes of excretion, and metabolic 
patterns could be determined. This chapter describes the results of 
these studies.
9.2 METHODS AND RESULTS
9.2.1 DOSING
Two healthy male volunteers, ages 42 and 45 > were given radio­
active tolamolol under controlled clinical conditions, one subject 
receiving 20 mg (0.24 mg/kg) intravenously, infused over 7 minutes', the 
other receiving 200 mg (2.5 mg/kg) orally. Both dosage forms were 
prepared using the formulations developed for use in clinical trials.
The specific activity of the administered drug was such that each subject 
received approximately 40 pCi of tritium, and 5 pCi of carbon-14.
9.2.2 PLASMA RADIOACTIVITY
Venous blood was collected at intervals from a catheter inserted 
in a forearm vein. The blood was taken into heparinised syringes and 
immediately centrifuged. The plasma was separated and stored at -15°.
For transport from Hammersmith to Pfizer Ltd., Sandwich, the plasma 
samples (and also urine samples) were kept frozen in large Dewar flasks 
containing solid carbon dioxide. ' v
Plasma was counted using Instagel scintillator. The results 
are given in Table 9*1 > and are presented graphically in Figure 9*1» 
peak plasma level of radioactivity in the orally-dosed subject was reached 
1*5 hours after dosing, but from the results in Table 9*1 absorption was 
apparently delayed for about 0.5 hour. The radioactivity levels for each 
experiment are approximately dose-related, and the isotope ratio tends 
to increase with time, as observed for the dog (section 8.2.2, Table 8.1).
The levels of radioactivity were too low for a chromatographic 
examination of drug-related material in plasma, or for assays of unchanged 
drug and tolamolol acid by the methods described in section 2.11.
TABLE 9.1
Plasma levels of radioactivity after oral and intravenous
administration of radioactive tolamolol to man
Radioactive tolamolol was given as an intravenous dose of 20 mg to one 
subject, and as an oral dose of 200 mg to a second subject. Results for 
plasma radioactivity are expressed as pg equivalents of tolamolol base per 
ml of plasma, and are the mean of tritium and carbon-14 values except for 
the 45.5 hour sample (oral dose): no carbon-14 was detected, and the value 
is for tritium only. Isotope ratios are measured values (section 2.7*3)«
Intravenous dose 20 mg Oral dose 200 mg
Hours 
after dose
pg/ml Isotoperatio pg/ml.
Isotope
ratio
0.02
r
0.85 100 —
0.03 0.49 95 - -
0.08 0.32 100 - -
0.17 0.25 105 - -
0.25 0.24 100 (0.0) -
0.34 0.22 105 - -
0.50 0.23 100 (0.02) -
0.75 0.23 100 0.3 110
1.00 0.22 100 1.6 v 105
1.50 - - 3.8 100
2.00 0.19 105 3.4 100
3.00 - - 2.7 95
4.00 0.14 105 2.0 100
5.92 - - 1.1 100
• 10.2 - - 0.5 115
19.5 0.03 140 -
21.3 - - 0.2 210
' 24.7 - - 0.2 240.
45.5 - - 0.2 -
' FIGURE 9.1
Plasma levels of radioactivity after oral and intravenous
administration of radioactive tolamolol to man
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Radioactive tolamolol was given as an intravenous dose of 20 mg to one 
subject, and as an oral dose of 200 mg to a second subject. Mean values 
of tritium and carbon-14 results are plotted, expressed as jig equivalents 
of tolamolol base per ml of plasma.
■9.2.5 EXCRETION OF RADIOACTIVITY IN URINE ACT) FAECES
Urine was collected as voided, the pH determined, and the volume 
measured after adding glacial acetic acid (0.5$ v/v) as preservative. The 
urine was stored at -15° and maintained in the frozen state for transport 
(see above). The urine pH for the intravenously-dosed subject varied from 
5.4 to 5*8 over the first 24 hours. Greater variation was found for the 
orally-dosed subject, the pH range being 5*2 to 6.9 (6.4 to 6.9 in the 
period up to 10 hours after dosing; the next two samples, obtained the 
following day, had a pH of 5*2). *
Radioactivity in urine was determined using Instagel scintillator.
r
The results for both subjects, expressed as percentage of the dose excreted 
.are given in Table 9.2, and the cumulative excretion of radioactivity is 
plotted in Figure 9.2. It is evident from Table 9.2 and Figure 9*2 that 
excretion of radioactivity in urine occurred very rapidly, and to a similar 
extent, for both subjects. Over 4 0 of the oral dose appeared in the urine 
in less than 5 hours, and this suggests rapid absorption. As 'JQffo of the 
dose was excreted in the urine within 24 hours, absorption is also 
extensive. The isotope ratio increases with time as observed with other 
species.
Faeces were frozen as soon as possible after collection, and 
kept frozen until required for homogenisation. The faeces were homogenised 
in water, the suspension freeze-dried, and radioactivity in the lyophilised 
faeces determined by the double-label combustion technique (section 2.7*4). 
The results are given in Table 9*2 and show that excretion of radioactivity 
in faeces is a minor route in man. The subject receiving the intravenous 
dose made only one collection of faeces, and it is probable that most of 
the radioactivity in faeces was excreted at 44 hours. The delayed 
excretion of radioactivity in faeces after oral dosing is interesting.
TABLE 9.2
Excretion of radioactivity in urine and faeces by man after oral and
intravenous administration of radioactive tolamolol
Radioactive tolamolol was given as an intravenous dose of 20 mg to one 
subject, and as an oral dose of 200 mg to a second subject. Results, 
expressed as percentage of dose, are the mean of tritium and carbon-14 
values. Isotope ratio was measured (section 2.7.3)• The orally-dosed 
subject made no urine collections after 44 hours; the 44-hour faeces sample 
after intravenous dosing was not collected (n.c.).
Intravenous dose 20 mg Oral dose 200 mg
Hours 
after dose io dose
Isotope
ratio io dose
Isotope
ratio
URINE
1.7
r
7.3 95
2.3 21.7 100 - -
4.6 - - . 36.1 95
6.8 23.1 105 - -
7.3 - - 11.7 95
. 10.6 - - 6.8 100
17.0 17.8 105 -
19.0 - - 7.1 95
19.8 2.6 95 -
24 3.0 95 3.1 95
44 - - 4.6 90
48 4*6 100 - -
72 1.4 150 - - ■
96 0.4 200 - -
120 0.1 6 20 - -
Total 0.-24 68.2 - 72.1 -
FAECES
44 n.c. . - - -
46 - - 0.2 -
68 1.4 130 - -
7° - - 0.2 -
94 - - 14.4 100
118 - - 0.6 90
Total
Urine+Faeces 76.1 - 92.1 -
FIGURE 9.2
Cumulative excretion of radioactivity in urine after oral and
intravenous administration of radioactive tolamolol to man
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Radioactive tolamolol was given as an intravenous dose of 20 mg to one 
subject, and as an oral dose of 200 mg to a second subject. The results 
are the mean of tritium and carbon-14 values, expressed as percentage of 
the administered dose. The isotope ratio did not differ significantly from 
100$ ( see Table 9*2).
9.2.4 METABOLITE PATTERNS IN URINE AND FAECES
Samples of urine were freeze-dried, and the residue extracted 
with methanol. Aliquots of the methanol extracts were chromatographed 
in solvents IV (cellulose plates) and VI (silica plates). These 
chromatograms showed a fairly complex pattern, with polar (low R^ ,) 
metabolites predominating, particularly in later samples of urine. To 
obtain a sample of urine equivalent to that which would have been obtained 
if a 0-24 hour collection had been made, i.e. 'Day 1 urine1, portions of 
the individual urine collections were combined in the ratio of their 
volumes. Chromatograms of the 'Day 1 urine' from both subjects (intravenous 
arid oral dosage) gave very similar patterns, as shown in Figure 9«3»
There are four major regions of radioactivity in the Urine
chromatograms, numbered 1 to 4 in order of increasing R^ , (but note thatJb
the numbers do not necessarily correspond to the rabbit metabolites
described in Chapter 7)* There is chromatographic evidence for the
presence of tolamolol acid (4)> and possibly unchanged drug, although
region 3 does not correspond exactly to the marker of tolamolol. In the
solvent system used (solvent III) tolamolol is not well separated from
hydroxy tolamolol, and the hydroxylated metabolite is probably contributing
to the radioactive peak. At the time this work on metabolite patterns
was carried out, authentic hydroxy tolamolol was not available for a
direct comparison with the urinary (or faecal) metabolites. In the light
of more recent work, however, it is clear that the R^ , of hydroxy tolamolol
is -similar but rather lower than the R,, of tolamolol in all the solventsF
used. Hydroxy tolamolol can therefore be tentatively, identified on the 
basis of relative R^ , values. Further tentative evidence for the presence 
of hydroxy tolamolol in urine was obtained as follows.
FIGURE 9.5
Chromatograms of human urine after oral and intravenous
administration of radioactive tolamolol
INTRAVENOUS DOSE 
20 mg300 - TA
0 J
' ORAL DOSE 
200 mg
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Solvent III (Bun0H/Ac0H/H20, 60:15:25). (Developed at 4°).
Markers: T = tolamolol, TA = tolamolol acid.
Two subjects were dosed with radioactive tolamolol as indicated.
’Day 1 urine’ (see text) was freeze-dried and the residue extracted with 
methanol for chromatography.
A sample (10 ml) of the urine obtained from the orally-dosed 
subject 4*6 hours after dosing was basified with sodium carbonate, ’and 
extracted three times with ethyl acetate. Chromatography of the entire 
extract using solvent VI showed a pronounced UV-absorbing band of slightly 
lower R-™ than tolamolol; this band was radioactive-, as shown by scanning.x *
The band was eluted with methanol into a tube containing about 0.5 ml of 
acetic anhydride. (At the time this work was in progress the rat faecal 
metabolite was being investigated, and as the R^ values of the human and 
rat metabolites were similar, it was decided to compare the two metabolites. 
However, as explained in section 5*2.6, the rat metabolite was unstable on 
chromatograms, probably due to oxidation, and this approach of eluting the 
radioactive material into acetic anhydride was tried as a method of 
.increasing the stability of the metabolite). A similar procedure, 
chromatography and elution into acetic anhydride, was carried out with a 
methanol extract of rat faeces.
The two acetylated residues, one from man and the other from 
rat faeces, were dissolved in methanol and chromatographed using as solvent 
ethyl acetate/toluene/acetic acid (50:40:10). In each' case the extract 
showed a major UV-absorbing component at R^ 0.13, with two minor components 
at Rp 0.23 and 0.30 (the latter being barely detectable). The metabolite 
giving rise to these acetylated products is therefore probably the same 
in both rat and man. The rat faecal metabolite was later identified as 
hydroxy tolamolol (section 5*2.6), and therefore it is probable that 
hydroxy tolamolol is excreted in human urine. The mixture of products 
obtained in this acetylation procedure is probably due to mono-, di- and 
tri-acetyl derivatives formed on the phenolic hydroxyl group, the 
secondary amine, and possibly the secondary alcohol; no further work was 
done to verify this assumption.
Glucuronidase hydrolysis (section 2.9.1) of ’Day 1 urine' from 
both subjects showed that metabolite 1 was a glucuronide, the aglycone 
almost certainly being hydroxy tolamolol, based on R^ values relative to 
-tolamolol in solvents III, IV (cellulose), and VI. Metabolite 2 (Figure 
9*3) was not appreciably affected by glucuronidase hydrolysis.
Faeces from the orally-dosed subject (96 hour sample) were 
extracted with methanol in a Soxhlet apparatus. Chromatography of the 
extract, which contained 95$ of the faecal radioactivity, using solvents
/•
III, VI, and VII showed clearly that, although traces of tolamolol acid 
were present, the major component was similar, but not identical to, 
tolamolol (Figure 9*4) On the basis of relative R„ values in the threeX
solvents, the faecal metabolite is probably hydroxy tolamolol.
9.2.5 ASSAYS FOR TOLAMOLOL AND TOLAMOLOL ACID IN URINE
The results of the assays for tolamolol and tolamolol acid in 
•Day 1 urine1, using the methods described in section 2.11, are given in 
Table 9»3 All the individual urine collections were assayed for tolamolol, 
but as no significant variation in the excretion of tolamolol with time 
was observed, these results are not included in the Table.
j
After oral dosing the percentage of the dose excreted as 
tolamolol and tolamolol acid was less than after intravenous dosing, 
although in terms of the weight of material excreted, more of these 
compounds were excreted after oral than after intravenous dosing. While 
it is unwise to generalise on the results obtained for two individuals, it 
does appear that neither compound is likely to represent a significant 
proportion of the dose excreted in urine.
FIGURE 9.4
Chromatogram of a faecal extract after oral administration of
radioactive tolamolol to man
200 - TA
(Bun0H/Ac0H/H90, 60:15:25). (Developed at 4°)
Markers: T = tolamolol, TA = tolamolol acid.
Faeces from man, %  hours after a 200 mg p.o. dose of tolamolol, extracted 
with methanol for chromatography.
TABLE 9.3
Excretion of tolamolol and tolamolol acid in human urine
after administration of radioactive tolamolol
’Day 1 urine’ (see text) from two subjects dosed as indicated in the 
table was assayed for tolamolol and tolamolol acid as described in section 
2.11. Results are expressed as percentage of the administered dose.
Compound Intravenous dose 20 mg
Oral dose 
200 mg
Tolamolol 4-9fo 2.0^
Tolamolol acid 4.0$ 2 ,&fo
9.3 DISCUSSION
The absorption of an oral dose of tolamolol in man is fast, 
as indicated by the rapid increase in the plasma radioactivity levels.
The capsules used for dosing were prepared to the same formulation as that 
developed for use in clinical trials, so that the disintegration rate was 
a known factor. The delay between administration of the drug and : 
appearance of radioactivity in the blood was therefore probably caused 
by tardy gastric emptying (see section 8.5). Some recent work on gastric 
emptying (Heading et al., 1973) has shorn that in fasted subjects the 
normal half-time for gastric emptying may be up to 55 .niinutes. In the 
present work the orally-dosed subject had eaten a light breakfast at about 
0800 hours, and was dosed at 1200 hours, so that a delay of about 50 
• minutes in absorption of the drug is not unexpected.
The concentration of radioactivity in the plasma after an oral 
dose of 200 mg of tolamolol is between 8 and 10 times that found after 
an intravenous dose of 20 mg, i.e. plasma levels of radioactivity are 
approximately dose-related. However, the pharmacologic effects of 
tolamolol for these two doses were similar. This suggests that, 
notwithstanding the higher levels of circulating radioactivity after oral 
dosing, the concentration of the pharmacologically active species is 
comparable with that obtained after the intravenous dose. It is therefore 
probable that there is a significant ’first pass effect’ (Gibaldi et al., 
1971) operating after oral dosing. The first pass effect is observed when 
significant metabolism of absorbed drug occurs on passage through the liver, 
so that the amount of unchanged drug reaching the systemic circulation is 
less than the amount of drug absorbed. The implication of a first pass 
effect for tolamolol in relation to the plasma radioactivity and the 
pharmacological effect is that it is tolamolol, and not a metabolite, that 
is responsible for the beta-blocking activity.
The high urinary excretion in the orally-dosed subject confirms 
that the drug is extensively absorbed; it is also extensively met&bolised 
as shown by the chromatograms of urine, and assays for unchanged drug. 
Chromatograms of the faecal extract after oral dosing show that the 
faecal radioactivity is not due to unchanged drug, but is probably 
hydroxy tolamolol. This suggests that absorption of tolamolol is complete 
since hydroxy tolamolol is unlikely to occur by the action of gut bacteria 
on tolamolol.
A high urinary excretion of radioactivity is also observed in 
the rabbit, and the metabolite pattern for rabbit urine is very similar 
to that found for man. Enzymic hydrolysis of human urine indicated that 
metabolite 1 (Figure 9-3) was a glucuronide. In view of the tentative 
identification of hydroxy tolamolol in human urine, and the apparent 
similarity of metabolites in human and rabbit urine, it is tempting to 
suggest that metabolite 1 in man corresponds to metabolite 1 in the rabbit, 
and is therefore hydroxy tolamolol glucuronide. Hydroxy tolamolol 
glucuronide would almost certainly be excreted in the bile to give rise 
to hydroxy tolamolol in the faeces (as described in earlier chapters).
The pattern of metabolites after oral and intravenous 
administration of tolamolol is very similar. This similarity in pattern 
occurs despite the large difference in plasma levels of radioactivity, 
and suggests that the plasma components are present in similar proportions 
after both routes of administration. If there was a significant ’first 
pass' effect, as suggested above, then it would be expected that a smaller 
proportion of the dose would be excreted as unchanged drug after oral than 
after intravenous dosing. This is found to be the case, although the 
difference can hardly be considered dramatic. It is clear that to detect 
any significant difference in metabolism between oral and intravenous doses 
of tolamolol will require quantitative data from a greater number of subjects 
and a wider range of dose-levels.
9.4 ADDENDUM TO CHAPTER 9
r
INTERSPECIES COMPARISON OF POLAR METABOLITES
Samples of the polar metabolites in rabbit, dog and human urine 
were isolated by XAD-2 resin treatment of urine, followed by preparative 
TLC of the methanol eluate in solvent III. In this solvent both rabbit 
and human urine showed two peaks of radioactivity corresponding to polar 
metabolites. Dog urine showed one major radioactive peak, with a minor 
peak at lower R^. For convenience the metabolites from these three species 
will be referred to as metabolites 1 and 2, in order of increasing R^ ,, 
although this numbering is not intended to imply identity of metabolites 
between species. Preparative TLC of rat bile (Addendum, Chapter 5) gave 
three polar metabolites, numbered 1 to 3; number 2 being the major 
metabolite.
Co-chromatography in solvents I and III of metabolite 1 from 
rabbit, dog and man, and metabolite 2 from rat showed that all four 
metabolites were identical. Since metabolite 1 in the rabbit has been 
identified as hydroxy tolamolol glucuronide (section 7-2.4»l)» this 
metabolite is also a major component of human urine and rat bile. It is, 
however, only a minor metabolite in the dog.
Samples of metabolite 2 from rabbit, dog and man, and metabolite 
5 from rat bile, were compared by co-chromatography in solvents I and III. 
The dog metabolite did not correspond to metabolites from the other three 
species. This is a major metabolite in the dog (tentatively identified 
as hydroxy tolamolol acid sulphate, Addendum to Chapter 8, page 19^
and therefore represents a pathway not followed to a significant extent 
by rat, rabbit or man.
In solvent III, metabolite 2 from both man and rabbit were each 
resolved into two bands; in solvent I the metabolites were each resolved 
into three bands. The major band in both solvents from both man and s
rabbit corresponded to metabolite 3 from rat bile. The major component 
of rabbit metabolite 2 has been tentatively identified as hydroxy tolamolol 
sulphate (section 7«2.4*3 and Addendum, Chapter 7)» and- this sulphate ester 
therefore also occurs in rat bile and human urine. The two minor components 
of metabolite 2 from rabbit and man were both radioactive, and hence 
drug-related. One of the rabbit metabolites is believed to be tolamolol 
glucuronide (Addendum, Chapter 7)» The presence of these metabolites in 
rat bile has not been investigated.
To summarise this work, in the rat, rabbit and man, tolamolol 
is metabolised primarily by hydroxylation of the beta ring followed by 
conjugation with glucuronic acid or sulphate, the glucuronide and sulphate 
conjugates being major metabolites. In the dog, this is a minor pathway, 
the main route for metabolism involving hydrolysis of the carbamoyl group.
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10.1 INTERSPECIES COMPARISON
The primary objective of this work was an interspecies comparison 
of the absorption, excretion and metabolism of tolamolol, particularly 
between those species used in the toxicity trials and man. Previous 
chapters have described work carried out in individual species, with little 
attempt at cross-correlation between species. It is the purpose of this 
section to provide an interspecies comparison; the next section will 
discuss the metabolism of tolamolol in relation to the other beta- 
blocking drugs discussed in Chapter 1, together with some possible 
clinical implications.
In all the species studied there was evidence for good absorption. 
A determination of the absorption half-life of- tolamolol in the rat, and 
other data such as extensive biliary excretion after intra-duodenal 
administration, showed that good absorption of the drug is obtained in 
this species.' Significant biliary excretion was also demonstrated in the 
guinea pig, and in addition the urinary metabolite patterns after oral and 
intravenous dosing were similar, which also suggests essentially complete 
absorption of the oral dose. Most of an- intravenous dose of tolamolol 
given to mice appears in the faeces, so that biliary excretion must have 
occurred, as it does in the rat and guinea pig. After oral doses of 
radioactive tolamolol to mice, most of the radioactivity is excreted in the 
faeces as metabolites, and therefore the predominance of the faecal route 
of excretion is not due to excretion of unabsorbed drug, but is probably 
the result of biliary excretion.
In the dog, blood levels of radioactivity, after oral dosing, 
together with the similarity of metabolite patterns after oral and
intravenous dosing confirm the rapid absorption of tolamolol. For both 
the rabbit and man, strong evidence for absorption is provided by the 
extensive urinary excretion after oral dosing. The general impression for 
all the species studied is that oral doses of tolamolol are extensively, 
if not completely,, absorbed, and in this respect tolamolol is similar to 
propranolol (Paterson et al., 1910; Hayes and Cooper, 1971)> practolol 
(Scales and Cosgrove, 1970; Barber and Bourne, 1971)? pronethalol (Bond
and Howe, 19&7) an& bunolol (Leinweber et al., 1971a).
" “ “  \
The six species considered in this study showed considerable 
differences in preferred routes of excretion of radioactivity, ranging 
from low urinary and high faecal excretion in the mouse, rat and guinea 
pig, to low faecal and high urinary excretion in the rabbit and man.
The dog occupied an intermediate position.' This species difference in
■
excretory routes does not indicate any fundamental difference in the 
metabolic fate of tolamolol, however, but is rather a manifestation of 
the different characteristics of biliary excretion in the various species.
It is now well-established that there is a threshold molecular 
weight for anions below which negligible biliary excretion occurs, and 
above which extensive biliary excretion can occur (Hirom et al., 1972b, 
and references cited therein). This threshold molecular weight varies 
with species and is 325 ± 50 for rats, 400 ± 50 for guinea pigs, and 
475 ± 50 for rabbits. The dog is considered a 'good1 biliary excretor 
(Abou-e 1-Makarem et al., 1967); the mouse-is probably similar to the rat 
in its biliary excretion ability, and can therefore also be classified 
as a 'good1 excretor. The available evidence for man suggests that the 
threshold molecular weight for anions is probably about 500 (Hirom jet al., 
1972b).
The polarity of an anion is also important in determining the 
extent of its biliary excretion, greater polarity favouring greater 
excretion (Millburn et al., 1967), or perhaps less re-absorption (Clark 
et al., 1971). This accounts for the ready elimination in the bile of 
compounds (unchanged drug or metabolites) capable of forming glucuronide 
or sulphate conjugates. Because there is a threshold molecular weight 
limit for biliary excretion, such compounds having molecular weights in the 
range 150 to.350 likely to show a species variation in excretory 
routes.
Little unchanged drug is excreted in the urine of the six species 
studied in this work, although the guinea pig, rabbit and dog apparently- 
do excrete some tolamolol in the faeces. While this could be due to poor 
absojrption, the appearance of tolamolol in'guinea pig faeces after intra­
venous dosing suggests that incomplete absorption is not the only 
explanation. The presence of tolamolol glucuronide in the rabbit (although 
only a minor metabolite in urine) shows that conjugation of the secondary 
alcohol can occur. Such a conjugate of tolamolol, molecular weight 520, 
would be well excreted in the bile, and could account for the presence of 
tolamolol in faeces.
Tolamolol is extensively metabolised, and in all the species 
examined, except the dog, the major Phase I metabolite is hydroxy 
tolamolol. This is not unexpected since a very common metabolic route for 
aromatic compounds is hydroxylation. Conjugation with glucuronic acid 
and sulphate is also a common metabolic reaction of phenols, and such 
conjugates of hydroxy tolamolol are therefore to be expected. Conjugation 
of hydroxy tolamolol with sulphate or glucuronic acid will give polar 
anionic compounds of molecular weight 440 or 536 respectively. Thus, from 
the concept of threshold molecular weights for biliary excretion, species
differences in the excretion of radioactivity might be expected. The 
observed preference for faecal excretion by the mouse, rat and guinea pig, 
and the low faecal excretion by rabbit and man fulfils this expectation.
The presence of mainly unconjugated compounds in urine from mice, rats and 
guinea pigs, whereas large quantities of conjugated compounds are excreted 
in the urine of rabbit and man is also explained on the basis of a species 
variation in threshold molecular weights.
The dog stands out from the other species in having tolamolol 
acid as the major Phase I metabolite, although small amounts of hydroxy 
tolamolol do occur. Aromatic carboxylic acids can form glucuronide 
conjugates, and glucuronide conjugation of the secondary alcohol group 
is also possible, but these are generally less common reactions than the 
conjugations of phenolic hydroxyl groups. Conjugation of tolamolol acid 
with glycine will give the hippuric-.acid, but apart from having a relatively 
low molecular weight (402), it will probably not be sufficiently polar 
for biliary excretion. Thus there is probably less opportunity for 
biliary excretion in the dog because of a relative lack of metabolites 
having the required properties. Nevertheless, biliary excretion does 
occur, and from the compounds tentatively identified in a faecal extract, 
tolamolol, tolamolol acid, and possibly hydroxy tolamolol are excreted in 
the bile, probably as conjugates.
Tolamolol acid is only a very minor metabolite in the mouse, 
rat, guinea pig and man, and its presence in the rabbit is probably a 
consequence of the high dose-level employed with this species (as 
mentioned in Chapter 7)« Parke, (1968), in discussing the hydrolysis of- 
aromatic carbamoyl groups, has pointed out that where alternative pathways 
of metabolism exist, for example, aromatic hydroxylation, these often 
take precedence over hydrolysis. The most likely explanation for the
appearance of tolamolol acid as a major metabolite in the dog, therefore, 
is that the dog possesses either a particularly accessible, or particularly 
potent, amidase.
Little systematic work has been published on the enzymic 
hydrolysis of amides, and as a result there is some doubt as to the 
location of the amidase(s) responsible. The enzyme hydrolysing the amides 
studied by Bray et al., (1950) was present in homogenates of liver and 
kidney, but the cellular location of this enzyme cannot be deduced from 
the method of preparation of the homogenates. An enzyme capable of 
hydrolysing certain aromatic amides is present in the microsomes of hog 
liver (Krisch, 1966), and amidase activity has been found in rabbit liver 
microsomes (Hollunger and Niklasson, 1962). Amidase activity is present 
in the 9>000 g supernatant of chicken liver homogenate (Schneck and Marks, 
1972), and an amidase hydrolysing chloramphenicol, is located in the 
microsomes of mouse liver (Hill and Struck, 1975)• There can be considerable 
species variation, however. Limethoate is hydrolysed by an amidase 
present mainly in microsomes from sheep and rat liver, but the enzyme occurs 
in the supernatant of mouse liver (Uchida et al., 1964)• Amidases are 
known to be present in blood plasma (Parke, 1968), but the activity of 
these enzymes towards foreign substrates does not appear to have been 
studied in any detail. This brief summary suggests that, although there 
is a wide variety of amidases, of varying substrate specificity, the 
microsomes are the most likely source of amidase activity for foreign 
compounds. If this is the case for the dog, the enzyme is not likely to 
be significantly more accessible to compounds entering the liver (or. 
kidneys) than the other microsomal enzymes. The preferred metabolic route 
for tolamolol in the dog, as compared to other species, is therefore 
probably not due to superior accessibility of the hydrolytic enzyme.
The alternative, and perhaps more likely, explanation for the 
presence of tolamolol acid as a major metabolite in dogs is that the dog 
contains a potent amidase. The dog is generally accepted as having a high 
aromatic deacylase activity (Leibman and Anaclerio, 19&2; Parke, 1968; 
Hathaway, 1970). This, together with the hydrolysis of tolbutamide by 
dogs, but not rabbits, rats and man (Scholz and Haussler, 1964), an(^  
hydrolysis of isoniazid by dogs when other species acetylate the drug 
(Williams, 1959)> suggest that the dog is better equipped than most 
species to hydrolyse -C0.NH- bonds. It is therefore probable that the 
preponderance of tolamolol acid as a metabolite in the dog rather than, 
hydroxy tolamolol is due to a high amidase activity rather than a low 
aromatic hydroxylation activity. The occurrence of hydroxy tolamolol 
acid sulphate in the urine shows that the dog is not deficient in its 
ability to hydroxylate aromatic rings.
The preference for amide hydrolysis in the dog rather than 
aromatic hydroxylation is an important species difference, more particularly 
because the dog has been used as a toxicity trial species for tolamolol.
The suggestion that the dog has a more potent amidase than other species 
should be investigated in more detail. Apart from determining the liver 
fraction containing the enzyme (mitochondria, microsomes or cytosol), its 
substrate specificity, tissue distribution and species distribution should 
be determined. Inhibition and stability studies should also be carried out 
to determine whether the amidase in the dog is the same as the amidase 
responsible for the appearance of tolamolol acid as a minor metabolite in 
other species. If the enzyme is widely distributed, the possibility of 
polymorphism in the metabolism of tolamolol in man must be considered; if 
the enzyme is peculiar to the dog, then this must place limitations on 
the value of the dog as a toxicity trial species for drugs containing 
a -C0.M- function.
10.2 COMPARISON WITH OTHER COMPOUNDS
In Chpater 1, the metabolic fate .of a number of compounds
containing the R 1 -CH(OH)CH^NH-R" structure was considered. It was
concluded that one factor accounting for the considerable differences
between these compounds in extent of metabolism and nature of metabolites
was lipid solubility, expressed in terms of the octanol/water partition
*
coefficient, P. On the basis of the calculated log P value, it,was 
predicted that tolamolol would be extensively metabolised, with an 
important metabolic route probably being fission of the alkyl chain.
In order to compare the metabolic fate of tolamolol with that 
of the other compounds described in Chapter 1, the data from Table 1.5 
have been reproduced in Table 10.1 (page 226, -which folds out for 
reference), together with the data for tolamolol. As stressed in Chapter 
1, the relative importance of the metabolic routes is only approximate; 
in the dog, for example, tolamolol is probably not extensively hydroxylated, 
although in all the other species investigated hydroxylation is the major 
route. Nevertheless, despite its limitations, Table 10.1 provides an 
interesting comparison.
' ' ■ . \
As predicted, tolamolol is extensively metabolised. On the 
basis of Table 10.1, however, N-dealkylation of tolamolol would be 
expected as ah important, if not major, metabolic reaction, but in fact 
it occurs only to a very small extent. This suggests that, compared to 
the other compounds in the table, N-dealkylation of tolamolol is less 
readily achieved, which implies that the bulky nature of the substituent 
groups (compared to isopropyl and tertiary butyl) is probably an important 
factor. Whether the N-dealkylation of the beta-blocking compounds is
carried out primarily by the microsomal enzyme system or by mitochondrial 
monoamine oxidase is in some doubt, as indicated in Chapter 1. However, 
the relatively low level of N-dealkylation of tolamolol does indicate a 
certain degree of substrate specificity by the enzymes involved.
. Some very preliminary in vitro work carried out in conjunction 
with Mr. J. Pry (University of Surrey) indicated that monoamine oxidase 
might be implicated in the N-dealkylation of. tolamolol in the rat. This 
work also suggested that the ^  -acid is not derived from the ^-lactic acid, 
which is an interesting observation since stepwise degradation of the 
side-chain, as shown in Scheme 1.1, page 26, is usually regarded as the 
route to the acetic acid derivative (beinweber et al., 1971b). However, . 
this work was of a preliminary nature, and it would certainly assist our 
understanding of the metabolism of tolamolol if this study was continued 
and extended.
All the major metabolites of tolamolol have been characterised, 
and so the main features of tolamolol "metabolism in animals and man are 
known. For salbutamol and propranolol, however, significant metabolites
have not been identified. In both cases these unidentified metabolites
<
are reported to be acid-labile, but resistant to glucuronidase or 
.sulphatase hydrolysis (Paterson et al.. 1970; Thomson et al., 1972; Walker 
jet al., 1972) . In the studies with tolamolol, when aromatic hydroxylation 
occurred as a metabolic reaction, conjugation with sulphate was usually 
observed. These conjugates were acid-labile, but were only partially 
hydrolysed by sulphatase, even after incubation for 3 days (section 2.9.2). 
The enzyme hydrolysed nitrocatechol sulphate within 30 minutes, so that 
the activity of the enzyme varies markedly with the substrate, and the 
possibility must be considered that the unidentified metabolites of 
salbutamol and propranolol are sulphate esters. Certainly, a sulphate
ester of hydroxy propranolol would have the electrophoretic behaviour at 
pH 4*5 shown by the unidentified metabolite of propranolol (with one 
acidic group and one basic group ionised, there would be no net charge, 
and therefore no migration except that due to electroendosmotic flow) 
(Paterson et al., 1970> Hayes and Cooper, 1971).
A number of minor metabolites of tolamolol were observed in all 
six species. Although in any given species one metabolic reaction may 
predominate, the non-specificity of the microsomal enzymes, together with 
the existence of many other non-microsomal enzyme systems capable of 
metabolising foreign compounds, means that competing reactions can, and 
probably do occur. It is therefore not surprising that in a molecule as 
complex as tolamolol many metabolites are found. Taking into account 
the possible Phase II reactions available for .tolamolol and its known 
Phase I metabolites (tolamolol acid, hydroxy tolamolol and hydroxy tolamolol 
acid), twelve metabolites can be postulated; chain cleavage would result 
in many more.' The investigation of minor metabolites will therefore be 
a lengthy procedure, and it is impossible at present to speculate on the
nature of the individual metabolites.
(
After oral administration of a drug, the absorbed compound must 
pass through the liver before reaching the systemic circulation. If a 
drug is readily metabolised, it may undergo significant metabolism during 
its first pass through the liver (the ’first pass effect’, Gibaldi et al., 
197l)» This effect is observed with propranolol, for which a ’threshold 
dose’ has been demonstrated after oral dosing. Below-this threshold the 
extraction of propranolol by the liver is lOO^ b, so that no unchanged 
propranolol enters the systemic circulation (Shand and Rangno, 1972).
A high hepatic extraction ratio has been demonstrated for propranolol • 
(Shand et al., 197l)> but this uptake process can be saturated, and the
threshold dose is-that dose which just causes saturation. Above the 
threshold dose, a fraction of the administered propranolol can reach the 
systemic circulation unchanged; The hepatic extraction ratio varies between 
individuals, and in one study, plasma levels of propranolol after oral 
dosing were found to vary seven-fold between different patients (Shand 
et al., 1970). As a result of this variation, it is necessary to 
’titrate’ the dose of propranolol against the pharmacological effect for 
each- patient.
The extensive metabolism of tolamolol suggests that it too may* 
exhibit a significant first pass effect. However, the results obtained 
in the rat-liver perfusion experiment, although possibly equivocal, 
indicated only about a 50$ hepatic extraction ratio for tolamolol at 
plasma concentrations of about 10 pg/ml; for propranolol, 100$ extraction 
ratios were obtained at plasma concentrations up to 15 pg/ml (Rangno and 
Shand, 1971)• It therefore seems that tolamolol is not so readily 
metabolised as propranolol. Additional evidence supporting this conclusion 
comes from the finding of significant concentrations of tolamolol in 
plasma from rats 1.5 hours after an intraduodenal dose of the drug. It 
may be, therefore, that tolamolol will show less inter-patient variation 
in blood-levels of unchanged drug compared with propranolol, and will 
be less likely to suffer, from the clinical problems associated with the 
need to titrate the dose to the patient. However, much more work needs 
to be done, and it is partly because of this aspect that so much time 
was (and is) being devoted to assay methods for tolamolol.
A further important study which requires an assay for tolamolol 
is the correlation of pharmacologic effect with plasma levels of unchanged 
drug. The major metabolite of tolamolol, hydroxy tolamolol, is 
pharmacologically active, being more selective, although less potent, than
the parent drug. This metabolite may therefore be contributing to the 
beta-blocking effect of tolamolol. Hydroxy propranolol, a metabolite of 
propranolol, is also pharmacologically active, but its half-life in plasma 
is shorter than that of propranolol (Cleaveland and Shand, 1972), 
presumably due to rapid inactivation by conjugation. As hydroxy tolamolol 
is readily conjugated with glucuronic acid or sulphate, it is probable 
that this, too, has a shorter half-life /than the parent drug. If so, then 
the pharmacologic effect of tolamolol is unlikely to be materially 
affected by the presence of small amounts of unconjugated hydroxy tolamolol. 
Nevertheless, when methods are available, a comparison of the half-lives 
of tolamolol and its metabolite should be carried out.
During the course of this work the relative importance of 
different metabolites has been assessed almost exclusively from chromato­
graphic data. This, as described in section 2.7.5 is likely to give a 
bias in favour of the less polar metabolites, and an important objective 
in any future work should be the quantitation of excreted metabolites.
TABLE 10.1
Comparison of the metabolic fate of tolamolol with
that of related compounds
Data taken from Table 1.5> with additional data for tolamolol. For 
structures of compounds see Table 1.4 (page 54) and Appendix I. Log P 
values calculated according to Tute (1971) and log P* values for pH 7*4 
calculated. Relative importance of metabolic routes only semi-quantitative 
- see legend to Table 1.5 (page 30).
Compound log P*
Urinary metabolites
Unchanged
drug
Ring
hydroxylation
Side-chain ‘ 
degradation
Salbutamol -1.66 +++++
Practolol -1.17 ++++ +
Terbutaline -1.04 +++++
Oxprenolol 0.17 ++ ++ +'
Roche fA ’ 0.21 +++
s.
+
Bunolol 0.75 ++ ++
Pronethalol 0.86
(
+++ ++
Propranolol 1.04 + ++++
TOLAMOLOL 1.36 + ++++
Roche 'B* 1.40 ++ +++
10.3 CONCLUSION
The main features of tolamolol metabolism are summarised in 
the following scheme. The dog, and possibly the rabbit, are the only 
species to excrete significant amounts of the hydrolysis product, tolamolol 
acid, the other species, including the rabbit, favouring hydroxylation as 
a metabolic route. The dog excretes hydroxy tolamolol acid sulphate, 
which is probably a secondary metabolite occurring as a result of entero- 
hepatic circulation of the primary metabolite, hydroxy tolamolol.
TOLAMOLOL
Mice, Rats, 
Guinea pigs, 
Rabbits, 
(Logs)
Man.
Hydroxylation
v
HT
Enterohepatic
circulation
(Rabbits), 
Logs.
Hydro-
Hydrolysis
*
lysis 3>HTA TA
HT-SO HT-Gluc
v
T-Gluc
Phase I
Y
HTA-SO ► Phase II
Key: T = tolamolol
HT = hydroxy tolamolol 
TA = tolamolol acid 
HTA = hydroxy tolamolol acid
Glue = glucuronide conjugate 
SO. = sulphate conjugate
An interspecies comparison of the metabolites excreted in urine 
and faeces is given in Table 10.2. It has been shown that the bile from 
rats and guinea pigs contains polar metabolites, so that the tendency for 
the smaller animals to excrete more unconjugated compounds than rabbits 
and man is the result of biliary excretion of conjugates, followed by 
hydrolysis in the gut, and not of a fundamental difference in metabolism. 
The dog is exceptional in that hydrolysis of the carbamoyl group occurs 
in preference to aromatic hydroxylation. Table 10.2 is not comprehensive' 
because in all species there are minor metabolites that have not been 
identified; for example, tolamolol probably occurs in rabbits, and 
hydroxy tolamolol probably occurs in man.
TABLE 10.2
Interspecies comparison of tolamolol metabolites
Species
Metabolite
HT-Gluc HT-SO,
4
T-Gluc HTA-SO. 
4
HT T TA
Mouse +++++
Rat - +++++
Guinea pig ++++ +
Rabbit ++++ +++ + + ++
Dog + ++ ++++
Man ++++ ++++ + + +
Note: the abbreviations for metabolites are those used on previous page.
The extensive metabolism of tolamolol is consistent with the 
partition coefficient correlation noted in Chapter 1. This correlation 
is based on relatively few compounds, related only by the presence of 
an aromatic ring system substituted.by a side-chain containing an 
ethanolamine structure. Tolamolol does not entirely conform to the 
predicted behaviour because N-dealkylation is not a significant reaction. 
This is probably due to the structurally different and physically more 
bulky groups substituted on the aliphatic nitrogen atom of tolamolol, as 
compared with the model compounds used in the prediction. The use of 
partition coefficients in a predictive sense is therefore unreliable in 
cases such as this where the compounds used in the correlation are not 
closely related.
The work described in this thesis has largely fulfilled the 
immediate objectives. Good absorption of tolamolol has been demonstrated, 
major metabolic routes, have been identified, and the interspecies 
differences in excretion have been rationalised. Nevertheless there 
remain many areas where additional work should be done, and these areas 
have been indicated. The results of clinical trials with tolamolol are - 
encouraging, and it is important not only from the point of view of drug 
safety, but also from the scientific viewpoint, that these studies should 
be continued.
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APPENDIX I
Structures of some compounds structurally related to tolamolol
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I write a piece, with a pen. I stare mournfully at it, and 
then say to myself, "Well, I suppose I might as well type it 
out". Then I think, Yes, it'll do. Then I get the galley- 
. proof, and I think, H'm, that'll look quite nice in the paper. 
When it appears in a book I think, "Heavens, did I write that?
Paul Jennings.
